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Introduction 
Foreword 
According to the last estimates, the incidence of gastric carcinoma is the second in rank 
world-wide (Parkin, 1998). In the so-called developed western countries, a steady 
decrease in the incidence of gastric carcinoma has been observed during the last two to 
three decades (Howson, et al. 1986; La Vecchia, et al. 1992). In contrast, this tendency 
is not so clear in Portugal, where the incidence and mortality rates of gastric carcinoma 
are among the highest in the world (Parkin, et al. 1988) and are even the highest in the 
European Union (Black, et al. 1997). In Portugal, gastric carcinoma is the second most 
incident cancer and the major cause of cancer mortality (Parkin, 1998). 
In a very simplified way, it is generally accepted that there are two main pathways of 
malignant transformation of gastric mucosa: one via intestinal metaplasia and 
adenomatous dysplasia, leading to intestinal carcinomas; the other via hyperplastic or de 
novo changes, with or without concurrent non-metaplastic dysplasia, leading to diffuse 
carcinomas and to a subset of intestinal carcinomas (Corrêa, 1992; Solcia, et al. 1996; 
Carneiro, 1997). 
Morphologic diversity of gastric carcinoma is much greater than what could be 
anticipated by the recognition of two main variants of carcinoma arising in the stomach 
— intestinal and diffuse. In fact, a large proportion of gastric carcinomas are 
polymorphic exhibiting a large diversity both at structural and cell differentiation level 
and the molecular counterpart underlying this heterogeneity is not well elucidated. 
Among the plethora of candidate molecular factors, potentially involved in the 
pathogenesis of gastric carcinoma, trefoil peptides and the cell adhesion molecule E-
Cadherin have been chosen, in the present study, as tools to analyse some aspects of cell 
differentiation and morphologic heterogeneity of gastric carcinoma. 
Broadly, trefoil peptides and E-Cadherin are involved in fundamental biological 
processes such as cell adhesion and motility and are normal constituents of the human 
gastric epithelium. Data on record support that disturbed function of these molecules 
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may play an important role in gastric carcinogenesis and in the biopathology of these 
tumours. 
In the following pages of the introductory section of this Thesis, a general overview on 
the morphologic heterogeneity and cell differentiation of gastric carcinoma, as well as 
on its putative molecular counterparts, will be presented. Furthermore, emphasis will be 
given to the general characterisation of the trefoil peptides and E-Cadherin molecules 
and to their potential role in cancer development. 
Introduction 
Classification, differentiation and ethiopathogenesis of gastric carcinoma 
From the morphologic standpoint gastric carcinoma is very heterogeneous, probably 
reflecting the complexity and diversity of the process(es) of malignant transformation of 
gastric mucosa (Lauren, 1965; Corrêa, 1992; Carneiro, et al. 1995b). This heterogeneity 
is amply reflected in the diversity of histopathological classifications on record 
(Borrman, 1926; Lauren, 1965; Ming, 1977; Watanabe, et al. 1991; Carneiro, et al. 
1995b), which are based on different criteria such as histological profile, degree of 
differentiation, histogenesis and pattern of growth. 
According to Lauren's classification (1965), there are two main types of gastric 
carcinoma — intestinal and diffuse carcinoma — which differ from each other 
morphologically, clinically and epidemiologically. Using Lauren's classification as a 
framework, Carneiro et al (1995b) proposed a histopathological classification of gastric 
carcinoma based on the tissue organisation of the tumours and individualising the group 
of cases designated as mixed carcinomas that display, in the same tumour a 
glandular/solid component and an isolated-cell component. The four groups of the 
proposed classification, found to carry independent prognostic meaning, are glanduliir 
carcinoma, isolated-cell carcinoma, solid carcinoma and mixed carcinoma. Glandular 
and isolated-cell carcinomas correspond to carcinomas that, according to Lauren's 
classification, are designated as intestinal and diffuse carcinomas, respectively. In our 
opinion, these two classifications are those that allow a more adequate interpretation of 
both the epidemiological and the ethiopathogenic aspects of gastric carcinoma. 
Accordingly, they will be used throughout the studies that constitute this Thesis. 
Morphologically, the diffuse carcinoma (Fig. 1A) is characterised by displaying isolated 
tumour cells, scattered throughout the stroma, which infiltrate the surrounding tissues 
and are associated with a desmoplastic reaction. The intestinal carcinoma (Fig. IB) is 
characterised by the formation of glandular structures with an expansive type of growth. 
At the clinicopathological level, the two main types of gastric carcinoma also show 
different behaviour: the diffuse carcinomas tend to invade locally the surrounding 
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tissues, to disseminate to the peritoneum and, through the lymphatic vessels, to the 
regional lymph nodes; intestinal carcinomas characteristically give rise to blood bora 
metastasis (Esaki, et al. 1990). 
Fig. 1 - Typical examples of a diffuse carcinoma (A) and of an intestinal carcinoma (B). 
From the epidemiological standpoint, diffuse carcinomas occur more frequently in 
young individuals and mainly in women, whereas intestinal carcinomas occur often in 
elderly individuals and more frequently in men (Ribeiro, et al. 1981; Mecklin, et al. 
1988; Maehara, et al. 1992). Earlier studies pointed to a hereditary conditioning of 
diffuse carcinomas occurring in the setting of familial gastric cancer (Lehtola, 1978; 
Mecklin, et al. 1988). More recent reports have described similar proportions of diffuse 
and intestinal gastric cancer in patients with a positive familial history (Palli, et al. 1994; 
Shinmura, et al. 1998). 
While the term "diffuse" is mainly related with the pattern of growth of this specific 
type of gastric carcinoma, the term "intestinal" encompasses two different concepts; the 
first is architectural and points to a tumour with a structure similar to that of most 
colonic carcinomas, while the second is histogenetic and based on the assumption that 
this type of gastric carcinoma originates from intestinal metaplasia of the stomach. 
Intestinal-type differentiation was described several years ago in gastric cancer (Lauren, 
1965; Goldman and Ming, 1968a; Goldman and Ming, 1968b) and it was believed that 
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this type of metaplastic differentiation was typical of intestinal-type gastric carcinomas 
(Lauren, 1965; Ghandur-Mnaymneh, et al. 1988). 
In recent years, however, ultrastructural studies (Fiocca, et al. 1987; Fiocca, et al. 1990; 
Carneiro, et al. 1992) showed that differentiated cell types of both gastric type (foveolar 
and mucopeptic) and intestinal type (columnar and goblet cells) can be recognised in 
most gastric tumours, regardless of the histological type. Moreover, histochemical and 
immunohistochemical studies (Bara, et al. 1981; Tatematsu, et al. 1986; Fiocca, et al. 
1987; Fiocca, et al. 1988a; Fiocca, et al. 1988b; Fiocca, et al. 1990; Kushima and 
Hattori, 1993; Kushima, et al. 1993), aiming at the identification of gastric-type and 
intestinal-type antigens in gastric carcinoma, provided additional support to the 
aforementioned ultrastructural findings. These results showed that both types of cell 
differentiation (gastric and intestinal) can be observed, alone or in combination, in 
intestinal as well as in diffuse carcinomas. Table 1 summarises the ultrastructural, 
histochemical and immunohistochemical features that serve to identify gastric- and 
intestinal-type cell differentiation. 
Corrêa (1988; 1992) proposed a model of gastric carcinogenesis according to which the 
intestinal carcinoma represents the end-product of a cascade of sequential changes of 
gastric mucosa including superficial gastritis, chronic atrophic gastritis, small intestinal 
metaplasia, colonic metaplasia and adenomatous (flat or polypoid) dysplasia. According 
to this model the major etiological factors would be excessive salt intake, Helicobacter 
pylori infection, low intake of ascorbic acid and carotenoids and intragastric nitrosation 
due to nitrate intake (Corrêa, 1988; Corrêa, 1992). However, Correa's model does not fit 
with the subset of intestinal carcinomas that show histochemical signs of gastric-type 
differentiation and no evidence of intestinal-type differentiation (Fiocca, et al. 1987; 
Fiocca, et al. 1988a; Carneiro, étal. 1992; Kushima and Hattori, 1993). 
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Table 1 - Ultrastructural, histochemical and immunohistochemical "markers" used to identify gastric-
and intestinal-type differentiation in gastric carcinoma. 
Cell differentiation "Markers'' 
Gastric-type 
Intestinal-type 
Punctate cerebroid granules 
Target-like or solid granules2 
GOS reactive mucins 
PACONA reactive mucins2 
Cathepsin-E1 
Pepsinogen II2 
Neutral mucins1,2 
Ml and M21 
Microvilli with cytoplasmic roots3 
Clear, coalescing granules 
CAR-53'4 
Sialyl-Tn3'4 
Acid mucins ' 
BD-53'4 
M34 
Markers of gastric foveolar cells (1), gastric mucopeptic cells (2), intestinal columnar cells (3) and 
intestinal goblet cells (4); GOS - Galactose-oxidase Schiff stain; PACONA - Periodic-acid-
biotynilated concanavalin A stain. For a review see refs. (Bara, et al. 1981; Tatematsu, et al. 1986; 
Fiocca, et al. 1987; Fiocca, et al. 1988a; Fiocca, et al. 1988b; Fiocca, et al. 1990; Carneiro, et al. 
1992; Kushima and Hattori, 1993; Kushima, étal. 1993). 
From the histogenetic standpoint it is generally accepted that diffuse carcinomas 
originate from gastric proper mucosa and that non-metaplastic dysplasia is a putative 
premalignant lesion of this type of carcinoma (Ghandur-Mnaymneh, et al. 1988), though 
little is known regarding the prevalence and clinicopathological features of the 
aforementioned type of dysplasia. Furthermore, there is growing evidence suggesting 
that hyperplastic lesions of gastric mucosa (foveolar hyperplasia and hyperplastic 
polyps) may also serve as precursor lesions of gastric carcinoma, namely of diffuse-type 
(Carneiro, et al. 1993a; Carneiro, et al. 1993b; Zea-Iriarte, et al. 1995). 
In summary, the aforementioned evidence suggests the existence of at least two 
pathways of malignant transformation of gastric mucosa: one via intestinal metaplasia 
and adenomatous (flat or polypoid) dysplasia, leading to intestinal carcinomas with 
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intestinal-type differentiation; the other via hyperplastic or de novo changes, with or 
without concurrent non-metaplastic dysplasia, leading to diffuse carcinomas and to a 
subset of intestinal carcinomas with gastric-type differentiation (Carneiro, 1997) (Fig. 
2). 
Normal mucosa 
/ 
Chronic gastritis 
/ 
Intestinal metaplasia 
/ 
Adenomatous dysplasia 
/ 
Intestinal carcinoma 
\ 
Chronic gastritis 
Hyperplastic/dysplastic lesions 
\ 
Diffuse carcinoma 
Fig. 2 - Model of gastric carcinogenesis illustrating the two main histogenetic pathways. 
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Molecular counterpart of the morphologic heterogeneity of gastric carcinoma 
Cancer has long been recognised as a multistage process involving, in most cases, an 
accumulation of multiple genetic alterations as the result of successive rounds of 
mutation and clonal selection in tumour cells (Nowell, 1976; Knudson, Jr. 1985), and 
the establishment of a specific "environment" in the tumour which involves an altered 
balance of transcription factors and expression/repression of different genes (Tahara, 
1990; Brattain, et al. 1994). Although the precise nature and sequence of those 
alterations remain mostly unclear, several abnormalities affecting both structure and 
expression of a vast number of genes have been identified (Fearon and Vogelstein, 
1990; Levine, 1990; Vogelstein and Kinzler, 1993; Tahara, 1995; Hussain and Harris, 
1998; Lengauer, et al. 1998). We are now aware that most of these genes code for 
proteins that belong to functional groups such as growth factors and their receptors, cell 
cycle regulators, hormone receptors, cell adhesion molecules, signal transduction 
proteins, DNA repair proteins, transcription factors or apoptosis related proteins. 
However, despite the huge amount of information regarding molecular changes that 
occur in gastric carcinoma and that have been identified by many groups using different 
methods, a sound molecular model for gastric carcinogenesis is far from being 
established (Lemoine, et al. 1992; Seruca, et al. 1992; Wright and Williams, 1993; 
Carneiro, et al. 1994; Corrêa and Shiao, 1994; David, et al. 1994; Seruca, et al. 1995; 
Santos, étal. 1996; Tahara, 1995; Amado, étal. 1998). 
Table 2 summarises, in a very simplified way, the most prominent data on the molecular 
alterations of gastric carcinoma, according to the two major histological types (diffuse 
and intestinal). Table 2 includes data on DNA content, loss of heterozygosity (LOH) in 
several chromosomes, microsatellite instability (MSI), proto-oncogenes {KSAM, RAS, 
ERBB2 and MET), tumour suppressor genes (P53, APC and DCC), growth factors 
(EGF, TGF-a and TGF-(3), glycoconjugates (S-Tn, T, S-T, CDw75 and S-Lex antigens), 
matrix components (laminin and collagen IV) and degradating matrix enzymes (u-Pa 
and Cat-D). 
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Table 2 - Summary of the molecular alterations in gastric carcinoma according to the two mam 
histological types. 
Intestinal carcinoma Diffuse carcinoma 
Aneuploidy 
#3p,6q,7q,13q(LOH) 
#lq,5q,17p(LOH) 
MSI+ 
RAS (mutation/overexpression) 
ERBB2 (amplification) 
TPR-MET rearrangement 
M£7/(6.0KbmRNA) 
P53 (LOH, mutation) 
APC (LOH, mutation) 
DCC (LOH) 
EGF overexpression 
TGF-a overexpression 
S-Tn, T, S-T 
CDw75, S-Lex 
Laminin, collagen IV 
u-Pa, Cat-D 
Diploidy 
#3p,6q,7q,13q(LOH) 
M£T (6.0 Kb mRNA) 
KSAM amplification 
P53 (LOH, mutation) 
TGF-P overexpression 
S-Tn, T, S-T 
CDw75, S-Lex 
For a thorough review see refs. (Lemoine, et al. 1992; Seruca, et al. 1992; Wright and Williams, 1993; 
Carneiro, et al. 1994; Corrêa and Shiao, 1994; David, et al. 1994; Seruca, étal. 1995; Santos, étal. 1996; 
Tahara, 1995; Machado, étal. 1997; Amado, étal. 1998). 
Taking together all the above evidence it is possible to conclude that some of the 
molecular alterations occur exclusively, or predominantly, in each of the major 
histotypes of gastric carcinoma; for example, aneuploidy, 5q and 17p LOH, MDSI+ 
phenotype, ERBB2 amplification, EGF and TGF-a overexpression are found mainly in 
intestinal carcinomas; at variance, diploidy, KSAM amplification and TGF-P 
overexpression are associated with diffuse carcinoma. Although a clear understanding 
of the molecular pathogenesis of gastric carcinoma is at an early stage, these 
observations support the assumption that there is, indeed, a molecular counterpart 
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underlying the two major histotypes of gastric carcinoma, which is in keeping with the 
existence of at least two histogenetic pathways of gastric carcinogenesis. 
However, this model is rendered more complex by the existence of mixed gastric 
carcinomas, that present both a diffuse histotype component and an intestinal 
histological component. It remains to be seen if mixed gastric carcinomas share 
molecular features of the "pure" histological types or if, on the contrary, they exhibit a 
distinct molecular profile. 
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Trefoil peptides 
General features 
Trefoil peptides are a group of small stable secreted peptides characterised by the 
presence of one up to six cysteine-rich domains, designated as trefoil domains (formerly 
P-domains) (Thim, 1989; Hoffmann and Hauser, 1993). This basic module defining the 
trefoil peptide family consists of 38 or 39 amino acids (CX9CX9CX4CCX9WCF) folded 
into a clover-leaf structure, and held together by three disulphide bridges (Fig. 3) (Thim, 
1989; Podolsky, etal. 1993). 
Fig. 3 - Analogy between the primary structure of a trefoil domain and a trefoil leaf, with the disulphide 
bonding of cysteine residues 1-5, 2-4 and 3-6. Adapted after Thim (1994). 
Members of this family of peptides have been discovered in different species from 
Xenopus laevis to human (Jorgensen, et al. 1982b; Masiakowski, et al. 1982; Hoffmann, 
1988; Tomasetto, et al. 1990; Hauser and Hoffmann, 1991; Suemori, et al. 1991; 
Hauser, et al. 1992; Hauser and Hoffmann, 1992; Hauser, et al. 1993; Podolsky, et al. 
1993). Table 3 summarises data regarding the number of trefoil domains and main sites 
of expression of known trefoil peptides. Interestingly, regardless of species and of organ 
of expression, all trefoil peptides are expressed in mucin secreting epithelia. 
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Table 3 - Number of trefoil domains and major sites of expression of trefoil peptides grouped 
according to their homology. 
Name Trefoil Typical 
domains localisation 
References 
human TFF1 
mouse TFF1 
X. laevis xPl 
human TFF2 
mouse TFF2 
porcine TFF2 
human TFF3 
rat TFF3 
X. laevis xP2 
X. laevis xP4 
X. laevis FIM-A.l 
X. laevis FIM-C.l 
1 Stomach (Masiakowski, etal. 1982; Rio, etal. 1988) 
1 Stomach (Otto, etal. 1996) 
1 Stomach (Hauser and Hoffmann, 1991) 
Stomach (Tomasetto, etal. 1990) 
Stomach (Tomasetto, et al. 1990) 
Pancreas (Rose, etal. 1989; Tomasetto, etal. 1990) 
Intestine (Hauser, etal. 1993; Podolsky, etal. 1993) 
Intestine (Suemori, etal. 1991;Chinery, etal. 1992) 
Skin (Hauser, et al. 1992) 
Stomach (Hauser and Hoffmann, 1991) 
Skin (Hoffmann, 1988; Hauser, etal. 1990) 
Skin (Hauser and Hoffmann, 1992) 
FIM - Frog integumentary mucin 
Three human trefoil peptides have been identified to date: TFF1 (formerly pS2) and 
TFF3 (formerly hlTF) with one trefoil domain each, and TFF2 (formerly hSP) with two 
trefoil domains. TFF1 was originally identified in 1982 as the product of an oestrogen-
responsive gene in the breast carcinoma cell line MCF-7 (Masiakowski, et al. 1982); 
TFF2 was discovered in 1990 (Tomasetto, et al. 1990) as a human homologue of a 
peptide isolated from porcine pancreas, the porcine TFF2 (formerly PSP) (Rose, et al. 
1989); and TFF3 was identified in 1993 (Hauser, et al. 1993; Podolsky, et al. 1993) as a 
human homologue of rat TFF3 (Suemori, et al. 1991). 
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Expression of trefoil peptides in normal tissues 
In normal human tissues, trefoil peptides are mainly expressed in gastrointestinal 
epithelial cells, where they are copackaged by the Golgi apparatus into mucus granules 
and secreted with mucins into the protective layer covering the mucosa (Hanby, et al. 
1993b; Sarraf, et al. 1995; Poulsom, 1996). Table 4 summarises data regarding the sites 
of physiological expression of trefoil peptides in normal human tissues. 
Table 4 - Sites of expression of trefoil peptides in normal human tissues. 
Trefoil Organ Description References 
peptide 
TFF1 Stomach Throughout (Rio, etal. 1988; Luqmani, etal. 1989; Hanby, 
superficial and etal. 1993b) 
foveolar mucosa 
Duodenum Upper ducts and 
surface cells of 
Brunner's glands 
(Hanby, etal. 1993a) 
Large intestine Some goblet cells of 
distal regions 
(Singh, etal. 1998) 
Pancreas Focally in duct 
epithelium 
(Wright, etal. 1990) 
Gall bladder Patchy epithelial 
expression 
(Seitz, etal. 1991) 
Salivary glands Patchy expression (Rio, et al. 1988) 
Breast Focally in duct 
luminal cells 
(Poulsom, et al. 1997) 
TFF2 Stomach Mucous glands of 
body and antrum 
(Hanby, etal. 1993b) 
Duodenum Brunner's glands acini 
and distal ducts 
(Piggott, etal. 1991) 
Pancreas Focally in duct 
epithelium 
(Wright, etal. 1990) 
Gall bladder Patchy epithelial 
expression 
(Seitz, etal. 1991) 
TFF3 Duodenum Brunner's glands acini (Suemori, etal. 1991; Chinery, etal. 1992; 
and ducts, goblet cells Hauser, etal. 1993;Podolsky, etal. 1993) 
Small and large Goblet cells (Suemori, etal. 1991; Chinery, etal. 1992; 
intestine Hauser, etal. 1993) 
Uterus Epithelium (Hauser, etal. 1993) 
Breast Focally in duct 
luminal cells 
(Poulsom, et al. 1997) 
Brain Hypothalamus, (Probst, etal. 1995; Schwarzberg, etal. 1999) 
pituitary * 
The main site of expression of TFF1 is the stomach, where it is abundantly expressed in 
the superficial and foveolar epithelium (Rio, et al. 1988; Luqmani, et al. 1989; Hanby, 
et al. 1993b). A high level of expression of TFF1 has also been described in upper ducts 
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and surface cells of Brunner's glands in the duodenum (Hanby, et al. 1993a). The small 
intestine generally appears not to express TFF1, although some staining of the tips of 
villi in the ileum and jejunum has been reported (Piggott, et al. 1991). In the normal 
large intestine, TFF1 expression has been demonstrated in some goblet cells, 
particularly in the distal regions (Singh, et al. 1998). In the pancreas only a few cells in 
large ducts appear positive (Wright, et al. 1990) and in gall bladder some patchy 
epithelial expression has been described (Seitz, et al. 1991). Salivary glands were 
reported as weakly immunopositive (Rio, et al. 1988). Outside of the gastrointestinal 
tract, TFF1 expression has been observed focally in duct luminal cells of normal breast 
(Poulsom, et al. 1997) (Table 4). 
The expression of TFF2 appears to be highly correlated with that of TFF1 in terms of 
organ specificity. In normal gastric mucosa, TFF2 expression is observed in mucous 
glands of body and antrum (Hanby, et al. 1993b). In duodenum, TFF2 expression is 
present in Brunner's glands acini and distal ducts (Piggott, et al. 1991). Some focal 
expression is also observed in duct epithelium of pancreas (Wright, et al. 1990) and in 
gall bladder epithelium (Seitz, et al. 1991). In contrast with TFF1, which shows a good 
agreement between data on protein and mRNA expression, some discrepancies have 
been reported for TFF2; in gastric mucosa TFF2 mRNA has been detected in the glands 
and in the foveolar epithelium, but the peptide is undetectable in the surface cells 
(Hanby, et al 1993b) (Table 4). 
While TFF1 and TFF2 are mainly expressed in the stomach, the major site of expression 
for TFF3 is the intestine. TFF3 is expressed in goblet cells throughout the intestine and 
in gland acini and distal ducts of Brunner's glands (Suemori, et al. 1991; Chinery, et al. 
1992; Hauser, et al. 1993; Podolsky, et al. 1993). In contrast with the apparent 
gastrointestinal specificity of TFF1 and TFF2, TFF3 expression has been observed in 
human uterus (Hauser, et al. 1993), normal breast (Poulsom, et al. 1997), some regions 
of the hypothalamus and in the pituitary gland (Probst, et al. 1995; Schwarzberg, et al. 
1999) (Table 4). 
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Structure of trefoil peptide genes and proteins 
The TFF1 locus, known as breast cancer oestrogen inducible (BCEI), is composed of 
three exons (Rio and Chambon, 1990); the single trefoil domain of TFF1 is coded by 
exon 2. The 5'-promoter region of the BCEI gene contains an oestrogen responsive 
element (ERE) as well as elements responsive to phorbol esters, c-Ha-ras and c-jun 
(Berry, et al. 1989; Nunez, et al. 1989). The gene structure of the TFF2 gene, whose 
locus is denominated SML1 (spasmolysin 1), exhibits four exons, two of which encode 
the two separate trefoil domains (Tomasetto, et al. 1990). Analysis of the human TFF3 
gene reveals the same basic structure of three exons as human BCEI (Hauser, et al. 
1993; Podolsky, et al. 1993). 
The three human trefoil peptide genes are clustered in the genomic region 21q22.3 
(Theisinger, et al. 1992; Tomasetto, et al. 1992; Chinery, et al. 1996; Gõtt, et al. 1996; 
Schmitt, et al. 1996), in a tandemly oriented fashion and within a 50 kbp genomic 
fragment (Gõtt, et al. 1996). The locus order is cen-TFF3-SMLI-BCEI-tc\ and the 
transcription of all three genes is directed towards the centromere (Gõtt, et al. 1996). 
Analysis of the exon structure of the three trefoil peptide genes reveals a very similar 
organisation among them. The first exon encodes the secretion signal sequence, the 
second exon (and the third exon of SML1) encode the trefoil domains, and the third 
exon (fourth exon of SML1) encodes three to four residues of the carboxyl terminus 
(Gõtt, et al. 1996). This conserved structural organisation may have evolved by gene 
duplication and exon shuffling (Gõtt, et al. 1996). 
Besides gene clustering and an identical transcription orientation of all three trefoil 
peptide genes, the 5'-flanking regions share several motifs with almost identical 
sequences and spacing, suggesting a co-ordinated regulation and/or a common locus-
controlling region (Gõtt, et al. 1996). Moreover, two motifs with identical sequence and 
position are shared exclusively by the stomach-specific genes BCEI and SML1, thus 
presenting possible targets for stomach specific gene regulation (Gõtt, et al. 1996). 
The three human members of the trefoil peptide family are small and stable secreted 
proteins: TFF1 is 84 amino acids long in its immature form and 60 amino acids long in 
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its mature form (Mori, et al. 1988); the immature TFF2 is 129 amino acids long and its 
mature form is 106 amino acids long (Tomasetto, et al. 1990); TFF3 has a sequence of 
80 amino acids in the immature form and 59 amino acids in the mature form (Thim, et 
al. 1995). 
The characteristic trefoil domain of these peptides presents a compact tri-dimensional 
trefoil structure that appears to confer marked resistance to proteolysis and acid 
digestion (Jorgensen, et al. 1982b; Mori, et al. 1988; Playford, et al. 1995; Thim, et al. 
1995). 
There is some evidence that trefoil peptides can exist naturally as dimers; TFF1 can 
bridge through the seventh cysteine residue either to another TFF1 molecule (Chadwick, 
et al. 1995; Chinery, et al. 1995) or perhaps to TFF3 (Chinery, et al. 1995); likewise, for 
TFF3 the possibility of homo-dimerisation was also demonstrated (Chinery, et al. 1995; 
Thim, et al. 1995). These data show that dimerisation is essential for some biological 
properties of trefoil peptides and raise the intriguing possibility that a spectrum of 
biological activities may be generated by combining different single-trefoil peptides. 
Function of trefoil peptides 
The first studies on the biological activity of trefoil peptides were performed by 
Jorgensen et al (1982a) on porcine TFF2 in experimental animals. These studies 
suggested that these peptides had a role in inhibition of gastrointestinal motility and in 
inhibition of pentagastrin-induced acid secretion (Jorgensen, et al. 1982a). However, 
recent studies on the human and porcine peptides have not supported these findings 
(Playford, et al. 1995; McKenzie, et al. 1997). 
Although the biological functions of trefoil peptides are not completely understood, 
there is growing evidence supporting the involvement of these peptide's in mucosal 
defence and reconstitution (Wright, et al. 1993; Dignass, et al. 1994; Babyatsky, et al. 
1996; Mashimo, et al. 1996; Playford, et al. 1996). Data on record demonstrates that the 
expression of trefoil peptides (mainly TFF1 and TFF2) is up-regulated in epithelial cells 
adjacent to ulcerative conditions of the gastrointestinal tract and in epithelial cells 
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undergoing migration across the base of such lesions (UACL - ulcer associated cell 
lineage) (Wright, et al. 1990; Rio, et al. 1991; Wright, et al. 1993). Experimental data 
have shown that trefoil peptides are able to promote epithelial cell migration in vitro and 
in vivo (Dignass, et al. 1994; Playford, et al. 1995) and to protect against induced 
gastrointestinal damage in vivo (Babyatsky, et al. 1996; Playford, et al. 1996). On the 
other hand, a transgenic mouse model lacking TFF3 (ITF) has been shown to have 
impaired mucosal healing (Mashimo, et al. 1996). 
There are two main theories regarding the mechanisms responsible for this protective 
function: one relies on the possibility that trefoil peptides act in a passive way, perhaps 
by enhancing the properties of the protective mucus gel covering the gastrointestinal 
epithelium; the other implies that trefoil peptides may be active via basolateral 
receptors, despite being secreted normally into the gut lumen, indicating that a receptor 
mediated response may be involved rather than a lumen-protective function. 
Following the first hypothesis, it has been proposed that trefoil peptides and mucins may 
act in a synergistic manner to protect and reconstitute epithelial tissues (Dignass, et al. 
1994; Otto and Wright, 1994; Kindon, et al. 1995). According to such a model, trefoil 
peptides and mucins would bind together to form a structure that could stabilise the 
viscoelastic gel of the protective mucus overlying the epithelium of the gut (Otto and 
Wright, 1994). This hypothesis is supported by data on the tri-dimensional structure of 
these molecules (Gajhede, et al. 1993; Carr, et al. 1994; De, et al. 1994) and on the co-
expression of trefoil peptides and mucins (Poulsom and Wright, 1993; Wright, et al. 
1993; Sands and Podolsky, 1996). TFF1 and TFF2 have been described as being co-
expressed with MUC1 in human gastric mucosa (Wright, et al. 1993), and colon 
carcinoma cell lines that express MUC2 also secrete TFF2 and TFF3 (Giraud, et al. 
1994). Curiously, in X. laevis several trefoil peptides are encoded by genes that also be;ar 
mucin core sequences (Hoffmann, 1988; Hauser, et al. 1990; Hauser and Hoffmann, 
1992), highlighting the possibility of some sort of common ancestrality, although in 
mammals no homologues are known. 
In accordance with the second hypothesis it has been shown that, in gastrointestinal 
cells, TFF3 can modulate epidermal growth factor (EGF) effects on epithelial ion 
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transport only when the basolateral surface of the cell is exposed to the peptide (Chinery 
and Cox, 1995). Furthermore, in in vitro cell models, TFF3 has been shown to be able to 
modulate its physiological function by at least two different mechanisms: induction of 
tyrosine phosphorylation of (3-catenin and epidermal growth factor receptor (EGFr) (Liu, 
et al. 1997); and inhibition of tyrosine phosphorylation of ERK (extracellular signal-
related protein kinase) (Kanai, et al. 1998). This capacity of signalling cytoplasmic 
proteins involved in signal transduction is highly suggestive of a receptor-mediated 
response, though no specific trefoil peptide receptors have been identified so far. 
Recent results suggest that the ability of trefoil peptides to act as motogens might be 
mediated through modulation of the E-cadherin/catenin complex function (Hanby, et al. 
1996; Liu, et al. 1997; Efstathiou, et al. 1998; Efstathiou, et al. 1999). E-cadherin has 
been found to be down-regulated in the reparative epithelium adjacent to ulcerative 
conditions of the gastrointestinal tract (Hanby, et al. 1996). Moreover, as mentioned 
before, in in vitro cell models TFF3 has been shown to modulate epithelial cell adhesion 
and migration through (3-catenin tyrosine phosphorylation and consequent perturbation 
of the complexes between (3-catenin, E-cadherin and associated proteins (Liu, et al. 
1997; Efstathiou, et al. 1998). In a very recent report, Efstathiou et al (1999) 
demonstrated that transfection of full-length E-cadherin cDNA into an E-cadherin 
defective colon carcinoma cell line restores responsiveness to the migratory effects 
induced by TFF2. 
Expression of trefoil peptides in cancer 
The expression of trefoil peptides has been described in carcinomas of a variety of 
organs. Table 5 summarises data on record regarding the expression of human trefoil 
peptides in carcinomas of different organs, as well as in different types of putative 
premalignant lesions. 
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Table 5 - Expression of human trefoil peptides in carcinomas of different organs, as well as in 
different types of putative premalignant lesions. 
Trefoil 
peptide 
Organ Description References 
TFF1 
TFF2 
TFF3 
Stomach Carcinoma: diffuse > 
intestinal 
Small intestine Gastric metaplasia 
Large intestine Carcinoma 
Hyperplastic polyps 
Adenoma 
Pancreas Carcinoma 
Lung Adenocarcinoma 
Endometrium Carcinoma 
Ovary Mucinous carcinoma 
Prostate Carcinoma 
Urinary bladder Carcinoma 
Gall bladder Carcinoma 
Oesophagus Carcinoma 
Barrett's metaplasia 
Skin Mucinous carcinoma 
Breast Carcinoma 
Stomach Carcinoma 
Small intestine Gastric metaplasia 
Large intestine Adenoma 
Hyperplastic polyps 
Pancreas Carcinoma 
Gall bladder Carcinoma 
Oesophagus Barrett's metaplasia 
Large intestine Carcinoma 
Adenoma 
Hyperplastic polyps 
Skin Mucinous carcinoma 
Breast Carcinoma 
(Luqmani, et al. 1989; Henry, et al. 
1991;Theisinger, étal. 1991;Muller 
and Borchard, 1993) 
(Hanby, etal. 1993a; Khulusi, etal. 
1995) 
(Hanby, etal. 1993c; Welter, etal. 
1994; Taupin, et al. 1996; Labouvie, et 
al. 1997) 
(Welter, etal. 1992) 
(Higashiyama, et al. 1994) 
(Henry, et al. 1991) 
(Dante, etal. 1994) 
(Bonkhoff, et al. 1995) 
(Lipponen and Eskelinen, 1994) 
(Seitz, etal. 1991) 
(Hanby, et al. 1994; Labouvie, et al. 
1999) 
(Hanby, etal. 1998) 
(Foekens, etal. 1990; Cappelletti, etal. 
1992) 
(Theisinger, etal. 1991) 
(Hanby, etal. 1993a; Khulusi, etal. 
1995) 
(Hanby, etal. 1993c; Taupin, etal. 
1996) 
(Welter, et al. 1992) 
(Theisinger, etal. 1991) 
(Hanby, et al. 1994; Labouvie, et al. 
1999) 
(Hanby, et al. 1993c; Taupin, et al. 
1996) 
(Hanby, etal. 1998) 
(Theisinger, et al. 1996; May and 
Westley, 1997;Poulsom, etal. 1997) 
The most widely studied trefoil peptide in cancer is TFF1, probable because it was the 
first human trefoil peptide to be discovered and because it was discovered in tumour 
cells of the breast carcinoma cell line MCF-7 (Masiakowski, et al. 1982). In human 
breast carcinoma, TFF1 expression can be detected in more than 50% of the tumours 
and is associated, though not exclusively, with oestrogen receptor expression (Rio, et al. 
1987; Skilton, et al. 1989; Pallud, et al. 1993), responsiveness to hormone therapy 
(Henry, et al. 1990) and favourable prognosis (Foekens, et al. 1990; Cappelletti, et al. 
1992). Other tumours found to express TFF1 include carcinomas occurring in different 
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organs: pancreas (Welter, et al. 1992), lung (Higashiyama, et al. 1994), endometrium 
(Henry, et al. 1991), ovary (mucinous carcinoma) (Dante, et al. 1994), prostate 
(Bonkhoff, et al. 1995), urinary bladder (Lipponen and Eskelinen, 1994), billiary tract 
(Seitz, et al. 1991), colorectum (Welter, et al. 1994; Labouvie, et al. 1997), oesophagus 
(Labouvie, et al. 1999) and skin (mucinous carcinoma) (Hanby, et al. 1998) (Table 5). 
In gastric carcinoma the expression of TFF1 has been described by several authors 
(Luqmani, et al. 1989; Henry, et al. 1991; Theisinger, et al. 1991; Millier and Borchard, 
1993) in a frequency ranging from 48% to 57%. Theisinger et al (1991) reported an 
association between the expression of TFF1 and the diffuse type of gastric carcinoma 
and Miiller and Borchard (1993) found an association between TFF1 expression and the 
extent of tumour growth. 
TFF2 expression in human carcinomas has been less extensively studied, but expression 
of this trefoil peptide has been reported in stomach (Theisinger, et al. 1991), billiary 
tract (Seitz, et al. 1991) and pancreatic carcinoma (Welter, et al. 1992) (Table 5). 
TFF3 is the most recently discovered trefoil peptide, and this fact is reflected in the 
scarce number of studies on its expression in human malignancies: TFF3 expression has 
been detected in colorectal carcinomas, associated with loss of differentiation and co-
localising with mucin (Taupin, et al. 1996); in skin mucinous carcinoma (Hanby, et al 
1998); as well as in breast carcinoma (Theisinger, et al. 1996; May and Westley, 1997; 
Poulsom, et al. 1997), where it co-localises with TFF1 (Poulsom, et al. 1997) (Table 5). 
TFF3 expression in breast, like expression of TFF1, is under control of oestrogen 
receptor (May and Westley, 1997). 
Besides their expression in human carcinomas and in ulcerative conditions of the 
gastrointestinal tract, trefoil peptides were shown to be expressed in several types of 
benign neoplastic lesions of the gastrointestinal epithelium. In Barrett's oesophagus 
(Hanby, et al. 1994; Labouvie, et al. 1999) and in duodenal gastric metaplasia (Hanby, 
et al. 1993a; Khulusi, et al. 1995) both TFF1 and TFF2 expression was observed with a 
pattern resembling that of the native gastric epithelium and UACL: expression of TFF1 
in the upper ducts and surface cells and expression of TFF2 in acinar cells and lower 
ducts. 
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In colorectal hyperplastic polyps and adenomas, the expression of all three trefoil 
peptides has been detected (Hanby, et al. 1993c; Taupin, et al. 1996) (Table 5); 
interestingly, and similarly to what has been described for TFF2 in gastric foveolar 
epithelium (Hanby, et al. 1993b), TFF2 and TFF3 mRNA is detectable in colorectal 
hyperplastic polyps despite the absence of expression of the respective proteins. 
Despite all the evidence pointing to an association between altered trefoil peptides 
expression and cancer development, the biological role of these proteins in 
tumourigenesis remains unclear. Experimental evidence for a role in tumour suppression 
comes from studies using knockout mice lacking the BCEI gene (Lefebvre, et al. 1996). 
Homozygous animals showed decreased and dysfunctional gastric mucin production 
with marked antral hyperplasia and dysplasia; all such animals developed antral 
adenomas and 30% developed multifocal intramucosal carcinomas. Recently, Familari 
et al (1998) demonstrated that trefoil peptides are early markers of epithelial cell 
maturation in the developing rat gut and suggested they may play a role in epithelial cell 
differentiation. These findings suggest that the BCEI gene rather than acting directly in 
tumour suppression at a genetic level may act, indirectly, via maintenance of a normal 
tissue differentiation. 
It remains to be seen if the ability of trefoil peptides to act as motogens may play any 
role in the mechanisms of invasion and metastisation of neoplastic cells. Noteworthy, 
among several cancer types surveyed, carcinoma of the pancreas — a very aggressive 
type of tumour — has the highest rate of TFF1 -positive tumours (Henry, et al. 1991; 
Welter, et al. 1992). In breast cancer, however, in which TFF1 has been studied in great 
detail, no convincing evidence was provided regarding a putative relationship between 
TFF1 expression and invasive/metastatic abilities of the tumours (Poulsom, et al. 1997). 
It seems clear that tumours presenting alteration of trefoil peptides expression should be 
divided in two main groups: those arising in organs without native expression of trefoil 
peptides, where the expression of these proteins constitutes a de novo event; and those 
arising in organs in which trefoil peptides are constitutivelly expressed, where the 
tumours either maintain or exhibit a (partial or complete) loss of the expression of these 
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proteins. Although the biological importance of trefoil peptides expression remains 
unclear for both groups, probably it is different in each of them. 
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E-cadherin 
General features 
E-cadherin belongs to the cadherin family of calcium dependent cell adhesion molecules 
(Takeichi, 1991). Together with other families of cell adhesion molecules, the cadherins 
play an essential role in biological processes such as ordering of cell sorting, migration 
and differentiation, regulation of inter- and intracellular signalling and control of gene 
transcription (Takeichi, 1991; Kemler, 1993; Ilyas and Tomlinson, 1997). 
Classically, three main groups of cadherins have been defined: E-cadherin, found in 
epithelial tissues and also known as uvomorulin, cell CAM 120/80, Arc-1 or L-CAM 
(Nagafuchi, et al. 1987; Mansouri, et al. 1988); P-cadherin, found primarily in placenta 
(Nose, et al. 1987; Shimoyama, et al. 1989); and N-cadherin, found in neural tissues and 
muscle (Hatta, et al. 1988; Miyatani, et al. 1989). This initial classification has rapidly 
expanded along with the identification of other molecules (e.g. M-cadherin, desmoglein 
and desmocollin), which share protein sequence similarities with cadherins (Heimark, et 
al. 1990; Koch, et al. 1990; Donalies, et al. 1991; Buxton and Magee, 1992). Each of 
the subclasses of cadherins displays a unique pattern of tissue distribution and, in many 
types of cells, several types of cadherins are co-expressed in varying combinations 
(Takeichi, 1988; Takeichi, 1990). 
Cadherins are transmembrane cell-cell adhesion molecules that bind to one another by 
means of homophilic interactions (Takeichi, 1991). Intracellularly, they attach to 
catenins which link the cytoplasmic domain of the cadherins to intermediate filaments 
of the cytoskeleton (Fig. 4) (Kemler, 1993). The expression of these molecules is 
developmentally regulated and the segregation and remodelling of embryonic tissues is 
associated with sequential expression of different cadherin molecules (Takeichi, 1988; 
Takeichi, 1990). The importance of cadherins in establishing and maintaining 
intercellular connections is reinforced by the fact that as long as cadherins are 
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functioning, inactivation of other adhesion systems seems to have little effect on cell-
cell adhesion (Duband, et al. 1987; Larjava, et al. 1990). 
Cadherins are involved both in junctional and nonjunctional adhesion mechanisms and 
are localised in lateral cell-cell contacts and enriched in the zonula adherens and 
desmosomal junctions (Fig. 4). 
Junctional adhesion 
mechanisms 
Nonjunctional adhesion 
mechanisms 
Fig. 4 - In junctional cell-cell adhesion mechanisms, cadherins are localised in zonula adherens, forming 
the adhesion belt, and in desmosomes; in nonjunctional adhesion mechanisms cadherins are dispersed 
along the lateral cell membrane with other types of cell adhesion molecules. The extracellular part of the 
cadherin molecules binds homophilically to one another and the cytoplasmic part is connected to 
intermediate filaments through catenins. Adapted after Alberts et al (1994). 
Expression ofE-cadherin in normal tissues 
The cell-cell adhesion molecule E-cadherin plays an essential role in morphogenesis and 
in the formation and maintenance of the normal architecture and function of epithelial 
tissues (Takeichi, 1991; Takeichi, 1995). Studies conducted in mice models show that, 
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in early development, E-cadherin first functions as an adhesion component during 
compaction of blastomers (Hyafil, et al. 1981; Takeichi, 1991); at later stages, it is 
confined to epithelial tissues, localised in lateral cell-cell contacts and enriched in the 
zonula adherens (Eidelman, et al. 1989; Takeichi, 1991). 
Structure of the E-cadherin gene and protein 
The human E-cadherin locus, denominated CDH1, contains 16 exons (Fig. 5), bridges a 
region of 100 kbp (Berx, et al. 1995b) and maps on chromosome 16q22.1 (Mansouri, et 
al. 1988; Natt, et al 1989; Berx, étal. 1995b). 
SIG PRE EC TM CP 
S Ca24 binding sequences 
| HAV sequence 
H] Catenin binding domain 
Fig. 5 - Schematic structure of the E-cadherin protein. In its precursor form E-cadherin is 882 amino 
acids long; after cleavage of the signalling sequence (SIG) and precursor sequence (PRE), the mature 
form of E-cadherin encompasses 729 amino acids and contains a cytoplasmic part (CP), a transmembrane 
domain (TM), and an extracellular part (EC), the latter with five repeated cadherin domains. The exonic 
structure of the E-cadherin mRNA is marked below the drawing. Adapted after Berx et al (1995a). 
E-cadherin is synthesised from a 4.5 kb mRNA as a 135 kDa precursor polypeptide 
which is rapidly (two hours) and efficiently (100%) processed to the mature 120 kDa 
form (Shore and Nelson, 1991). It is delivered in its mature form to the cell surface, 
where it exists as a dimer and has a half-life of about 5 hours (Shore and Nelson, 1991). 
The mature E-cadherin is an integral membrane glycoprotein with a single membrane 
spanning domain and an extracellular part (N-terminal) that is implicated in homophilic 
binding (Fig. 5); the cytoplasmic domain (C-terminal) is noncovalently linked to 
catenins through a catenin binding domain (Fig. 5) (Kemler, 1993). 
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The extracellular part of E-cadherin is largely composed of five homologous repeated 
domains, known as cadherin domains, each containing about 110 amino acid residues 
(Fig. 5) (Kemler, 1993). Each cadherin domain contains two highly conserved calcium 
binding motifs, formed by four calcium binding sequences (Fig. 6) and found at similar 
locations in all cadherins (Kemler, 1993). These motifs play a key role in the correct 
folding and dimerisation of these proteins as well as in the adhesion mechanism itself 
(Overduin, etal. 1995; Shapiro, et al. 1995; Nagar, et al. 1996). The homophilic binding 
specificity of cadherins appears to be governed by their N-terminal cadherin domain 
through a surface that includes the HAV motif (Overduin, et al. 1995) (Figs. 5 and 6); 
however, recent data demonstrates that besides homophilic homotypic interactions, E-
cadherin can also establish homophilic heterotypic (Tang, et al. 1993) and heterophils: 
heterotypic (Cepek, et al. 1994) interactions. 
Fig. 6 - A schematic drawing of E-cadherin molecules presented by two cells. On the left side cadherin 
domains are depicted as barrels and calcium ions are represented by spheres that are sandwiched between 
tandem cadherin domains by the four calcium binding sequences (DAD, DQND, PENE and LDRE) seen 
in the enlargement of cadherin domains 1 and 2 on the right side. The HAV-containing surface on the 
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cadherin 1 domain contributes to homophilic binding specificity between cadherins. C, cytoplasmic 
domain; CYT, cytoplasm; E-CADn, cadherin domains. Adapted after Overduin et al (1995). 
The role ofE-cadherin in the epithelial cell-cell adhesion system 
E-cadherin is only part of a complex cell adhesion system and its function is dependent 
on the interaction of its conserved cytoplasmic domain with the cytoskeleton via 
molecular complexes involving a-, |3- and y-catenin (Fig. 7). Both P-catenin and y-
catenin/plakoglobin are members of the armadillo protein family (Aberle, et al. 1996) 
and link E-cadherin via a-catenin (member of the vinculin family) to the actin 
cytoskeleton. Another catenin, pl20ctn, which was originally identified as a substrate of 
Src and several receptor tyrosine kinases, also interacts with the cytoplasmic domain of 
E-cadherin, but its function remains unclear (Fig. 7) (Reynolds, et al. 1994). This 
mechanism allows E-cadherin to be directly involved in the cell-cell adhesion process 
and in nuclear signalling via catenins and the cytoskeleton; furthermore, E-cadherin 
participates in the regulation of the levels of (3-catenin in the cytoplasm, which in turn 
functions in the Wnt signal transduction pathway (Miller and Moon, 1996; Barth, et al. 
1997; Gumbiner, 1997). 
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Fig. 7 - Schematic overview of the E-cadherin-catenin-cytoskeleton complex at the plasma membrane 
(PM) of two neighbouring cells. The N-terminal ends of E-cadherin dimers extend into the intercellular 
space, where they interact in a homophilic zipper-like fashion with similar E-cadherin dimers (dark 
globules), extending from the opposing cell surface. Calcium ions are essential for the correct 
conformation and functionality of the cadherins. The C-terminal ends of the E-cadherin molecules extend 
into the cytoplasm. These domains associate with the catenins ((3-catenin, y-catenin/plakoglobin, pl20ctn). 
Disk-like structures in the latter molecules represent armadillo tandem repeats. The P-catenin and 
plakoglobin molecules in turn associate with a-catenin. This latter forms the molecular link to the F-actin 
microfilaments, either directly or via a-actinin. P, phosphorylation on Ser or Tyr residues. Adapted after 
Vermeulen et al (1996) and Berx et al (1998). 
I^oss of E-cadherin function in human cancer 
Given the essential role of E-cadherin in the processes of cellular adhesion, migration 
and growth control, it has been postulated that changes in expression or function of E-
cadherin may account for the ability of cancer cells to detach from the parent tumour 
structure and invade locally. In fact, aberrant expression, reduction and/or loss of 
expression of E-cadherin have been observed in several types of carcinoma, and 
frequently associated with poorly differentiated/undifferentiated carcinomas and/or 
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invasive tumours, including carcinomas of the colon (Dorudi, et al. 1993), prostate 
(Umbas, et al. 1997), breast (Moll, et al. 1993), bladder (Bringuier, et al. 1993; Hong, et 
al. 1995), pancreas (Pignatelli, et al. 1994), oesophagus (Jankowski, et al. 1994; 
Krishnadath, et al. 1997), stomach (Mayer, et al. 1993; Shino, et al. 1995; Gabbert, et 
al. 1996; Jawhari, et al. 1997), head and neck (Schipper, et al. 1991), cervix (Vessey, et 
al. 1995) and thyroid (Soares, et al. 1997). 
Loss of expression of E-cadherin has been associated with mutations of the E-cadherin 
gene CDH1 and/or loss of heterozygosity (LOH) in 16q22.1, that have been reported in 
diffuse gastric carcinoma (Becker, et al. 1994; Muta, et al. 1996; Guilford, et al. 1998), 
lobular carcinoma of the breast (Berx, et al. 1995a; Berx, et al. 1996), colon carcinoma 
(Efstathiou, et al. 1999) and carcinomas of the endometrium and ovary (Risinger, et al. 
1994). These findings support a role of E-cadherin as a tumour and/or invasion 
suppressor gene, as previously suggested by in vitro observations demonstrating that 
transfection of invasive E-cadherin-negative cell lines with vectors which express fully 
functional E-cadherin results in loss of invasive features (Frixen, et al. 1991; 
Vleminckx, et al. 1991). 
Loss of E-cadherin function can, however, occur in the absence of CDH1 mutation: 
mutation of other members of the cadherin/catenin complex, such as a- and P-catenin, 
can abolish E-cadherin mediated adhesion (Morton, et al. 1993; Oyama, et al. 1994); 
and phosphorylation of P-catenin renders it useless for cell adhesion. This later effect 
has been shown for EGFr (Hoschuetzky, et al. 1994), c-erbB2 (Ochiai, et al. 1994), 
hepatocyte growth factor receptor MET (Shibamoto, et al. 1994), the oncoprotein p60irc 
(Matsuyoshi, et al. 1992; Behrens, et al. 1993), the mucin MUC1 (Yamamoto, et al. 
1997; Li, et al. 1998) and the trefoil peptide TFF3 (Liu, et al. 1997; Efstathiou, et al. 
1998) which can either phosphorylate or induce phosphorylation of P-catenin; in 
addition, transcriptional silencing of CDH1 by methylation of the promoter leads to 
down-regulation of E-cadherin expression in some tumours (Graff, et al. 1995; Hennig, 
et al. 1995; Yoshiura, étal. 1995). 
In support of an important role of the E-cadherin/catenin complex during tumour 
development is the interaction of P-catenin with the adenomatous polyposis coli (APC) 
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tumour suppressor protein (Su, et al. 1993). Truncation mutants of APC, as frequently 
found in colon tumours, loose their ability to regulate (3-catenin and to trigger its 
degradation, resulting in elevated cytoplasmic and nuclear concentrations of P-catenin. 
This, in turn, leads to modification of gene expression patterns, e.g. C-MYC (He, et al. 
1998), by a complex of (3-catenin with members of the TCF/LEF1 transcription factor 
family (Behrens, et al. 1996). 
Altogether, the data on record regarding the involvement of E-cadherin in different types 
of tumours support the existence of a close association between loss of function of E-
cadherin and infiltrative/invasive growth pattern of the tumours with reduced or no 
adhesion between cancer cells, features that are shared by diffuse gastric carcinoma 
(Mayer, etal. 1993; Yonemura, etal. 1995). 
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The introduction of the Thesis highlights that one of the most striking features of gastric 
carcinoma is its morphologic heterogeneity and consequent diversity of biological 
behaviours. Among the many structural patterns recognised in gastric carcinoma 
(Borrman, 1926; Lauren, 1965; Ming, 1977; Watanabe, et al. 1991; Carneiro, et al. 
1995b), two morphologie entities — with distinct epidemiological, histogenetic and 
clinicopathological profiles — emerge: the so-called intestinal and diffuse carcinoma. 
At variance with this, a relatively broad group of gastric carcinomas, displaying either a 
mixed structure — encompassing different structural components — or exhibiting a 
solid architecture, remain poorly characterised. 
Regarding cell differentiation, data from ultrastructural studies (Fiocca, et al. 1987; 
Carneiro, et al. 1992; Carneiro, 1997) and from histochemical and 
immunohistochemical analyses (Bara, et al. 1981; Tatematsu, et al. 1986; Fiocca, et al. 
1988a; Fiocca, et al. 1988b; Fiocca, et al. 1990; Kushima, et al. 1993; Kushima and 
Hattori, 1993; Carneiro, 1997; Yamachika, et al. 1997) show that gastric carcinoma 
exhibits, alone or in combination, two main types of cell differentiation — gastric and 
intestinal. 
When we started this study, in 1994, several molecular changes had been identified in 
gastric carcinoma (Lemoine, et al. 1992; Seruca, et al. 1992; Wright and Williams, 
1993; Carneiro, et al. 1994; Corrêa and Shiao, 1994; David, et al. 1994; Seruca, et al. 
1995; Santos, et al. 1996; Tahara, 1995; Amado, et al. 1998), suggesting that there is a 
molecular counterpart for each of the two main types of gastric carcinoma. However, by 
that time, the molecular change(s) underneath the establishment of the two distinct 
structural patterns of gastric carcinoma — gland-forming or diffuse growth pattern — 
were not clearly identified. 
Taking all these aspects into account, the present study was elaborated in order to 
address the following four topics: 
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1 - Study of the pattern of cell differentiation along the process of gastric 
carcinogenesis. 
In this part of the study we aimed at characterising the cell differentiation patterns of 
gastric carcinoma and different premalignant lesions of the stomach, namely chronic 
atrophic gastritis, intestinal metaplasia and gastric polyps, in an attempt to see if this 
approach might contribute to the clarification of the histogenesis and cell differentiation 
of gastric carcinoma. 
In order to accomplish this goal we evaluated the expression patterns of the two stomach 
specific trefoil peptides (TFF1 and TFF2) in the aforementioned lesions. Furthermore, 
the expression patterns of gastric trefoil peptides were co-analysed with those of two 
gastric mucins MUC5AC and MUC6, the intestinal mucin MUC2 and the more 
ubiquitous MUC1 mucin. 
2 - Analysis of molecular events underlying the intestinal and diffuse histotype of 
gastric carcinoma. 
Shortly before the starting of the present study, alterations at the structural and 
expression levels of E-cadherin were described in sporadic diffuse-type gastric 
carcinoma (Becker, et al. 1993; Becker, et al. 1994), suggesting that this molecule could 
play a major role in the carcinogenesis of diffuse carcinoma. 
Having this in mind we analysed E-cadherin changes in different types of gastric 
carcinoma. Our aim was twofold: to study the patterns of expression of E-cadherin at the 
protein level and to clarify, at the gene level, the alterations behind altered expression; 
to see, whether or not, the study of E-cadherin changes could shed some light into the 
elucidation of the molecular mechanisms underlying the dichotomic structural pattern of 
gastric carcinoma, expressed in its two main histotypes — intestinal and diffuse. 
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3 - Analysis of some molecular and phenotypic features underlying mixed gastric 
carcinoma. 
The morphologic heterogeneity of gastric carcinomas is also reflected in individual 
cases; many gastric carcinomas are pluriform, displaying two or more distinct 
components. Most classifications overcome this aspect by grouping gastric carcinomas 
according to the predominant component of the tumours (Nakamura, et al. 1968; 
Mulligan, 1972; Watanabe, et al. 1991) and only a few authors stress the existence of 
gastric carcinomas with mixed morphologic patterns (Lauren, 1965; Carneiro, et al. 
1995b). 
As a consequence, the available knowledge on the biopathology of mixed gastric 
carcinoma is scarce and it is still unknown if these tumours derive from carcinomas with 
a "pure" histological type (and, if yes, from which type) or if they originate ab initio as 
mixed carcinomas. 
In an attempt to contribute to the clarification of the nature of mixed gastric carcinomas, 
we performed a comparative study of the intestinal and diffuse histological components 
of these tumours. The comparison was focused on the analysis of cell differentiation 
(expression pattern of trefoil peptides and mucins) and on the search of molecular 
events putatively related with the phenotypic (structural) divergence of the tumours (E-
cadherin alterations). 
4 - Re-evaluation of the histogenetic pathways leading to intestinal, diffuse and 
mixed gastric carcinoma. 
Finally, our ultimate goal was to integrate all the information drawn from the 
aforedescribed studies and to provide additional evidence in order to progress in the 
understanding of the histogenetic pathways leading to intestinal, diffuse and mixed 
gastric carcinoma. 
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Material and Methods 
The methods used in the different studies are described in detail in Papers I to VI. 
Briefly, the following methods were used: 
Immunohistochemistry (IHC) - Avidin-biotin-peroxidase method used in the studies of 
the expression of the trefoil peptides TFF1 (Papers I - IV) and TFF2 (Papers ED and TV), 
the mucins MUC1, MUC2, MUC5AC and MUC6 (Papers m and IV) and E-cadherin 
(Paper V). 
Histochemical methods - Periodic acid Schiff (PAS), alcian blue pH 2.5/PAS (AB/PAS) 
and alcian blue pH 2.5/high iron diamine (HTD/AB), used in the histochemical 
characterisation of mucins (Paper I). 
Immunoradiometric assay (IRMA) - Used for the quantification of TFF1 protein 
expression (Paper II). 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) - Used for the semi-
quantification of TFF1 and TFF2 mRNA expression (Paper III). 
Polymerase Chain Reaction (PCR) - Used in the LOH analysis and mutation screening 
of the CDZ/7/E-cadherin gene (Paper VI). 
Single Strain Conformation Polymorphism (SSCP) - Used in the mutation screening of 
the CDHi/E-cadherin gene (Paper VI). 
Sequencing - Used in the automated DNA sequencing of the CD//i/E-cadherin gene 
(Paper VI). 
Statistical analysis - Pearson %2 test (papers I - VI), unpaired Student's Mest (Paper II), 
Mann-Whitney U test (Paper H), Kaplan-Meier survival curves (Papers II and V), 
Mantel-Cox test (Papers II and V), Cox's proportional hazards model (Paper V) and 
MPLR (maximum partial likelihood ratio) method (Paper V). 
The biological material included in the different studies is described in papers I-VI; due 
to the diversity of the lesions included in each of these studies, their description will 
now be omitted. 
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The results are documented in detail in papers I to VI. In this section, a summary will be 
presented stressing the most interesting findings in relation to the issues raised in the 
Aims section. 
Expression of TFF1 in premalignant lesions of the stomach and in gastric 
carcinoma (Papers I and II). 
Normal mucosa and chronic atrophic gastritis 
TFF1 was expressed throughout foveolar and superficial epithelium of normal gastric 
mucosa and this pattern was retained in chronic atrophic gastritis, out of intestinal 
metaplasia (IM) lesions. 
Intestinal metaplasia 
In IM, TFF1 expression was observed in every case. Furthermore, there was a clear 
difference between complete and incomplete BVI types: in complete type EVI, TFF1 
expression was restricted to goblet cells, whereas in incomplete type IM TFF1 was 
expressed both in goblet and columnar cells. 
Gastric polyps 
In hyperplastic polyps of the stomach, TFF1 was expressed in every case (Table 6). In 
gastric adenomatous polyps, TFF1 expression was found in eight out of 11 cases 
(72.7%) (Table 6). 
The percentage of cases expressing TFF1 in the majority of cells was. significantly 
higher (p=0.0002) in hyperplastic polyps than in adenomatous polyps (Table 6). 
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Table 6: Relationship between TFF1 immunoreactivity and gastric polyp type. 
Polyps % of immunoreactive cells 
<50% >50% 
Hyperplastic (n=10) 
Adenomatous (n=l 1) 
0 (0) 0 (0) 10(100) 
3(27.3) 7(63.6) 1(9.1) 
p value=0.0002 
Gastric carcinoma 
In gastric carcinomas, TFF1 immunostaining was observed in 33 out of 50 cases 
(66.0%): in 16 out of 18 (88.9%) diffuse carcinomas and in 15 out of 28 (53.6%) 
intestinal carcinomas. This difference was found to be statistically significant (p=0.037) 
(Table 7). 
Table 7: Relationship between the histological type of gastric carcinomas and TFF1 
expression. 
No. of cases (%) 
TFF1IHC 
Histological type Negative Positive p value 
Intestinal 28 (56.0) 13 (46.4) 15 (53.6) 
Diffuse 18 (36.0) 2(11.1) 16 (88.9) 0.037 
Unclassifiable 4 (8.0) 2 (50.0) 2 (50.0) 
Total 50(100) 17 (34) 33 (66) 
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Co-expression of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, 
MUC5AC and MUC6) in gastric polyps and in gastric carcinoma (Papers HI and 
IV). 
Gastric polyps 
In hyperplastic polyps, TFF1, MUC1 and MUC5AC were detected in every case. TFF2 
expression was not observed in any case. Two cases presented focal MUC2 expression 
and MUC6 immunoreactivity was detected in another two cases (Table 8). 
In adenomatous polyps, TFF1 expression was observed in 16 cases (84.2%); TFF2 
expression was not detected in any case; MUC1 was detected in 14 cases (73.7%); 
MUC2 expression was found in seven cases (36.8%); MUC5AC expression was 
observed in nine cases (47.4%), all of them co-expressing TFF1 and MUC1; and MUC6 
was expressed in 7 cases (36.8%), all of them displaying also TFF1, MUC1 and 
MUC5AC immunoreactivity (Table 8). 
Table 8- Pattern of expression of trefoil peptides and mucins in hyperplastic and adenomatous 
polyps. 
Number of positive cases (%) 
Polyps TFF1 TFF2 MUC1 MUC2 MUC5AC MUC6 
Hyperplastic 10(100%) 0 (0%) 10(100%) 2 (20%) 10(100%) 2 (20%) 
(n=10) 
Adenomatous 16(84.2%) 0(0%) 14(73.7%) 7(36.8%) 9(47.4%) 7(36.8%) 
(n=19) 
Gastric carcinoma 
TFF1 and TFF2 expression was observed, respectively, in 64 cases (66.7%) and in 10 
cases (10.4%) of 96 gastric carcinomas; MUC1 was detected in 79 cases (82.3%); 
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MUC2 immunoreactivity was seen in 22 cases (22.9%); expression for MUC5AC was 
detected in 61 cases (63.5%); and MUC6 immunoexpression was found in 36 cases 
(37.5%) (Table 9). 
Table 9 - Comparison between the immunoexpression pattern of trefoil peptides and mucins and the 
histological type of 96 gastric carcinomas. 
Histological type IHC positive cases (%) 
TFF1 TFF2 MUC1 MUC2 MUC5AC MUC6 
Diffuse ca (n = 33) 25 (75.8) 5(15.2) 24 (72.7) 8 (24.2) 23 (69.7) 8 (24.2) 
Intestinal ca (n = 53) 30(56.6) 4(7.5) 46(86.8) 11(20.8) 29(54.7) 22(41.5) 
Unclassifiable ca (n = 10) 9(90.0) 1(10.0) 9(90.0) 3(30.0) 9(90.0) 6(60.0) 
p value 0.05 NS NS NS 0.07 NS 
Total (n = 96) 64 (66.7) 10(10.4) 79 (82.3) 22 (22.9) 61 (63.5) 36 (37.5) 
NS, Not significant. 
The comparison between the immunohistochemical expression of the antigens under 
study and the histological classification of the tumours revealed a significant association 
(p=0.05) between the expression of TFF1 and the diffuse and unclassifiable histological 
types (Table 9). A suggestive association (p=0.07) was observed between MUC5AC 
expression and the diffuse and unclassifiable histotype (Table 9). No relationship was 
found between the expression of TFF2, MUC1, MUC2 or MUC6 and the histotype of 
the tumours. 
Pattern of cell differentiation 
The definition of the patterns of cell differentiation was based upon the expression of 
trefoil peptides and mucins typically expressed in the superficial zone of normal gastric 
mucosa. Three main phenotypes were defined: 1) complete gastric phenotype — co-
expression of TFF1 and MUC5AC regardless of the expression of TFF2 and MTJC6; 2) 
incomplete gastric phenotype — expression of either TFF1 or MUC5AC regardless of 
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the expression of TFF2 and MUC6; 3) non-gastric phenotype — no expression of TFF1, 
TFF2, MUC5AC and MUC6. 
Gastric polyps 
All hyperplastic polyps exhibited a complete gastric phenotype (Table 10). In 
adenomatous polyps three main phenotypes could be identified: complete gastric 
phenotype — 9 cases (47.4%); incomplete gastric phenotype — 7 cases (36.8%); and 
non-gastric phenotype — 3 cases (15.8%) (Table 10). 
Table 10 - Pattern of cellular differentiation in hyperplastic and adenomatous polyps. 
Phenotype (%) 
Polyps Complete gastric Incomplete gastric Non-gastric 
Hyperplastic (n=10) 
Adenomatous (n=19) 
10(100%) 
9 (47.4%) 
0 (0%) 
7 (36.8%) 
0 (0%) 
3 (15.8%) 
Gastric carcinoma 
According to the expression pattern of trefoil peptides and mucins, 50 cases (52.1%) 
presenting co-expression of TFF1 and MUC5AC were identified as complete gastric-
type. Incomplete gastric phenotype was observed in 28 cases (29.2%). Lack of 
expression of TFF1, TFF2, MUC5AC and MUC6 was found in the remaining 18 cases 
(18.7%), therefore identified as non-gastric phenotype (Table 11). 
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Table 11 - Comparison between phenotypic differentiation and histological type of gastric 
carcinomas. 
Histology 
Cases 
Phenotype (%) 
Complete Incomplete Non- p value 
(%) Gastric gastric gastric 
Diffuse ca 33 (34.4) 18 (54.5) 12 (36.4) 3(9.1) 
Intestinal ca 53 (55.2) 24 (45.3) 14 (26.4) 15 (28.3) 0.06 
Unclassifiable ca 10(10.4) 8 (80.0) 2 (20.0) 0(0) 
Total 96(100) 50(52.1) 28 (29.2) 18(18.7) 
The prevalence of MUC1 expression was similar in the three phenotypes: in 44 out of 
50 cases (88.0%) with complete gastric-type differentiation; in 22 out of 28 cases 
(78.6%) presenting incomplete gastric-type differentiation; and in 13 out of 18 cases 
(72.2%) classified as non-gastric phenotype. The same holds true regarding the 
expression of MUC2, which was seen in 14 out of 50 cases (28.0%) displaying complete 
gastric phenotype; in six out of 28 cases (21.4%) presenting incomplete gastric-type 
differentiation; and in two out of 18 cases (11.1%) with non-gastric phenotype. 
The comparison between the histological type of the cases and the phenotype disclosed 
a suggestive association (p=0.06) between the diffuse and unclassifiable histotypes and 
the gastric (complete and incomplete) phenotype, and between the intestinal histotype 
and non-gastric type of differentiation (Table 11). 
Most of the early tumours were identified as complete gastric-type (8/13 - 61.5%) or 
incomplete gastric-type (4/13 - 30.8%) and only one early tumour, with intestinal 
histotype, was found to present a non-gastric phenotype (7.7%) (Table 12); in contrast to 
this, in the group of advanced tumours, 17 out of 83 cases (20.5%) had a non-gastric 
phenotype (Table 12); these differences did not attain, however, the threshold of 
statistical significance (p=0.53) (Table 12). The same holds true regarding MUC2 
expression, which was found to be more prevalent, though not significantly, in advanced 
tumours than in early tumours (p=0.16) (Table 13). 
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Table 12 - Comparison between phenotypic differentiation and extent of tumour growth of 
gastric carcinomas, according to the histological type. 
T stage 
Cases 
Phenotype (%) 
Complete Incomplete Non-gastric p value 
(%) Gastric gastric 
Diffuse 
Early 5(15.2) 3 (60.0) 2 (40.0) 0 NS 
Advanced 28 (84.8) 15(53.5) 10(35.7) 3(10.7) 
Intestinal 
Early 8(15.1) 5 (62.5) 2 (25.0) 1 (12.5) NS 
Advanced 45 (84.9) 19 (42.2) 12 (26.7) 14(31.1) 
Total 
1 
Early 13(13.5) 8 (61.5) 4 (30.8) 1 (7.7) NS 
Advanced 83 (86.5) 42 (50.6) 24 (28.9) 17 (20.5) 
NS, Not significant 
Table 13 - Comparison between MUC2 expression and extent of tumour growth of gastric 
carcinomas according to the histological type. 
T stage 
Cases (%) 
MUC2 IHC (%) 
Diffuse 
Early 5(15.2) 0(0) 5 (100) 
Advanced 28 (84.8) 8 (28.6) 20(71.4) 
Intestinal 
Early 8(15.1) 1 (12.5) 7 (87.5) 
Advanced 45 (84.9) 10 (22.2) 35 (77.8) 
Total 
Early 13 (13.5) 1 (7.7) 12 (92.3) 
Advanced 83 (86.5) 21 (25.3) 62 (74.7) 
NS, Not significant 
p value 
NS 
NS 
NS 
In figure 8 we summarised the results obtained in the present study, regarding the 
pattern of cell differentiation along the process of gastric carcinogenesis, having as 
background the model proposed by Carneiro (1997) and previously depicted in figure 2. 
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Fig. 8 - Simplified model of gastric carcinogenesis illustrating the two main pathways of malignant 
transformation, and the prevalences of complete gastric, incomplete gastric and non-gastric phenotypes 
observed in the different types of pre-malignant and malignant lesions. 
Twenty gastric carcinoma cases, classified according to the predominant histological 
type as intestinal or diffuse carcinomas, displayed small foci with a structure different 
from the main component of the tumour and were classified as mixed carcinomas. In 
most cases (n=15), the same cell differentiation pattern was observed in both 
histological components of the tumours: 11 out of 20 cases (55.0%) were evaluated as 
complete gastric-type; two cases (10.0%) were classified as incomplete gastric-type; and 
non-gastric phenotype was observed in two other cases (10.0%). 
In five mixed carcinomas (25.0%) we found phenotypic differences between the 
isolated-cell and glandular components: in two cases complete gastric-type 
differentiation was observed in the isolated-cell component, whereas in the glandular 
component we found an expression pattern compatible with incomplete gastric-type 
differentiation; in one case complete gastric-type differentiation was restricted to the 
isolated-cell component and non-gastric differentiation was observed in the glandular 
component; in the remaining two cases, the isolated-cell component of the tumours 
displayed incomplete gastric phenotype and the glandular component presented non-
gastric phenotype. 
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E-cadherin expression and gene mutations in gastric carcinoma (Papers V and VI). 
E-cadherin expression 
The pattern of E-cadherin expression was classified as normal whenever the tumours 
displayed a membranous pattern of staining. All tumours with loss of normal 
membranous pattern of staining were classified as abnormal, including absence of 
staining and diffuse cytoplasmic staining. 
A normal pattern of E-cadherin expression was observed in 13 out of 50 carcinomas 
(26.0%) of the whole series. This pattern of immunoreactivity was observed in 11/20 
(55.0%) intestinal carcinomas and in 2/28 (7.1%) diffuse carcinomas (Table 14). 
An abnormal pattern of E-cadherin staining was observed in 37 out of 50 gastric 
carcinomas (74.0%). In intestinal carcinomas we observed an abnormal pattern of E-
cadherin expression in 9/20 (45.0%) cases and in diffuse carcinomas an abnormal 
pattern of E-cadherin expression was observed in 26/28 (92.9%). The comparison of the 
results obtained in the two histotypes yielded statistically significant differences 
(p=0.0007) (Table 14). 
Table 14 - Relationship between the histological type of gastric carcinomas and E-cadherin expression 
E-cadherin IHC 
Histology No. of cases (%) Normal (%) Abnormal (%) p value 
Intestinal 20 (40.0) 11(55.0) 9 (45.0) 
Diffuse 28 (56.0) 2(7.1) 26 (92.9) 0.0007 
Unclassified 2 (4.0) 0 (0.0) 2 (100.0) 
Total 50 (100.0) 13 (26.0) 37 (74.0) 
Eighteen cases were subclassified as mixed carcinomas. In seven of these mixed 
carcinomas a normal pattern of immunoreactivity was observed in the glandular 
component and an abnormal pattern was seen in the isolated cell component. In 10 cases 
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both components of mixed carcinomas displayed an abnormal pattern of 
immunoreactivity and, in the remaining case, a normal pattern of immunostaining was 
observed in the two components. 
E-cadherin gene mutations 
E-cadherin mutations were screened in 26 cases out of the 50 cases included in the 
whole series. Fifteen mutations of the E-cadherin gene were identified in 12 cases 
(46.2%); mutations included 10 missense mutations, seven of which occurred in 
sequences coding for calcium binding motifs, three splice site mutations, one nonsense 
mutation and one frameshift deletion (Table 15). 
In a group of 10 "pure" intestinal carcinomas no mutations were found, and IHC 
analysis of these cases showed normal E-cadherin expression in eight cases and 
abnormal expression in two cases (Table 15). Out of 10 "pure" diffuse carcinomas we 
found mutations in seven cases (70.0%); every diffuse carcinoma harbouring mutations 
of the E-cadherin gene displayed abnormal E-cadherin expression (Table 15). In two 
diffuse carcinomas with abnormal expression of E-cadherin (cases 11 and 18) and in the 
single case of diffuse carcinoma presenting normal E-cadherin expression (case 19) no 
mutations were detected. 
E-cadherin mutations were detected in five of the six cases of mixed gastric carcinoma 
(83.3%) (Table 15). In four cases we detected mutation of the E-cadherin gene and 
abnormal E-cadherin expression restricted to the diffuse component of the tumours 
(cases 21, 23, 24 and 25). In case 26, we found two different mutations in the distinct 
histological components of the tumour: in the intestinal type component we identified a 
missense mutation and normal E-cadherin expression; and in the diffuse type 
component a splice site mutation was associated with abnormal expression of E-
cadherin (Table 15). In the single case without detectable E-cadherin mutations, both 
histological components exhibited normal expression of E-cadherin at the cell 
membrane (case 22). 
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A significant relationship was found between the diffuse histotype (both in "pure" and 
in mixed carcinomas) and E-cadherin mutations (p<0.0001). In 16 samples of the 
diffuse type (10 "pure" diffuse carcinomas and six diffuse components of mixed 
carcinomas) we found 12 (75.0%) samples presenting E-cadherin mutations. In contrast 
to this, only one out of the 16 samples of the intestinal type displayed an E-cadherin 
mutation (conservative missense mutation) and occurring in the intestinal component of 
a mixed carcinoma. 
Loss of heterozygosity analysis. 
All cases included in the present study were informative for at least one of the two 
microsatellite markers analysed. One case out of the 26 (3.8%) showed LOH for marker 
D16S301. In this case, a missense mutation in one of the calcium binding sequences of 
the gene was also found (Table 15, case 13). Regarding the DNA polymorphisms 
detected in this study, the same pattern was observed in tumoural and matched 
constitutional DNA. 
Results 
Table 15 - Summary of the results regarding histological type of the cases, E-cadherin mutations and 
E-cadherin expression pattern in 26 gastric carcinomas. 
Case Histologic 
al 
type 
Mutation IHC 
Exon no. Codon Nucleotide Predicted protein 
change" change 
1 Intestinal - - - - Normal 
2 Intestinal - - - - Normal 
3 Intestinal - - - - Normal 
4 Intestinal - - - - Normal 
5 Intestinal - - - - Normal 
6 Intestinal - - - - Normal 
7 Intestinal - - - - Normal 
8 Intestinal - - - - Abnormal 
9 Intestinal - - - - Abnormal 
10 Intestinal - - - - Normal 
11 Diffuse - - - - Abnormal 
12 Diffuse 8 353 1057GH>T E353X (stop) Abnormal 
13 Diffuse 8 370 1108G->C D370H (missense) Abnormal 
14 Diffuse 10 479 1436A->G D479G (missense) Abnormal 
15 Diffuse 8 343 1027delC Frameshift Abnormal 
9 402 1204G->A D402N (missense) 
16 Diffuse 12 581 1742T->C L581P (missense) Abnormal 
17 Diffuse Intron 7 - 1009-1G->A In frame deletion Abnormal 
8 347 1040C->T A347V (missense) 
18 Diffuse - - - - Abnormal 
19 Diffuse - - - - Normal 
20 Diffuse 7 334 lOOOG^C D334H (missense) Abnormal 
21 Mixed 
D 8 369 1105A-M3 N369D (missense) Abnormal 
I - - - - Normal 
22 Mixed 
D - - - - Normal 
I - - - - Normal 
23 Mixed 
D Intron 7 - 1009-1G->A In frame deletion Abnormal 
I - - - - Normal 
24 Mixed 
D 9 400 1198G->T D400Y (missense) Abnormal 
I - - - - Normal 
25 Mixed 
D 8 370 1108G^C D370H (missense) Abnormal 
I - - - - Normal 
26 Mixed 
D Intron 7 - 1009-1G->A In frame deletion Abnormal 
I 8 365 1093G->C V365L (missense) Normal 
umberin I is according ; to the cDNA starting at the A in the start codon (Antonarakis Ï998) (Genbank 
Accession no. Z13009). 
D - Diffuse component of mixed carcinoma. 
I - Intestinal component of mixed carcinoma. 
IHC - Immunohistochemistry 
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Discussion 
In this section we will discuss our results according to the proposed objectives in the 
aims. As much as possible, we will try to focus this discussion on the integration of the 
main results obtained in this study. A detailed discussion of all results is present in 
Papers I to VI. 
Pattern of cell differentiation along the process of gastric carcinogenesis 
TFF1 expression 
In the first two papers included in this study, we characterised the expression of TFF1 
along the process of gastric carcinogenesis. Our findings in normal gastric mucosa 
confirmed those previously reported by other authors (Rio, et al. 1988; Luqmani, et al. 
1989; Hanby, et al. 1993b; Millier and Borchard, 1993): TFF1 expression was detected 
in the foveolar and superficial epithelium of gastric mucosa, both in the antrum and 
body/fundus. The expression of TFF1 in gastric epithelium in chronic gastritis was 
similar to that observed in normal mucosa. 
TFF1 immunostaining was found in every case of EVI, and we observed that the features 
of TFF1 expression in metaplastic lesions were specific of EV1 type; in complete EVI, 
TFF1 expression was restricted to goblet cells and, in types II and IH incomplete M , the 
staining was observed both in goblet and columnar cells. 
These results challenge the sequential evolution of complete to incomplete EVI types, 
along the process of malignant transformation of gastric mucosa, as suggested in the 
Correa's model of gastric carcinogenesis (Corrêa, et al. 1990a; Corrêa, et al. 1990b; 
Corrêa, 1992), which is based mainly upon epidemiological evidence. Although 
realising the limitations of our study to address such a problem we think we have 
obtained enough data to claim that in contrast to complete EM, incomplete EVI "still" 
displays features of gastric differentiation, as shown by TFF1 immunostaining in 
columnar mucus-secreting cells. We feel thus tempted to advance that complete and 
incomplete types of EvI may represent two alternative pathways of metaplastic change in 
gastric mucosa, rather than two successive steps of phenotypic changes, with complete 
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1M leading to incomplete IM, as suggested in Correa's model. This hypothesis is 
supported by the recent results of Reis et al (1999), showing that complete IM lacks 
expression of the gastric mucins MUC5AC and MUC6, while the incomplete forms of 
IM express MUC5AC in every case and MUC6 in 65.9% of the cases. It remains 
unclarified, however, if the different IM types represent peculiar responses to different 
environmental factors or specific adaptations related to physiopathological conditions of 
the gastric epithelium. 
We observed a clear difference between TFF1 expression in hyperplastic and 
adenomatous polyps, the former displaying a pattern of TFF1 expression which was 
similar to that observed in normal foveolar and surface epithelium of gastric mucosa. 
These results fit with the assumption that hyperplastic polyps represent proliferative 
epithelial lesions which are phenotypically similar to normal gastric epithelium. 
At variance with hyperplastic polyps, which display TFF1 immunoreactivity in 100% of 
the cases, TFF1 was detected in 72.7% of the adenomatous polyps and, in the positive 
cases, the percentage of immunoreactive cells was significantly lower than in 
hyperplastic polyps. This down-regulation of TFF1 expression in adenomatous lesions is 
in keeping with the assumption that adenomatous polyps may serve as precursor lesions 
of gastric carcinoma of intestinal type, in which we also observed a reduced expression 
ofTFFl. 
In gastric carcinomas we found TFF1 expression in about 66% of the cases, and we 
observed a significantly higher frequency of TFF1 immunoreactivity in diffuse 
carcinomas than in intestinal carcinomas. These findings concur with those of 
Theisinger et al (1991) and contrast with the results obtained by Miiller and Borchard 
(1993) who did not find any significant relationship between TFF1 expression and the 
histotype of gastric carcinoma. 
Miiller and Borchard (1993) found a highly significant correlation between TFF1 
immunoreactivity and expression of markers of gastric differentiation, such as 
pepsinogen II and 2B5, which were co-expressed in most of the TFF1 immunoreactive 
cells. If we assume, as Miiller and Borchard (1993) did, that TFF1 immunoreactivity 
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discloses the gastric phenotype of neoplastic cells, we may conclude that most diffuse 
carcinomas display gastric-type differentiation. 
These findings are in accordance with ultrastructural data, showing that gastric-type 
(foveolar and/or mucopeptic) cells are observed in the majority of diffuse carcinomas 
(Fiocca, et al. 1987; Carneiro, et al. 1992). Furthermore, about half of the so-called 
intestinal carcinomas of our series — those displaying TFF1 immunostaining — 
exhibited signs of gastric-type differentiation. These findings concur with those of 
Fiocca et al (1988a) who showed that, in their series, 55% of the cases of gastric 
carcinoma with glandular structure expressed pepsinogen H, and with those of Kushima 
and Hattori (1993) who showed that gastric-type differentiation was present exclusively 
(23.2%) or in association with intestinal-type differentiation (46.5%) in a series of 43 
early gastric carcinomas with glandular structure. 
The present and the aforementioned studies show that gastric-type differentiation is 
present both in diffuse carcinomas and in intestinal carcinomas, though much more 
often and more expressively in the former than in the latter. The prominence of gastric-
type differentiation in diffuse carcinomas suggests that this is the type of carcinoma 
which is more closely linked to the gastric mucosa both histogenetically and from the 
differentiation standpoint. 
Taking all the above evidence together we think our results fit with the model proposed 
by Carneiro (1997) (Fig. 2) of at least two pathways of malignant transformation of 
gastric mucosa: one via intestinal metaplasia and adenomatous (flat or polypoid) 
dysplasia, leading to intestinal carcinomas with intestinal-type differentiation; the other 
via hyperplastic or de novo changes, with or without concurrent non-metaplastic 
dysplasia, leading to diffuse carcinomas and to a subset of intestinal carcinomas with 
gastric-type differentiation. 
Co-expression of trefoil peptides and mucins 
In Papers EH and IV, we studied the expression of trefoil peptides (TFF1 and TFF2) and 
mucins (MUC1, MUC2, MUC5AC and MUC6) in premalignant lesions of the stomach 
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and gastric carcinoma. Our aim was to characterise the expression profile of trefoil 
peptides and mucins along the process of gastric carcinogenesis, in an attempt to further 
the understanding of the histogenesis and cell differentiation of gastric carcinoma.. 
Based on the pattern of expression of trefoil peptides and mucins, we defined three main 
phenotypes of cell differentiation: complete gastric, incomplete gastric and non-gastric. 
In agreement with the conclusions drawn from the study of the expression of TFF1 
alone, the results obtained in the analysis of the co-expression of trefoil peptides and 
mucins showed that hyperplastic polyps displayed a complete gastric-type 
differentiation. In adenomatous polyps, the pattern of expression of trefoil peptides and 
mucins was heterogeneous. Complete gastric differentiation was detected in 47.4% of 
the cases, incomplete gastric differentiation in 36.8% and, in 15.8% of the cases, a non-
gastric phenotype was observed. 
The present results show that the majority of gastric carcinomas retain signs of complete 
(52.1%) or incomplete (29.2%) gastric-type differentiation. Such signs are more often 
exhibited in diffuse and unclassifiable carcinomas than in intestinal-type carcinomas, 
although gastric-type differentiation was also observed in the latter. In a minority of the 
cases (18.7%), mostly of the intestinal histotype, we found no signs of gastric-type 
differentiation. 
The comparison of the cell differentiation pattern along the process of gastric 
carcinogenesis reinforces some of our previous conclusions based on the expression of 
TFF1 and highlights four points: firstly, the demonstration that intestinal metaplasia of 
incomplete type displays immunohistochemical markers of gastric differentiation, such 
as gastric type mucins (Reis, et al. 1999) and TFF1 fits with the hypothesis that, in the 
cascade of events leading to intestinal carcinoma, incomplete intestinal metaplasia 
(namely type HI) (Rokkas, et al. 1991; Filipe, et al. 1994) may serve as precursor of the 
adenomatous/dysplastic lesions exhibiting signs of gastric differentiation. Secondly, the 
three types of cell differentiation are similarly prevalent in the adenomatous lesions and 
in the intestinal type carcinomas thus supporting the hypothesis that 
adenomatous/dysplastic lesions do serve as precursors of intestinal-type gastric 
carcinoma. Thirdly, cell differentiation of gastric type is characteristically retained along 
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the process of gastric carcinogenesis that leads to diffuse carcinomas, in keeping with 
the origin of these tumours either de novo or from hyperplastic lesions (Carneiro, et al. 
1993a; Carneiro, et al. 1995a). Fourthly, we observed that the absence (loss?) of signs of 
gastric differentiation occurs in both pathways of gastric carcinogenesis, though more 
prominently in that leading to intestinal-type carcinomas than that leading to diffuse 
carcinomas. 
The relationship between the pattern of cell differentiation and the histological type of 
the tumours, is further supported by our findings in mixed gastric carcinoma. In cases 
where the two histological components of the tumours presented a different pattern of 
cell differentiation, the isolated-cell component always displayed a more conserved 
gastric-type differentiation. Our finding that most mixed carcinomas keep a similar cell 
differentiation pattern in both histological components supports the assumption that 
both components of these tumours derive from the same parental neoplasia. 
MUC2 is characteristically expressed in goblet cells of native intestinal epithelium (Ho, 
et al. 1993; Ho, et al. 1995; Reis, et al. 1998). In the present study, MUC2 was 
expressed in relatively few cases (22.9%). We found no significant relationship between 
the expression of this molecule and the histotype and cell differentiation pattern of the 
tumours, in keeping with data previously reported (Filipe, et al. 1996; Reis, et al. 1998). 
The expression of MUC2 in carcinomas displaying a gastric phenotype may indicate the 
existence of a mixed differentiation (gastric and intestinal) in these tumours; this 
possibility remains however disputable because we observed a low prevalence of MUC2 
expression in the group of tumours that in principle should depict the highest degree of 
intestinal differentiation: carcinomas of the intestinal histotype with a non-gastric 
phenotype. 
Regarding the relationship between cell differentiation pattern and tumour growth, we 
observed that absence (loss?) of native gastric differentiation appears to be related with 
tumour progression, increasing from early to advanced carcinomas, both in intestinal 
and diffuse carcinomas. Ultrastructural and immunohistochemical data on record 
(Fiocca, et al. 1987; Yamachika, et al. 1997) led to the suggestion that there is 
acquisition of signs of intestinal differentiation along tumour progression. Our own 
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results show that MUC2 expression increases from early (7.7%) to advanced (25.3%) 
carcinomas, though the differences did not attain the threshold of statistical significance. 
Putting together our findings and those previously reported we can not exclude that, at 
least in some cases, absence/loss of gastric differentiation may be paralleled by 
intestinalisation of gastric carcinomas. 
Altogether, our data suggest that a large proportion of gastric carcinomas, regardless of 
histotype, derive from native gastric epithelium and retain signs of gastric 
differentiation. Whether these carcinomas arise de novo or from hyperplastic/dysplastic 
lesions remains to be fully elucidated. The expression of MUC2 mucin both in intestinal 
and diffuse carcinomas is in keeping with data on record pointing to the existence of 
signs of intestinal differentiation in both types of carcinomas (Tatematsu, et al. 1986; 
Fiocca, et al. 1987; Fiocca, et al. 1988b; Carneiro, et al. 1992; Kushima, et al. 1993; 
Yamachika, et al. 1997). It remains to be seen if the signs of intestinal differentiation are 
related with the precursor lesions of these tumours or, otherwise, reflect a phenomenon 
of intestinalisation along tumour progression, as previously described in the literature 
(Fiocca, et al. 1987; Yamachika, et al. 1997). The former being true, highlights the 
possibility that at least some diffuse carcinomas may also originate from the histogenetic 
pathway leading to intestinal carcinomas with mixed- or intestinal-type differentiation. 
Role of E-cadherin in morphologic heterogeneity of gastric carcinoma 
In the present study, we found abnormal E-cadherin expression in 74.0% of gastric 
carcinomas, a prevalence that is close to that reported by other authors (Yonemura, et al. 
1995; Gabbert, et al. 1996). Furthermore, we found a significant higher frequency of 
abnormal E-cadherin expression in diffuse carcinomas (92.9%) than in intestinal 
carcinomas (45.0%). This finding is in agreement with those reported previously, 
pointing to a correlation between altered expression of E-cadherin and either diffuse or 
poorly differentiated/undifferentiated gastric carcinoma (Mayer, et al. 1993; Shino, et al. 
1995; Gabbert, étal. 1996; Jawhari, étal. 1997). 
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The separate evaluation of E-cadherin expression in distinct histological components of 
the mixed carcinomas consistently reproduced the association between E-cadherin 
expression pattern and the histotype. E-cadherin expression was scored as abnormal in 
the diffuse/isolated cell-type component in 17/18 (94.4%) mixed carcinomas. At 
variance with this, in the intestinal/glandular component of mixed carcinomas, abnormal 
E-cadherin expression was observed in 10/18 (55.6%) cases, the remaining eight cases 
(44.4%) exhibiting, in the glandular areas, a normal (polarised) pattern of E-cadherin 
expression at the cell membrane. 
This significant relationship between an abnormal expression of E-cadherin and diffuse 
carcinomas, which is kept both in "pure" carcinomas and in the isolated-cell component 
of mixed carcinomas, is in keeping with the hypothesis that E-cadherin plays a crucial 
role in the adhesion among neoplastic cells which, if disrupted, leads to dissociation of 
cells and scattered growth. 
This hypothesis is further supported by our results on the mutational analysis of the E-
cadherin gene. We detected E-cadherin gene mutations in 46.2% of gastric carcinomas 
and by sequencing analysis we identified 15 mutations in 12 cases, mostly of the 
missense type. 
In the classical two hit model of tumour suppressor gene inactivation, mutations in one 
allele are accompanied by deletion of the remaining normal allele. Our results appear to 
challenge this model since LOH of 16q22.1 was found in only one of the 12 cases 
presenting mutation of the E-cadherin gene. Noteworthy, in case 15 two different 
inactivating mutations were identified thus fulfilling also the two hit inactivation model. 
These findings contrast with those of Berx et al (1996) in lobular carcinoma of the 
breast, showing that 93% of cases with E-cadherin gene mutation displayed also LOH. 
Alternative inactivation mechanisms of the remaining normal allele may include 
specific allelic exclusion (Becker and Hofler, 1995) or alterations at the gene promoter 
level (Hennig, et al. 1995). Methylation within the promoter or the 5'-CpG island of the 
E-cadherin gene has been shown in breast and prostate carcinomas (Graff, et al. 1995; 
Hennig, et al. 1995; Yoshiura, et al. 1995). Additionally, one can speculate that the 
mutation of one allele may result in a dominant-negative effect over the remaining 
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normal allele. Cadherins exist at the cell surface as dimers linked by interactions at each 
cadherin domain (Shapiro, et al. 1995). One may admit that a mutated E-cadherin 
protein may still bind to wild-type protein leading to a non-functional E-cadherin 
complex. 
Although we observed a very good correlation between abnormal E-cadherin expression 
and gene mutations it is not possible to establish a linear relationship between the type 
of mutation and the expression patterns of the protein. While the occurrence of 
mutations in the E-cadherin gene seems to be a critical step in diffuse gastric 
carcinogenesis and remains fixed throughout progression of the tumour, the expression 
pattern at the moment of analysis is the result of both mutation in the E-cadherin gene 
and the specific "tumour-environment" interplay, which involves an altered balance of 
transcription factors, expression and repression of many genes and frequent structural 
modifications at the DNA level. Regardless of the type of mutation, abnormal E-
cadherin expression was mainly characterised by cytoplasmic expression and, in some 
cases, by a mixture of cytoplasmic expression and lack of expression. We may speculate 
that the internalisation of a non-functional E-cadherin complex (Kartenbeck, et al. 1991) 
or deficient transport of an abnormal E-cadherin protein to the cell membrane could 
explain the cytoplasmic immunoreactivity. 
In the present series, E-cadherin mutations occurred in 70% of "pure" diffuse gastric 
carcinomas and were not detected in "pure" intestinal carcinomas. This very strong 
association between E-cadherin mutations and the diffuse histotype is in agreement with 
the results of Becker et al (1994), who reported mutations of the E-cadherin gene in 
50% of diffuse gastric carcinomas and their absence in intestinal type carcinomas. 
Furthermore, E-cadherin mutations were detected in gastric carcinoma cell lines with a 
diffuse phenotype (Oda, et al. 1994) and in families of patients with diffuse gastric 
carcinoma (Gayther, et al. 1998; Guilford, et al. 1998; Richards, et al. 1999). In mixed 
gastric carcinomas, we observed that inactivating E-cadherin mutations were restricted 
to the diffuse component of the tumours in five out of six cases. This finding suggests 
the existence of genotypically divergent tumour clones in mixed gastric carcinoma and 
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indicates that E-cadherin inactivation is the hallmark of the dual morphologic 
divergence in this type of tumours. 
Altogether, these results suggest that inactivation of the E-cadherin gene determines the 
diffuse histotype of gastric carcinoma. This putative cause-effect relationship between 
E-cadherin inactivation and the diffuse histotype is challenged by the existence of a 
small percentage of cases presenting diffuse histotype without detectable E-cadherin 
mutation and, in two cases (casel9 and diffuse component of case 22), even displaying 
normal protein expression. In such cases, one has to admit that the adhesion of 
neoplastic cells is disrupted by an alteration at another level of the cell adhesion system. 
As pointed out in the introductory section of this Thesis, E-cadherin is only one of the 
constituents of a complex cell adhesion system and its function is dependent on the 
interaction of its conserved cytoplasmic domain (C-terminal) with the cytoskeleton via 
molecular complexes involving a-, (3- and y-catenin (Kemler, 1993). Alterations in the 
associated cytoplasmic molecules, such as the catenins, are thought to impair cell 
adhesion in tumours exhibiting normal E-cadherin expression (Shimoyama, et al. 1992; 
Jawhari, et al. 1997; Smith and Pignatelli, 1997; Bukholm, et al. 1998). 
The significant relationship between E-cadherin mutation and the diffuse histotype of 
gastric carcinoma and the restriction of E-cadherin inactivating mutations to the diffuse 
component of mixed carcinomas, suggest that the timing of E-cadherin inactivation and 
the timing of phenotypic divergence probably coincide in mixed gastric carcinomas. The 
findings of Muta et al (1996) and Vos et al (1997), showing E-cadherin alterations in 
intramucosal diffuse gastric carcinoma and in in situ lobular carcinoma of the breast, 
respectively, indicate that E-cadherin inactivation is an early event in carcinogenesis. 
Moreover, it has been recently shown that loss of E-cadherin expression occurs in the 
transition from adenoma to carcinoma in a transgenic mouse model of pancreatic (3-cell 
carcinogenesis (Perl, et al. 1998). Based on these findings it is tempting to suggest that 
phenotypic divergence of mixed gastric carcinoma occurs early during neoplastic 
development. This assumption is indirectly supported by the presence of E-cadherin 
mutations in patients with familial diffuse gastric carcinoma (Gayther, et al. 1998; 
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Guilford, et al. 1998; Richards, et al. 1999) indicating that E-cadherin inactivation may 
even be an initiation event in gastric carcinogenesis. 
Putting together data we obtained and that on record we feel tempted to suggest that the 
involvement of the E-cadherin gene in gastric carcinogenesis can be summarised as 
follows: 
Familial carcinoma oï 
diffuse type 
Somatic mutation 
after initiation 
Sporadic carcinoma 
of mixed type 
Histogenetic pathways of gastric carcinogenesis revisited 
The results obtained in this study show that the majority of gastric carcinomas retain 
signs of gastric-type differentiation, more often exhibited in diffuse than in intestinal 
carcinomas. These findings support our contention that carcinomas forming glands 
should be designated as glandular carcinomas rather than intestinal carcinomas in order 
to avoid mixing structural with cell differentiation concepts. Non-gastric phenotype 
occurs also in both types of gastric carcinoma, though more prominently in intestinal 
carcinoma. Furthermore, we observed that loss of native gastric differentiation is related 
with tumour progression, increasing from early to advanced carcinomas, both in 
intestinal and diffuse carcinomas. 
The comparison of the patterns of cell differentiation between premalignant lesions and 
gastric carcinomas shows good agreement with the model proposed by Carneiro (1997) 
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and supports that there are at least two pathways of malignant transformation of gastric 
mucosa: one via intestinal metaplasia and adenomatous (flat or polypoid) dysplasia, 
leading to intestinal-type carcinomas; the other via hyperplastic or de novo changes, 
with or without concurrent non-metaplastic dysplasia, leading to diffuse carcinomas 
and to a subset of intestinal carcinomas with gastric-type differentiation (Fig. 2). 
Our results on the expression of MUC2 in gastric carcinoma and data on the literature 
(Tatematsu, et al. 1986; Fiocca, et al. 1987; Fiocca, et al. 1988b; Carneiro, et al. 1992; 
Kushima, et al. 1993; Yamachika, et al. 1997) show that intestinal-type differentiation 
may occur both in intestinal and diffuse carcinoma. It remains to be seen if MUC2 
expression reflects a histogenetic pathway related with intestinal metaplasia or, 
otherwise, represents de novo expression along tumour progression. 
Together with the data provided by other authors on E-cadherin inactivation in sporadic 
(Becker, et al. 1993; Becker, et al. 1994) and familial (Gayther, et al. 1998; Guilford, et 
al. 1998; Richards, et al. 1999) gastric carcinoma, our results strongly support that E-
cadherin inactivation (or, more generally, loss of cell-cell adhesion) determines the 
diffuse histotype. Furthermore, we have shown that mixed gastric carcinomas originate 
most probably from intestinal-type carcinomas through loss of E-cadherin function, 
leading to the establishment of an isolated-cell histological component. 
Accepting this hypothesis as valid, the study of trefoil peptides and mucins suggests that 
the majority of mixed carcinomas may originate from intestinal carcinomas with gastric 
phenotype. Loss of gastric differentiation in the intestinal component of some mixed 
carcinomas that display signs of gastric differentiation in the diffuse component remains 
to be explained. 
Gastric carcinogenesis is a multistage process in which successive rounds of mutation 
and clonal selection in tumour cells underlie the progression of the neoplasia. If we 
extrapolate this reality to the model of mixed carcinoma, one may admit that in the 
natural history of this type of tumour one of the histological components may overgrow 
the other. Despite this possibility, it seems that the two histological components of 
mixed carcinomas may coexist and, perhaps, even co-operate, providing a putative 
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explanation for the biological aggressiveness of mixed carcinoma reflected in the poor 
survival of the patients (Carneiro, et al. 1995b; Carneiro, 1997). 
This hypothesis implies that mixed gastric carcinoma is one, eventually the major, 
player in the generation of gastric carcinoma diversity, providing theoretical ground for 
the structural and cell differentiation heterogeneity observed in carcinoma of the 
stomach. 
Based on the aforementioned evidence and on our personal interpretation of the data, we 
propose the model depicted in figure 9 as a backbone to explain the morphologic and 
cell differentiation heterogeneity associated with gastric carcinoma. Among the many 
limitations that this model certainly presents, we would like to stress the following two: 
firstly, we can still not exclude the possibility that gastric carcinoma arises de novo from 
normal gastric epithelium; secondly, the histogenesis of unclassifiable/solid carcinomas 
is still an enigma, i.e. it is not known if it represents the end-stage of one and/or two of 
the major types of gastric carcinoma or if it is the result of an independent pathway of 
carcinogenesis. 
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Fig. 9 - Model of gastric carcinogenesis illustrating the two main histogenetic pathways and the central 
role of mixed carcinoma in the generation of morphologic and cell differentiation heterogeneity. 
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Future perspectives 
We believe that the results of this study will help to further the understanding of the 
biopathogenesis of gastric carcinoma. Nevertheless, many problems remain unsolved 
and our own results raise some additional questions. 
An increasing amount of evidence is being produced in support of the hypothesis that 
trefoil peptides act as motogenic factors in the process of restitution of gastrointestinal 
epithelia. Most probably, this effect occurs through modulation of the E-cadherin-
mediated cell-cell adhesion system. The elucidation of this putative inter-relation 
between trefoil peptides and E-cadherin constitutes a very promising research field. 
Although we and other authors have shown that E-cadherin inactivation appears to be 
one of the key events underlying both initiation and/or progression of a large part of 
diffuse gastric carcinomas, a proportion of these type of tumours, including sporadic and 
familial forms, keep an apparently normal E-cadherin. In the discussion chapter of the 
Thesis we have advanced that in these cases other components of the E-cadherin cell-
cell adhesion system may be inactivated rendering the normal E-cadherin protein useless 
for the adhesion process. This is an aspect that needs further investigation. 
One of the most interesting findings of our results is the fact that E-cadherin inactivation 
seems to underlie the histological divergence of mixed gastric carcinoma that gives rise 
to two individual morphologic components. In order to fully elucidate this finding one 
needs to confirm the monoclonal origin of these type of tumours. Furthermore, the study 
of additional genetic alterations which may, or may not, be shared by the two 
histological components of mixed carcinomas will further our understanding of the 
biopathology of this particular type of tumour. 
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O carcinoma do estômago continua a constituir uma das principais causas de morte por 
doença oncológica em Portugal. A incidência de carcinoma gástrico em Portugal é a 
mais elevada da União Europeia e, contrariamente ao verificado na maior parte dos 
países ocidentais, não se tem assistido, entre nós, a um declínio significativo das taxas 
de incidência e mortalidade por este tipo de neoplasia. 
É geralmente aceite a existência de duas vias principais de transformação maligna da 
mucosa gástrica: uma através da metaplasia intestinal e da displasia adenomatosa, 
levando à formação de carcinomas do tipo intestinal; a outra através de alterações 
hiperplásicas/displásicas originando carcinomas do tipo difuso e um subgrupo de 
carcinomas do tipo intestinal. 
A diversidade morfológica do carcinoma gástrico é muito maior do que a esperada 
tendo em conta a existência de dois tipos histológicos principais — intestinal e difuso. 
De facto, uma grande parte dos carcinomas gástricos são polimórficos e exibem grande 
diversidade tanto estrutural como de diferenciação celular. Do ponto de vista molecular, 
as alterações subjacentes à heterogeneidade do carcinoma gástrico estão longe de estar 
esclarecidas. 
No presente trabalho seleccionámos os "trefoil peptides" (e a sua co-expressão com 
mucinas) e a caderina-E como "instrumentos" para estudar alguns aspectos de 
diferenciação celular e de diversidade estrutural do carcinoma do estômago. Foi nosso 
objectivo analisar os seguintes aspectos da biopatologia do carcinoma gástrico: 1-) 
padrão de diferenciação celular do carcinoma gástrico e de lesões pré-malignas do 
estômago; 2-) mecanismos moleculares subjacentes à divergência estrutural do 
carcinoma do estômago, reflectida na existência de dois tipos principais de carcinoma 
— intestinal e difuso; 3-) características fenotípicas e moleculares associadas ao 
carcinoma gástrico de tipo misto; 4-) contribuição dos resultados dos diferentes estudos 
para a clarificação da histogenèse do carcinoma gástrico. 
Apresentam-se resumidamente os resultados de cada um destes estudos: 
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1 - Padrão de diferenciação celular do carcinoma gástrico e de lesões pré-malignas 
do estômago. 
Dados da literatura relativos à caracterização ultrastrutural, histoquímica e 
imunohistoquímica das neoplasias permitiram verificar que o carcinoma gástrico exibe, 
de forma isolada ou em combinação, dois tipos principais de diferenciação celular — 
gástrica e intestinal. 
Nesta parte do estudo caracterizámos os padrões de diferenciação celular no carcinoma 
gástrico e em lesões pré-malignas do estômago, incluindo gastrite crónica atrófica, 
metaplasia intestinal e pólipos gástricos (de tipo hiperplásico e adenomatoso). 
Para a prossecução deste objectivo procedemos à avaliação dos padrões de expressão de 
"trefoil peptides" específicos do estômago (TFF1 e TFF2) em lesões pré-malignas e no 
carcinoma gástrico. Paralelamente, analisámos a co-expressão destes "trefoil peptides" 
com mucinas — MUC5AC e MUC6 (mucinas gástricas), MUC2 (mucina intestinal ) e 
MUC1. 
Os resultados obtidos neste estudo mostraram que a maioria dos carcinomas gástricos 
retêm sinais de diferenciação gástrica, mais frequentemente expressa nos carcinomas de 
tipo difuso do que nos carcinomas de tipo intestinal. A ausência de diferenciação 
gástrica (fenótipo não-gástrico) foi observada numa pequena percentagem de casos de 
ambos os tipos histológicos principais de carcinoma do estômago, sendo mais notória no 
carcinoma intestinal. Verificámos ainda uma tendência para a perda de diferenciação 
gástrica ao longo da progressão do carcinoma gástrico, mais acentuada no carcinoma 
intestinal. 
Detectámos a expressão de MUC2 (mucina intestinal) em pequena percentagem de 
carcinomas gástricos. Observámos ainda uma tendência para o aumento de expressão de 
MUC2 em carcinomas avançados. No entanto, os nossos resultados não permitem 
esclarecer de forma conclusiva se a expressão de MUC2 reflecte uma histogenèse 
relacionada com a metaplasia intestinal (onde a mucina MUC2 é expressa normalmente:) 
ou, pelo contrário, representa uma expressão de novo relacionada com a progressão 
tumoral (traduzindo a designada "intestinalização" do carcinoma gástrico). 
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2 - Mecanismos moleculares subjacentes à divergência estrutural do carcinoma do 
estômago. 
Estudámos a expressão da caderina-E no carcinoma gástrico e analisámos as alterações 
do respectivo gene subjacentes às alterações de expressão da proteína. Encontrámos 
uma associação significativa entre a expressão anormal (ausente e/ou citoplasmática) da 
caderina-E e o carcinoma gástrico difuso. Através da pesquisa de mutações no gene da 
caderina-E verificámos a ocorrência de diversos tipos de mutações ("missense", "non-
sense", "frameshift deletion" e "splice site") na maior parte (70%) dos carcinomas 
difusos e a sua ausência nos carcinomas de tipo intestinal. Estes resultados, 
concordantes com os da literatura, indicam que a inactivação da caderina-E é 
determinante para a definição do fenótipo de tipo difuso do carcinoma gástrico. 
3 - Características fenotípicas e moleculares associadas ao carcinoma gástrico de 
tipo misto. 
A heterogeneidade morfológica do carcinoma gástrico reflecte-se também nos casos 
individuais; muitos carcinomas gástricos são pluriformes, exibindo dois ou mais 
componentes histológicos distintos. A maioria das classificações histológicas ignoram 
este aspecto, agrupando os carcinomas gástricos de acordo com o componente 
histológico predominante. Este facto tem dificultado o esclarecimento da biopatologia 
do carcinoma gástrico de tipo misto. 
Neste estudo decidimos analisar individualmente os diferentes componentes do 
carcinoma misto relativamente à diferenciação celular e à existência de alterações 
estruturais e/ou de expressão da caderina-E. 
Verificámos que, na maior parte dos carcinomas mistos, o padrão de diferenciação 
celular é o mesmo em ambos os componentes histológicos do tumor e é 
predominantemente de tipo gástrico. Pesquisámos mutações do gene da caderina-E, 
estudando separadamente os diferentes componentes das neoplasias através de 
microdissecção dos tumores, e observámos a ocorrência de mutações do gene da 
caderina-E apenas no componente difuso das neoplasias. A única mutação que 
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identificámos no componente glandular de tumores mistos foi uma mutação silenciosa, 
sem consequências funcionais para a proteína codificada. 
Estes resultados permitiram-nos sugerir, pela primeira vez na literatura, a existência de 
uma base genética para a divergência fenotípica do carcinoma gástrico. Estes resultados, 
aliados aos obtidos no estudo das alterações da caderina-E em carcinomas gástricos 
"puros", levam-nos a sugerir que o envolvimento da caderina-E na carcinogénese 
gástrica de tipo esporádico é de dois tipos; mutações somáticas coincidentes com a 
iniciação neoplásica e associadas ao carcinoma difuso; mutações somáticas após a 
iniciação neoplásica, associadas ao carcinoma de tipo misto. 
4 - Contribuição dos resultados dos diferentes estudos para a clarificação da 
histogenèse do carcinoma gástrico. 
O nosso objectivo último foi o de integrar a informação derivada dos estudos 
previamente descritos na tentativa de contribuir para a clarificação das vias 
histogenéticas conducentes ao carcinoma gástrico de tipo intestinal, difuso e misto. 
Com base nos resultados que obtivemos, propomos o modelo representado na figura 
seguinte para explicar a heterogeneidade morfológica e de diferenciação celular do 
carcinoma gástrico, no qual o carcinoma gástrico de tipo misto desempenha um papel 
central. 
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The aim of this study was to evaluate the pattern of pS2 protein expression in premalignant and malignant lesions of 
gastric epithelium. We analysed, by immunohistochemistry, the pS2 expression in six samples of normal gastric 
mucosa, 18 cases of chronic atrophic gastritis with intestinal metaplasia (IM), 10 hyperplastic polyps, 11 
adenomatous polyps and 50 gastric carcinomas, together with the respective samples of adjacent non-neoplastic 
mucosa. pS2 is expressed throughout foveolar and superficial epithelium of normal gastric mucosa and this pattern 
is retained in chronic atrophic gastritis out of IM lesions. pS2 expression is confined to goblet cells in complete IM 
and occurs both in goblet and columnar cells in incomplete BV1. Hyperplastic polyps displayed significantly higher 
pS2 expression than adenomatous polyps. In gastric carcinomas, pS2 expression was observed in 66.0% of cases, 
being significantly higher in diffuse (88.9%) than intestinal type carcinomas (53.6%). A subset of carcinomas of the 
latter group displayed pS2 immunorcactivity in a high percentage of cells with a pattern similar to mat of 
hyperplastic polyps. Our results demonstrate mere are major changes in pS2 expression, which can be used as a 
marker of gastric-type differentiation during the process of gastric carcinogenesis, and support the existence of at 
least two pathways of malignant transformation of gastric mucosa: one via intestinal metaplasia and adenomatous 
dysplasia, leading to glandular carcinomas with intestinal-type differentiation, the other via hyperplastic changes or 
de novo changes, leading to diffuse carcinomas and to a subset of glandular carcinomas displaying gastric-type 
differentiation. 
Key words: Chronic atrophic gastritis, gastric carcinoma, gastric polyps, immunohistochemistry, intestinal 
metaplasia, mucins, pS2, stomach, trefoil peptides. 
Introduction 
Gastric carcinoma is very heterogeneous from the 
morphologic standpoint, probably reflecting the 
complexity and diversity of the process(es) of 
malignant transformation of gastric mucosa (Lauren 
1965; Corrêa 1992; Carneiro et al, 1995b). According 
to Lauren's classification, there are two main types of 
gastric carcinoma—intestinal and diffuse—which 
differ from each other epidemiologically, morpholo-
gically and clinically (Lauren 1965; Carneiro et al, 
1995b). 
Corrêa proposed a model of gastric carcinogenesis, 
according to which the so-called intestinal carcinoma 
represents the end-product of a cascade of sequential 
changes of gastric mucosa including superficial 
gastritis, chronic atrophic gastritis, small intestinal 
metaplasia, colonic metaplasia and adenomatous (flat 
or polypoid) dysplasia (Corrêa 1988, 1992). 
Correa's proposal found strong support in many 
morphologic and epidemiologic studies (Corrêa et al, 
1990a,b; Filipe et al, 1994). However, this model does 
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not fit with a subset of glandular carcinomas 
(classified as intestinal carcinomas according to 
Lauren's classification) that show histochemical signs 
of gastric-type differentiation and no evidence of 
intestinal-type differentiation. These gastric-type 
adenocarcinomas were thought to originate from 
foveolar hyperplasia rather than from intestinal 
metaplasia (IM) Hattori 1985; Kushima and Hat-
tori, 1993). 
From the histogenetic standpoint it is generally 
accepted that diffuse carcinomas originate from 
gastric proper mucosa (Ghandur-Mnaymneh et al, 
1988) and that non-metaplastic dysplasia is a putative 
premalignant lesion of this type of carcinoma 
(Ghandur-Mnaymneh et al, 1988), although little is 
known regarding the prevalence and clinicopathologic 
features of the aforementioned form of dysplasia. 
Furthermore, there is growing evidence that hyper-
plastic lesions of gastric mucosa (foveolar hyperplasia 
and hyperplastic polyps) may also serve as precursor 
lesions of the diffuse type of gastric carcinoma 
(Carneiro et al, 1993a,b; Zea-Iriarte et al, 1995). 
pS2 protein is a member of the trefoil peptide 
family whose gene was originally cloned in MCF-7 
breast cancer cell line (Masiakowski et al, 1982). The 
ultimate function of trefoil peptides is presently 
unclear, but recent data suggest that they may play 
a major role in the mechanisms of protection and 
regeneration of epithelia of the gastrointestinal tract 
(Wright et al, 1990; Rio et al, 1991; Seitz et al, 1991; 
Hanby et al, 1993b,c; Alison et al, 1995). 
In normal human tissues pS2 immunoexpression 
has only been consistently reported in stomach (Rio et 
al, 1988; Piggott et al, 1991), where it decorates the 
superficial and foveolar epithelium (Rio et al, 1988; 
Luqmani et al, 1989; Wright et al, 1990; Hanby et al, 
1993b; Mûller and Borchard, 1993). Apart from a 
very brief description of pS2 expression in superficial 
gastritis, atrophie gastritis and dysplasia by Luqmani 
et al (1989), there are no reports on the pattern of pS2 
expression in the so-called premalignant lesions of 
gastric mucosa on record. 
The few reports on the pS2 immunoexpression in 
gastric carcinoma (Luqmani et al, 1989; Henry et al, 
1991; Theisinger et al, 1991; Mûller and Borchard, 
1993) show a tendency towards the loss of pS2 
immunoexpression in carcinomas in comparison to its 
expression in normal epithelium. Theisinger et al 
(1991) observed, moreover, an association between 
retention of pS2 expression and diffuse type of gastric 
carcinoma, but this finding was not confirmed in the 
series of Mûller and Borchard (1993). 
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In the present study we evaluated the immunohis-
tochemical expression of pS2 in six samples of normal 
gastric mucosa, 18 cases of chronic atrophic gastritis 
with IM, 21 gastric polyps (10 hyperplastic polyps and 
11 adenomatous polyps) and 50 gastric carcinomas, 
together with the respective samples of adjacent non-
neoplastic mucosa, in an attempt to analyse the 
changes of pS2 expression along the process of gastric 
carcinogenesis. 
Material and methods 
Tissue material 
Six cases with normal gastric biopsies and 18 cases of 
chronic atrophic gastritis with IM, all of them from 
dyspeptic patients without gastric carcinoma or other 
focal lesions at endoscopy, were included in the study. 
From each patient there were six biopsies available 
(two from the antrum, two from the incisura angularis 
and two from the body/fundus). Twenty-one gaistric 
polyps and surgical specimens from 50 gastric 
carcinomas consecutively resected at Hospital S. 
João-Medical Faculty of Porto were also studied. 
The tissue fragments were fixed in 10% formalde-
hyde and embedded in paraffin. Serial sections of 4 
ixm were cut from each block and used for routine 
staining with haematoxylin and eosin, histochemical 
study with periodic acid-Schiff (PAS), alcian blue pH 
2.5 (AB)/PAS and AB/high iron diamine (HID), and 
immunohistochemistry. 
Histological and histochemical classifications 
Gastritis was classified according to Whitehead 
(1985). In the presence of glandular atrophy, gastritis 
was considered as chronic atrophic gastritis, regard-
less of the co-existence of IM. IM was classified 
according to Filipe and Jass (1986) into types I, II and 
III in sections stained with AB/PAS and HID/AB. 
Gastric polyps were classified according to Whitehead 
(1985) into hyperplastic polyps (n = 10) and 
adenomatous polyps (n = 11). Gastric carcinomas 
were classified according to Lauren (1965) as 
intestinal (n = 28), diffuse (n = 18) and unclassifiable 
carcinomas (n = 4). 
Immunohistochemistry 
Monoclonal antibody (MoAb) BC4 (CIS Bio Inter-
national, Gif-Sur-Yvette, France) was used for the 
immunohistochemical study of the expression of pS2 
in formalin-fixed paraffin-embedded tissues. A mod-
ification of the avidin-biotin-peroxidase complex 
method (Hsu et al, 1981) was applied. The paraffin 
sections (4 /zm thick) were dewaxed, incubated for 30 
min at 37°C in a 0.01 M HC1 solution containing 
0.4% pepsin and then rinsed in TRIS-buffered saline 
(TBS), pH 7.6. The sections were treated with 0.3% 
hydrogen peroxide in methanol for 30 min to block 
endogenous peroxidase, washed in TBS, then incu-
bated for 20 min with normal rabbit serum, at a 
dilution of 1:5 in TBS containing 25% bovine serum 
albumin (BSA). Excess normal serum was removed 
and replaced by the MoAb BC4 diluted at 1:4. After 
overnight incubation (18 hours) at 4°C, slides were 
washed with TBS, and the sections incubated with a 
1:200 dilution of biotin-labelled secondary antibody, 
for 30 min. After washing with TBS, sections were 
incubated with avidin-biotin-peroxidase complex (10 
mg/ml of biotin-labelled peroxidase) for 60 min. This 
was followed by staining the sections for 5 min with 
0.05% diaminobenzidine, freshly prepared in 0.05 M 
TRIS buffer, pH 7.6, containing 0.01% hydrogen 
peroxide. Finally, sections were counterstained with 
haematoxylin, dehydrated and mounted. Dilution of 
primary antibodies, biotin-labelled secondary antibo-
dies and avidin-biotin-peroxidase complex were 
made with TBS containing 12.5% BSA. 
All series included normal gastric mucosa as 
positive controls. Negative controls were performed 
by substitution of the primary antibody with IgGi 
immunoglobulins of the same class and concentration 
as the MoAb. 
Scoring 
A case was considered positive whenever more than 
5% of the cells displayed histochemical or immuno-
histochemical staining, irrespective of the localization 
of the positive cells and the intensity of the staining. 
Whenever possible, the cell localization of the staining 
was classified as perinuclear (Golgi area), cytoplasmic 
(diffuse or apical) or membranous (at the cell 
membrane). 
Statistical analysis 
The statistical analysis of the results was performed by 
Pearson x2 t e s t using Statview 4.01 software. 
Differences were considered statistically significant 
at values of P < 0.05 and suggestively different at 
values of P < 0.10. 
Results 
Normal mucosa 
pS2 immunostaining was observed in every case of 
normal gastric mucosa. pS2 expression was seen 
pS2 protein in gastric tissues 
Figure 1. Normal stomach: The superficial and foveolar 
epithelium of the antral mucosa displays intense pS2 
immunoreactivity, x 140. 
throughout the superficial and foveolar epithelium 
of antrum, incisura angularis and body (Figure 1), as 
well as in mucopeptic cells of the neck. pS2 
immunostaining was also seen, focally, in antrum 
glands but not in body glands. The intensity of the 
staining was much stronger in the superficial part of 
the mucosa than in the glands. At the cellular level the 
pattern of pS2 expression was mainly cytoplasmic 
(diffuse), but strong immunostaining was also seen in 
the perinuclear region (Golgi area), apical membrane 
and luminal secretions. 
IM in gastric biopsies from dyspeptic patients 
In this group there were six cases of complete (type I) 
IM and 12 cases of incomplete [types II (« = 6) and III 
(n = 6)] IM. pS2 expression was found in every case of 
IM. There was a clear difference between the two 
types: in complete IM, pS2 expression was restricted 
to goblet cells (Figure 2a), whereas in incomplete IM 
pS2 was expressed in both goblet and columnar cells 
(Figure 2b). In columnar cells, the intensity of 
immunoreactivity was weaker than in gastric epithe-
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Figure 2. pS2 immunoreactivity in intestinal metaplasia (IM): 
goblet and columnar cells of incomplete IM x 700. 
Table 1. Relationship between pS2 immunoreactivity and 
gastric polyp type 
Polyp type Immunoreactivity (% of cells) 
0 <50 >50 
Hyperplastic (n = 10) 
Adenomatous (u = 11) 
0 (0) 0 (0) 10 (100) 
3 (27.3) 7 (63.6) 1 (9.1) 
P value = 0.0002. 
Hum. No differences were found between types II and 
UK of incomplete IM. 
Gastric polyps 
In hyperplastic polyps, pS2 was expressed in every 
case and always in more than 50% of the cells (Figure 
3a, Table 1). At the cellular level, pS2 was expressed 
in the perinuclear region, diffusely in the cytoplasm 
and at the apical membrane, as well as in secretions. 
In adenomatous polyps, pS2 expression was found 
in eight out of 11 cases (72.7%; Table 1) and the 
intensity of staining was generally weaker than that of 
hyperplastic polyps. In seven cases (63.6%) pS2 was 
expressed focally, in less than 50% of the cells (Table 
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restricted to goblet cells in complete IM; b observed both in 
1), usually in the apical cytoplasm or in single goblet 
cells. In the remaining positive case (9.1%), pS2 was 
detected in more than 50% of the cells (Table 1). In 
the three negative cases (27.3%) the absence of pS2 
expression in the adenomatous lesion contrasted with 
its prominence in the surrounding gastric mucosa 
(Figure 3b). 
The percentage of cases expressing pS2 in the 
majority of cells was significantly higher (P = 0.0002) 
in hyperplastic polyps than in adenomatous polyps 
(Table 1). 
Histochemical study of the expression of neutral 
mucins (PAS staining) and acid mucins (HID/AB) 
was performed in nine hyperplastic polyps (there was 
no material available from one case) and in the 11 
adenomatous polyps. The results, summarized in 
Table 2, show that hyperplastic polyps secrete mainly 
neutral mucins, which were expressed, in every case, 
in more than 50% of the cells. Acid mucins were found 
in five out of nine hyperplastic polyps (55.6%), always 
in less than 50% of the cells, with a «predominance of 
sialomucins (Table 2). Neutral mucins were detected 
in every adenomatous polyp, either focally and mainly 
in the apical cytoplasm of the cells (seven cases) or in 
pS2 protein in gastric tissues 
Vigore 3. pS2 immunoreactivity in gastric polyps, a Hyperplastic polyp: immunoreactivity is observed in almost every cell. 
Inset, higher magnification showing the localization of pS2 immunoreactivity in the perinuclear area and also, although less 
intensely, in the cytoplasm of the cells, b Adenomatous polyp: the glands of the adenomatous lesion do not display pS2 
immunoreactivity, in contrast with the intense immunostaining observed in the adjacent gastric mucosa, a x 140, Inset x 700; 
b x 350. 
more than 50% of the cells (four cases; Table 2). Acid 
mucins were observed, focally, in every adenomatous 
f K>lyp (Table 2). In serial sections, it was possible to 
demonstrate that pS2 positive cells were system-
atically positive for mucin staining. 
Mucosa adjacent to gastric carcinomas 
The mucosa adjacent to gastric carcinomas displayed 
either superficial gastritis (six cases) or chronic 
atrophic gastritis (44 cases). The pS2 expression in 
fbveolar and surface epithelium of non-neoplastic 
gastric mucosa adjacent to carcinomas was similar to 
that observed in normal mucosa. In 23 cases of 
chronic atrophic gastritis there were foci of IM. In 
these lesions the pattern of pS2 expression was similar 
to that observed in IM present in gastric biopsies from 
dyspeptic patients. In complete (type I) IM pS2 
expression was restricted to goblet cells. In incom-
plete (types II and III) IM pS2 was observed both in 
goblet and columnar cells. 
Gastric carcinomas 
pS2 immunostaining was found in 33 out of the 50 
gastric carcinomas (66.0%). pS2 immunostaining was 
observed in 16 out of 18 (88.9%) diffuse carcinomas 
and in 15 out of 28 (53.6%) intestinal carcinomas, and 
this difference was found to be statistically significant 
(P = 0.037). Of the diffuse carcinomas, 22.2% showed 
immunoreactivity in the majority of neoplastic cells 
(> 50% of the cells; Figure 4). The corresponding 
frequency in intestinal carcinomas was 10.7% 
(Figure 5). 
No significant correlations were found between pS2 
immunostaining and the gender or age of patients, 
stage of the neoplastic disease, depth of penetration of 
gastric wall, lymph node metastasization and venous 
invasion. 
The study of several sections, demonstrated a 
topographic overlap between pS2 expression and 
mucin secretion, regardless of the histological type 
of the carcinomas. 
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Table 2. pS2 and mucin expression in hyperplastic and adenomatous polyps of the stomach 
Type Dysplasia 
pS2 
(% of cells) 
Mucin histochemistry 
Case no. 
Neutral 
(% of cells) 
Acid 
(% of cells) Type 
1 H _ >50 >50 _ _ 
2 H - >50 >50 <50 Si+Su 
3 H - >50 >50 <50 Si 
4 H - >50 NA NA NA 
5 H - >50 >50 <50 Si 
6 H - >50 >50 - -
7 H - >50 >50 <50 Si+Su 
8 H - >50 >50 - -
9 H - >50 >50 <50 Si+Su 
10 H - >50 >50 _ -
11 Ad Moderate - <50 <50 Si+Su 
12 Ad Moderate - <50 <50 Si+Su 
13 Ad Moderate - >50 <50 Si+Su 
14 Ad Moderate <50 <50 <50 Si+Su 
15 Ad Moderate <50 >50 <50 Su 
16 Ad Severe <50 <50 <50 Si+Su 
17 Ad Severe <50 <50 <50 Su 
18 Ad Moderate <50 >50 <50 Si+Su 
19 Ad Moderate <50 <50 <50 Su 
20 Ad Moderate <50 <50 <50 Su 
21 Ad Moderate >50 >50 <50 Si+Su 
H, hyperplastic polyp; Ad, adenomatous polyp; Si, sialomucins; Su, sulphomucins; NA, not available for 
histochemical study. 
Discussion 
Trefoil peptides are members of a family of small 
secreted molecules, with 1-6 highly conserved 6-
cysteine-rich regions (P-domains) which are respon-
sible for their distinctive three-loop structure (Thim et 
al, 1985; Hauser and Hoffmann, 1992). 
These peptides have been found in many species 
from amphibians to mammals and have been shown 
to be closely associated with mucus-secreting epithelia 
(Wright et al, 1993). In humans, three trefoil peptides 
have been identified to date (pS2/BCEI, hSP/SMLl 
and hrTF/TTFl). Their distribution in the gastro-
intestinal mucosa follows a specific pattern: for 
example, in the gastric mucosa pS2 and hSP are co-
expressed in foveolar and superficial epithelium, 
whereas hSP alone is seen in pyloric and Brutiner 
glands (Wright et al, 1990; Hanby et al, 1993b) and 
hlTF is mainly expressed in small intestinal and 
colonic goblet cells (Hauser et al, 1993; Podolsky et al, 
1993). In ulcerative conditions of the gastrointestinal 
tract it has been shown that trefoil peptides, mainly 
pS2 and hSP, are expressed at the periphery of 
mucosal ulcerative lesions in the so-called ulcer-
Figure 4. Diffuse carcinoma: almost every neoplastic cell associated cell lineage (Wright et al, 1990, 1993; Rio 
displays intense pS2 immunoreactivity. x 350. et al> 1991). Trefoil peptides have also been detected 
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Figure 5. pS2 immunoreactivity in intestinal carcinomas: a pS2-negative intestinal carcinoma. Note the intense pS2 
immunoreactivity in the adjacent gastric epithelium, b pS2-positive intestinal carcinoma. Most of the neoplastic cells display 
intense pS2 immunoreactivity x 350. 
in other pathological conditions of the gastrointestinal 
tract, such as Barrett's oesophagus (Hanby et al, 
1994) and gastric metaplasia of proximal duodenum 
(Hanby et al, 1993a). 
pS2 is the trefoil peptide that has been most 
extensively studied in humans, both in normal and 
neoplastic tissues (for a thorough review see Thim, 
1994). In human breast cancer pS2 expression was 
originally reported as being restricted to a sub-group 
of tumours expressing oestrogen receptors (Rio et al, 
1987) and associated with hormone therapy respon-
siveness (Henry et al, 1990). In the stomach, pS2 
expression is oestrogen-independent since oestrogen 
receptors have not been found in this organ in either 
non-neoplastic mucosa or carcinomas (Rio et al, 1988; 
Machado et al, 1994). 
In the present study we analysed the pattern of pS2 
immunohistochemical expression in normal gastric 
mucosa and premalignant and malignant lesions of 
the stomach. To the best of our knowledge this is the 
first study to provide a thorough description of pS2 
expression in premalignant lesions of the stomach 
such as chronic atrophic gastritis, IM and gastric 
polyps. 
Our findings in normal gastric mucosa confirm 
those previously reported by other authors (Rio et al, 
1988; Luqmani et al, 1989; Hanby et al, 1993b; Mûller 
and Borchard, 1993). pS2 expression was detected in 
the foveolar and superficial epithelium of gastric 
mucosa, both in the antrum and body/fundus. 
Immunostaining was observed in every case, at slight 
variance with the results reported by Mullet and 
Borchard (1993) who found pS2 immunostaining in 
95% of the cases included in their series. At variance 
with other studies (Rio et al, 1988; Hanby et al, 
1993b), we observed also focal and weak immuno-
staining for pS2 in mucus glands of the gastric 
antrum. The pS2 expression in gastric epithelium in 
chronic gastritis was similar to that observed in 
normal mucosa. 
In every instance (foveolar/surJerficial epithelium, 
IM, polyps and carcinomas) we found a good 
correlation between the amount and topographic 
distribution of pS2 positive cells and mucus secreting 
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cells, in keeping with the consistent co-expression of 
pS2 and mucins advanced by Wright et al (1993). 
We observed pS2 immunostaining in every case of 
IM, in agreement with Hanby et al (1993b) and at 
variance with the findings of Luqmani et al (1989) and 
Mûller and Borchard (1993). We observed, further-
more, that the features of pS2 expression in 
metaplastic lesions are IM type-specific and indepen-
dent of the presence of gastric carcinoma in the 
neighbourhood. Our results demonstrate distinctive 
patterns of pS2 expression in complete and incomplete 
IM. In the former pS2 expression is restricted to 
goblet cells and in the latter the staining is observed 
both in goblet and columnar cells. The pattern of pS2 
expression is similar in the two types (II and III) of 
incomplete IM. These findings strongly support the 
aforementioned co-expression of pS2 and mucins, 
since columnar cells in incomplete IM are mucus-
producing cells, whereas in complete IM, columnar 
cells are non-mucus-producing, mature absorptive 
cells. Since Hanby et al (1993b) found pS2 expression 
only in the goblet cells of their series of IM it is 
tempting to suggest the cases studied by Hanby et al 
(1993b) probably displayed solely the complete type 
oflM. 
Our results regarding pS2 expression in the different 
types of IM raise two additional issues. The first 
concerns type III IM, which is designated by some 
authors, colonic metaplasia (Sipponen et al, 1980; 
Corrêa, 1992). Our finding of pS2 expression in goblet 
and columnar cells in this type of IM contrasts with 
the pattern of pS2 expression in the colon, where it has 
been reported either as absent (Rio et al, 1988; Piggott 
et al, 1991; Hanby et al, 1993c) or present in only a 
few goblet cells (Welter et al, 1994). Our finding thus 
reinforces the contention of Filipe and Jass (1986) as 
well as our own (Carneiro et al, 1994) that use of the 
term 'colonic metaplasia' to designate this type of IM 
is inappropriate and misleading. 
The second issue concerns the sequential evolution 
of complete to incomplete IM types, along the process 
of malignant transformation of gastric mucosa, as 
suggested, based mainly upon epidemiologic evidence, 
in Correa's model of gastric carcinogenesis (Corrêa et 
al, 1990a,b; Corrêa, 1992). Although realizing the 
limitations of our study in addressing such a problem 
we think we have obtained enough data to claim that, 
in contrast to complete IM, the metaplasia of 
incomplete IM 'still' displays features of gastric 
differentiation, as shown by pS2 immunostaining in 
columnar mucus-secreting cells. We feel thus tempted 
to advance that the complete and incomplete types of 
IM may represent two alternative pathways of 
176 European Journal of Cancer Prevention. Vol 5. 1996 
metaplastic change in gastric mucosa, rather than 
two successive steps of phenotypic changes, with 
complete IM leading to incomplete IM, as suggested 
in Correa's model. It remains unclarified, however 
whether the different IM types represent peculiar 
responses to different environmental factors or 
specific adaptations related to physiopathological 
conditions of the gastric epithelium. 
We observed a clear difference between hyperplas-
tic and adenomatous polyps. The former display a 
pattern of pS2 expression which is similar to that 
observed in normal foveolar and surface epithelium. 
In hyperplastic polyps we observed, moreover, a good 
correlation between pS2 expression and the produc-
tion of mucins, mainly the neutral mucins which are 
the mucins normally expressed in gastric mucosa. 
These results fit with the assumption that hyperplastic 
polyps represent proliferative epithelial lesions which 
are phenotypically similar to normal gastric epithe-
lium, but they do not provide conclusive evidence for 
or against our previous contention that foveolar 
hyperplasia/hyperplastic polyps may serve as precur-
sor lesions of gastric carcinoma of the diffuse type 
(Carneiro et al, 1993a,b, 1995a). 
At variance with hyperplastic polyps, pS2 was 
detected only in 72.7% of the adenomatous polyps 
and, in the positive cases, the percentage of 
immunoreactive cells was significantly lower than in 
hyperplastic polyps. This down-regulation of pS2 
expression in adenomatous lesions supports the idea 
that adenomatous polyps are precursor lesions of 
gastric carcinoma of intestinal type, in which we also 
observed a reduced expression of pS2. 
In gastric carcinomas we found pS2 expression in 
66.0% of the cases, a frequency that is close to those 
reported by Luqmani et al (1989), Henry et al (1991) 
and Mûller and Borchard (1993) (57, 56 and 48%, 
respectively) and substantially inferior to that 
reported by Theisinger et al (1991). Differences in 
the methodologies and criteria used in the five series 
probably account for the aforementioned discrepancy. 
We observed a significantly higher frequency of pS2 
immunoreactivity in diffuse carcinomas (88.9%) than 
in intestinal carcinomas (53.6%). Furthermore, we 
observed that the frequency of carcinomas with a high 
percentage of immunoreactive cells (> 50%) was 
higher in diffuse than in intestinal carcinomas (22.2 
and 10.7%, respectively). These findings concur with 
those of Theisinger et al (1991) and contrast with the 
results obtained by Mûller and 'Borchard (1993) 
who did not find any significant relationship between 
pS2 expression and the histologic type of gastric 
carcinoma. 
pS2 protein in gastric tissues 
Millier and Borchard (1993) found a highly 
significant correlation between pS2 immunoreactivity 
and expression of markers of gastric differentiation, 
such as pepsinogen II and 2B5, which were co-
expressed in most of the pS2 immunoreactive cells. If 
we assume, as Millier and Borchard (1993) did, that 
pS2 immunoreactivity discloses the gastric phenotype 
of neoplastic cells, we may conclude that most diffuse 
carcinomas (88.9%) display gastric-type differentia-
tion, which is exhibited in the majority of the 
neoplastic cells in about one-fifth of the cases. These 
findings are in accordance with ultrastructural data, 
showing that gastric-type (foveolar and/or mucopep-
tic) cells are observed in the majority of diffuse 
carcinomas (Fiocca et al, 1987; Carneiro et al, 1992). 
Furthermore, about half of the so-called intestinal 
carcinomas of our series—those displaying pS2 
immunostaining—exhibited focal (42.9% of the 
cases) or extensive (10.7% of the cases) signs of 
gastric-type differentiation. These findings concur 
with those of Fiocca et al (1988), in whose series 
55% of the cases of gastric carcinoma with glandular 
structure expressed pepsinogen II, and with those of 
Kushima and Hattori (1993), who showed that 
gastric-type differentiation was present exclusively 
(23.2%) or in association with intestinal-type differ-
entiation (46.5%) in a series of 43 early gastric 
carcinomas with glandular structure. 
The present and the aforementioned studies show 
that gastric-type differentiation is present in both 
diffuse carcinomas and intestinal carcinomas, 
although much more often and more expressively in 
the former than in the latter. The prominence of 
gastric-type differentiation in diffuse carcinomas 
suggests that this is the type of carcinoma which is 
more closely linked to the gastric mucosa both 
histogenetically and from the differentiation stand-
point, whereas the group of intestinal carcinomas 
encompasses gastric-type adenocarcinomas, carcino-
mas with intestinal-type differentiation and tumours 
with dual differentiation. The heterogeneity of this 
latter group reinforces our previous contention that 
gastric carcinomas with gland formation should be 
designated as 'glandular' carcinomas instead of 
'intestinal' carcinomas (Carneiro et al, 1995b), in 
order to avoid the mixture of structural and cell 
differentiation concepts. 
The existence of glandular adenocarcinomas with 
gastric-type differentiation challenges the universality 
of Correa's model regarding the histogenesis of the 
intestinal carcinomas of Lauren's classification. With-
out denying the intestinal pathway of gastric 
carcinogenesis, whose magnitude still remains unclar-
ified, one has to admit also the possibility of 
development of gastric carcinoma with glandular 
structure from gastric proper mucosa, either de novo 
or via hyperplastic lesions, as suggested by several 
authors (Hattori, 1985; Watanabe et al, 1992; 
Kushima and Hattori, 1993). Our finding of a similar 
pattern of pS2 immunoexpression in foveolar/surface 
epithelium, hyperplastic lesions and some glandular 
carcinomas with gastric-type differentiation is in 
keeping with the latter possibility. 
Taking all the above evidence together, we think 
one should admit the existence of at least two 
pathways of malignant transformation of gastric 
mucosa: one via intestinal metaplasia and adenoma-
tous (flat or polypoid) dysplasia, leading to glandular 
carcinomas with intestinal-type differentiation, and 
the other via hyperplastic or de novo changes, with or 
without concurrent non-metaplastic dysplasia, leading 
to isolated-cell carcinomas (diffuse carcinomas of 
Lauren's classification) and to a subset of glandular 
carcinomas with gastric-type differentiation. The 
carcinomas with dual differentiation raise the possi-
bility of a phenotypic shift from gastric- to intestinal-
type differentiation during the progression of some 
gastric-type adenocarcinomas. 
Thus, our results show that there are major changes 
in the immunoexpression of pS2 protein along the 
process of gastric carcinogenesis, which are reflected 
in the specific patterns of pS2 immunoreactivity 
observed in the different types of IM and gastric 
polyps. In gastric carcinomas, pS2 expression can be 
used as a marker of gastric-type differentiation and is 
associated with gastric carcinomas of the diffuse type 
and with a subset of glandular carcinomas. 
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The aim of this study was to examine the prevalence of pS2 expression in gastric carcinoma and to 
determine its prognostic significance. We analysed pS2 protein expression in 50 gastric carcinomas 
and respective adjacent mucosas by immunohistochemistry and immunoradiometric assay (IRMA). 
pS2 was consistently expressed in superficial and foveolar epithelium of non-neoplastic mucosa and in 
66.0% of the carcinomas. pS2 irrtmunoreactivity was significantly higher in diffuse than in intestinal 
carcinomas, and in those cases with nodal metastases than in those without. No correlation was found 
between pS2 immunostaining and gender, age, staging, depth of wall penetration, venous invasion, 
ploidy and S-phase fraction. The mean levels of pS2 (IRMA) were significantly lower in gastric 
carcinomas than in non-neoplastic mucosas, and were not correlated with any of the aforementioned 
clinicopathological features. The survival of patients with pS2-positive tumours was not significantly 
different from that of patients with pS2-negative tumours. We conclude that pS2 expression, which can 
be used as a marker of gastric-type differentiation, is associated with gastric carcinoma of diffuse type. 
The lack of correlation between pS2 expression and most features of tumour aggressiveness and 
patients' survival precludes its use as a prognostic tool in gastric carcinoma. Copyright © 1996 Elsevier 
Science Ltd 
Key words: gastric carcinoma, immunohistochemistry, immunoradiometric assay (IRMA), mucins, 
pS2j stomach, survival, trefoil peptides 
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INTRODUCTION variable intensity in every carcinoma of their series, whereas 
pS2 PROTEIN is a member of the trefoil peptide family whose the prevalence of pS2 immunoreactivity varied from 48 to 57 
gene was cloned from the MCF-7 breast cancer cell line by per cent in other series [10, 14, 15]. In contrast to Muller and 
Masiakowski and colleagues [1]. In human breast cancer, pS2 Borchard [14] who did not find any significant relationship 
is associated, though not exclusively, with oestrogen receptor between pS2 expression and the histological type, Theisinger 
expression [2-4], responsiveness to hormone therapy [5] and and colleagues [16] found a close association between diffuse 
favourable prognosis [6, 7]. gastric carcinoma and a high percentage of strongly stained 
In normal human tissues, and excluding the pS2 expression pS2 immunoreactive cells. Finally, Mûller and Borchard [14] 
in some apparently normal breast specimens [4, 8], pS2 has reported a significant relationship between pS2 expression 
only-been consistently detected in the superficial and foveolar and extent of tumour growth (pT stage); despite this, they did 
epithelium of gastric mucosa [9-14]. not observe any significant influence of the immunohisto-
Thie few published reports on pS2 immunoexpression in chemical expression of pS2 on the outcome of the patients 
gastric carcinoma [10, 14-16] provide discrepant data on [14]. 
some of the clinicopathological parameters under analysis. We undertook the present immunohistochemical and 
Theisinger and colleagues [16] observed pS2 expression of immunoradiometric study of pS2 in a series of gastric carci-
nomas in an attempt to settle the aforementioned discrep-
Comspondence to J.-C. Machado. ancies. We also intended to determine whether the immuno-
Reviscd 3 Feb. 1996; accepted 8 Feb. 1996. histochemical evaluation of pS2 carries any meaningful 
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prognostic information as has been observed in mammary and 
pulmonary adenocarcinomas [6, 17]. 
MATERIALS AND METHODS 
Tissue material 
Six cases of normal gastric biopsies obtained from dyspeptic 
patients without gastric carcinoma or other focal lesions at 
endoscopy were included in this study. From each patient, 
there were six biopsies available (two from the antrum, two 
from the incisura and two from the body/fundus). Surgical 
specimens from 50 gastric carcinomas consecutively resected 
at Hospital S. João-Medical Faculty (IPATIMUP), Porto, 
Portugal, were studied. The mucosa adjacent to each case of 
gastric carcinoma was also studied. 
The tissue fragments were fixed in 10% formaldehyde and 
embedded in paraffin. Serial sections of 4 u.m were cut from 
each block and used for routine staining with haematoxylin 
and eosin (H&E), periodic acid Schiff (PAS) and alcian blue 
pH 2.5/high iron diamine (HID/AB) and immunohistochem-
ical stains. Frozen samples from 33 carcinomas were available 
for flow cytometry performed as previously described [18]. 
Immunohistochemistry 
Monoclonal antibody (MAb) BC4 (CIS bio international, 
Gif-Sur-Yvette, France) was used for immunohistochemical 
(IHC) study of the expression of pS2 in formalin-fixed paraf-
fin-embedded tissues. A modification of the avidin-biotin-
peroxidase complex method [19] was applied. The paraffin 
sections (4 u.m thick) were dewaxed, incubated for 30 min at 
37°C in a 0.01 M HC1 solution containing 0.4% pepsin and 
then rinsed in TRIS buffered saline (TBS), pH 7.6. The 
sections were treated with 0.3% hydrogen peroxide in meth-
anol for 30 min to block endogenous peroxidase, washed in 
TBS, and then incubated for 20 min with normal rabbit 
serum, at a dilution of 1:5 in TBS containing 25% bovine 
serum albumin (BSA). Excess normal serum was removed 
and replaced by the MAb BC4 diluted 1:4. After overnight 
incubation (18 h) at 4°C, slides were washed with TBS and 
the sections incubated with a 1:200 dilution of biotin-labelled 
secondary antibody for 30 min. After washing with TBS, 
sections were incubated with avidin-biotin-peroxidase com-
plex (10 mg/ml of biotin-labelled peroxidase) for 60 min. This 
was followed by staining the sections for 5 min with 0.05% 
diaminobenzidine, freshly prepared in 0.05 M TRIS buffer, 
pH7.6 , containing 0.01% hydrogen peroxide. Finally, sec-
tions were counterstained with haematoxylin, dehydrated and 
mounted. Dilution of primary antibodies, biotin-labelled sec-
ondary antibodies, and avidin-biotin-peroxidase complex 
were made with TBS containing 12.5% BSA. 
All series included normal gastric mucosa as positive con-
trols. Negative controls were performed by substitution of the 
primary antibody with IgGl immunoglobulins of the same 
subclass and concentration as the MAb. 
Scoring 
A case was considered to be negative (0) whenever histo-
chemical or immunohistochemical staining was absent or 
present in only very few cells. A semiquantitative approach 
was used to score the staining of the positive cases into cases 
with moderate number of positive cells (+) and cases in which 
the majority of the neoplastic cells were immunorcactive (++), 
irrespective of the localisation of the positive cells and the 
intensity of the staining. 
Immunoradiometric assay (IRMA) for pS2 
Immunoradiometric assay for pS2 was performed in 30 
tumours and 12 samples of non-neoplastic mucosa. From 
every case, a parallel sample of neoplastic or non-neoplastic 
tissue was obtained in order to monitor, by histological exam-
ination, if the IRMA samples were representative. Frozen 
tissues were homogenised at 0°C in a Polytron homogeniser. 
Homogenization buffer, pH 7.4, included 10 mM Tris, 
1.5 nM EDTA, 1 mM ditiothreitol, 1% v/v monotioglycerol, 
and 10% v/v glycerol. The homogenates were centrifuged at 
105000^ at 0°C, for 70 min. The obtained supernatant frac-
tion was used for immunoradiometric assay and for total 
protein quantification according to Bradford [20]. pS2 immu-
noradiometric assay kit ELSA-pS2 was purchased from CIS 
bio international (Gif-Sur-Yvette, France) and used according 
to the supplier's recommendations. Briefly, samples were 
incubated with pS2 125I-radiolabelled monoclonal antibody in 
pS2 monoclonal antibody coated tubes (standards and tissue 
supernatant fractions) at room temperature for 1 h. Unbound 
radiolabeled antibody was removed by washing the tubes and 
radioactivity was measured. 
Statistical analysis 
The results are expressed as a percentage or as a 
mean ± standard deviation. The statistical analysis of the 
results was performed by Pearson-chi squared test, unpaired 
Student's t-test and Mann-Whitney U test using Statview 
4.01 software. Follow-up data was obtained in every case. 
The median follow-up was 17 months (range 3-63 months). 
Survival curves were calculated according to the Kaplan-
Meier method and statistically compared using the Mantel-
Cox test using BMDP statistical software package. Differences 
were considered to be statistically significant at values of 
P<0.05. 
RESULTS 
Normal mucosa 
We found pS2 immunostaining in every case of normal 
gastric mucosa. pS2 expression was seen throughout the 
superficial and foveolar epithelium of antrum and body 
(Figure 1), as well as in mucopeptic cells of the neck. pS2 
immunostaining was also seen, focally, in antrum glands but 
not in body glands. In the antral glands, the intensity of 
immunostaining was much weaker than in the superficial 
part of the mucosa. At trie cellular level, the pattern of pS2 
expression was mainly cytoplasmic (diffuse) but strong 
immunostaining was also seen in the perinuclear region (Golgi 
area), apical membrane and luminal secretions (Figure 1). 
Mucosa adjacent to gastric carcinomas 
The mucosa adjacent to gastric carcinomas displayed either 
superficial gastritis (six cases) or chronic atrophic gastritis (44 
cases). The pS2 expression in foveolar and surface epithelium 
of non-neoplastic gastric mucosa adjacent to carcinomas was 
similar to that of normal mucosa. 
Gastric carcinoma 
Table 1 summarises the clinicopathological features of the 
50 cases included in the present series and the immunohisto-
chemical findings regarding pS2 expression. All 50 carcinomas 
were classified according to Lauren [21] as intestinal (n = 28), 
diffuse (« = 18) and unclassifiable (n = 4). pS2 immunostain-
ing was observed in 33 of the 50 gastric carcinomas (66.0%), 
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Figure 1. Normal gastric mucosa: pS2 immunoreactivity is 
observed throughout the superficial and foveolar epithelium of 
antral mucosa (original magnification x 140). 
which included 16 of 18 (88.9%) diffuse carcinomas 
(Figure 2) and 15 of 28 (53.6%) intestinal carcinomas 
(Figure 3). This difference was found to be statistically sig-
nificant (P= 0.037) (Table 1). The frequency of cases exhibit-
ing immunoreactivity in the majority of neoplastic cells (++) 
was higher in diffuse (22.2%) than in intestinal (10.7%) carci-
nomas. 
Sixteen cases, classified according to the predominant histo-
logical type as intestinal or diffuse carcinomas, displayed small 
Figure 2. pS2-positive diffuse carcinoma: intense pS2 im-
munoreactivity is observed in almost every neoplastic cell 
(original magnification x 350). 
Table 1. Relationship between the clinicopathological features of gastric carcinomas andpS2 expression 
Number of cases (%) Negative 
pS2 IHC 
Positive P value 
Gender 
Male 
Female 
Age 
<40 years 
5*40 years 
Stage 
I 
II 
m 
rv 
Histological type 
Intestinal 
Diffuse 
Unclassifiable 
Depth of invasion 
Mucosa and submucosa 
Muscular and serosa 
Metastases to the lymph nodes 
Negative 
Positive 
Venous invasion 
Negative 
Positive 
Ploidy (n = 33) 
Diploid 
Aneuploid 
Total 
34 (68.0) 
16 (32.0) 
12 (35.3) 
5 (31.2) 
22 (64.7) 
11 (68.8) 
9 (18.0) 
41 (82.0) 
2 (22.2) 
15 (36.6) 
7 (77.8) 
26 (63.4) 
23 (46.0) 
10 (20.0) 
16 (32.0) 
1 (2.0) 
9 (39.1) 
6 (60.0) 
2 (12.5) 
0(0) 
14 (60.9) 
4 (40.0) 
14 (87.5) 
1 (100) 
28 (56.0) 
18 (36.0) 
4 (8.0) 
13 (46.4) 
2(11.1) 
2 (50.0) 
15 (53.6) 
16 (88.9) 
2 (50.0) 
9 (18.0) 
41 (82.0) 
2 (22.2) 
15 (36.6) 
7 (77.8) 
26 (63.4) 
28 (56.0) 
22 (44.0) 
13 (46.4) 
4 (18.2) 
15 (53.6) 
18 (81.8) 
29 (58.0) 
21 (42.0) 
11 (37.9) 
6 (28.6) 
18 (62.1) 
15 (71.4) 
16 (48.5) 
17 (51.5) 
50 (100) 
8 (50.0) 
7 (41.2) 
17 (34) 
8 (50.0) 
10 (58.8) 
33 (66) 
NS 
NS 
NS 
0.037 
NS 
0.036 
NS; 
NÍ; 
NS, not significant. 
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Figure 3. pS2-positïve intestinal carcinoma: pS2 Immuno-
reaclivity is observed in less than 50% of the neoplastic cells 
(original magnification X 140). 
foci with a structure different from the main component of the 
tumour—foci of intestinal carcinoma in diffuse carcinomas 
(» = 10) and foci of diffuse carcinomas in intestinal carcinomas 
(« = 6). pS2 immunoreactivity was observed in every one of 
these 'mixed' carcinomas. In most cases (« = 12), immunore-
activity was observed in both the diffuse and the intestinal 
component of the tumours (Figure 4). In the remaining four 
cases;, irnmunostaining was restricted to the diffuse compo-
nent (Figure 5). 
In the whole series we found a significant correlation 
between pS2 irnmunostaining and metastasis to lymph nodes 
(P= 0.036) (Table 1). Within each group of the different 
histological types, no significant correlation was found 
between pS2 expression and lymph node metastases (data 
not shown). 
No significant correlations were found between pS2 
irnmunostaining and the gender or age of patients, stage of the 
neoplastic disease, depth of penetration of gastric wall and 
venous invasion (Table 1). Similarly, no significant correlation 
was observed with regard to ploidy (Table 1) and S-phase 
fraction (SPF) (16.8 ±16.5% in the positive cases and 
17.4 ± 10.3% in the negative cases). 
The comparison of the pS2 immunoexpression with mucin 
histochemical expression in serial sections of the gastric carci-
nomas revealed that there was a close topographic overlap 
Figure 4. In this 'mixed' carcinoma pS2 immunoreactivity is 
observed in both components of the tumour: intestinal compo-
nent (left) and diffuse component (right) (original 
magnification x 350). 
Figure 5. In this 'mixed' carcinoma pS2 immunoreactivity is 
restricted to one of the components of the tumour: diffuse 
component (left) with positive cells and intestinal component 
(right) with no immunoreactive cells (original magnification x 
350). 
between both stainings, regardless of mucin type (neutral 
and/or acid) and the histological type of the tumours. 
The mean level of pS2 in gastric carcinomas as measured 
by IRMA was significantly lower (P= 0.05) than that of non-
neoplastic mucosa (58.8 ± 42.6 and 76.5 ± 21.6, respectively). 
pS2 mean level detected by IRMA was higher in immuno-
histochemical positive cases (64.5 ±46.9) than in negative 
cases (52.3 ±37.8), but the difference did not attain the 
threshold of statistical significance. No significant correlation 
was found between the mean levels of pS2 and the different 
clinicopathological features of the cases, namely the histologi-
cal type of the carcinomas and the presence of nodal metastas-
es. 
The comparison of the postoperative survival curves of 
patients with pS2-positive and patients with pS2-negative 
gastric carcinomas revealed no significant difference between 
the two groups (Figure 6). 
DISCUSSION 
We found pS2 expression in 66.0% of the gastric carci-
nomas, a frequency that is close to those reported by Luqmani 
and colleagues [10], Henry and colleagues [15] and Miiller 
and Borchard [14] (57, 56 and 48%, respectively) and sub-
stantially inferior to that reported by Theisinger and col-
leagues [16]. Differences in the methodologies and criteria 
used in the five series probably account for the discrepancies. 
We observed a significantly higher frequency of pS2 im-
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Figure 6. Survival curves of patients with pS2-positive and 
pS2-negative gastric carcinoma. 
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munoreactivity in diffuse carcinomas (88.9%) than in intesti-
nal carcinomas (53.6%). Furthermore, we observed that the 
frequency of carcinomas displaying immunoreactivity in the 
majority of neoplastic cells was higher in diffuse than in 
intestinal carcinomas (22.2 and 10.7%, respectively). These 
findings concur with those of Theisinger and colleagues [16] 
and contrast with the results obtained by Mûller and Borchard 
[14] who did not find any significant relationship between pS2 
expression and the histological type of gastric carcinoma. 
The close relationship we found between pS2 expression and 
carcinomas of the diffuse type was also observed in some of 
the 'mixed' carcinomas of the present series, which displayed 
immunoreactivity in the diffuse component in contrast to the 
absence of immunostaining in the intestinal component. 
Mûller and Borchard [14] found a highly significant corre-
lation between pS2 immunoreactivity and expression of mark-
ers of gastric differentiation, such as pepsinogen II and 2B5, 
which were co-expressed in most of the pS2 immunoreactive 
cells. If we assume, as Muller and Borchard [14] did, that pS2 
imimunoreactivity discloses the gastric phenotype of neoplastic 
cells, we may conclude that most diffuse carcinomas (88.9%) 
display a gastric-type differentiation, which is exhibited in the 
majority of the neoplastic cells in about one-fifth of the cases. 
These findings are in accordance with the evidence provided 
by ultrastructural studies, which have shown that gastric-type 
cells (foveolar and/or mucopeptic) are observed in the majority 
of diffuse carcinomas [22, 23]. Furthermore, almost half of 
the intestinal carcinomas of our series—those displaying pS2 
immunostainmg—exhibited focally (42.9% of the cases) or 
extensively (10.7% of the cases) signs of gastric-type differen-
tiation. These findings are in agreement with the data of 
Fiocca and colleagues [24] who showed that, in their series, 
55% of the cases of gastric carcinoma with glandular structure 
expressed pepsinogen II. Kushima and Hattori [25] searched 
for signs of gastric and intestinal differentiation using histo-
chemical methods and showed that gastric-type differentiation 
was present—exclusively or in association with intestinal-type 
differentiation—in 69.8% of differentiated-type carcinomas 
(with glandular structure). The evidence provided by ultra-
structural studies [22, 23] also demonstrates the presence of 
different cell types, including foveolar and mucopeptic cells 
(gastric-type cells), besides intestinal columnar or goblet cells 
(intestinal-type cells) in gastric carcinomas forming glands 
[22, 23]. 
Overall, the present and the aforementioned studies provide 
enough evidence to claim that gastric-type differentiation is 
present both in diffuse and intestinal types of gastric carci-
noma, though much more often and more expressively in 
the former than in the latter. The prominence of cellular 
differentiation of gastric-type in diffuse carcinomas suggests 
that this is the type of carcinoma which is more closely 
linked to the gastric mucosa both histogenetically and from a 
differentiation standpoint, whereas the so-called intestinal 
carcinomas encompass gastric-type adenocarcinomas, carci-
nomas with intestinal-type differentiation and tumours with 
dual differentiation. The latter finding reinforces our previous 
contention that gastric carcinomas with gland formation 
should be designated as 'glandular' carcinomas instead of 
'intestinal' carcinomas [26], in order to avoid the mixture of 
structural and cell differentiation concepts. 
We found a significant correlation between pS2 expression 
and lymph node metastases. This finding is a side-effect 
related to the histological type since, in our series, most of the 
cases with lymph node metastases were diffuse carcinomas 
(68.2%) which were also those expressing more often pS2 
immunoreactivity. Within each histological type, no signifi-
cant correlation was found between pS2 immunoreactivity 
and nodal metastases. We found no other significant corre-
lation of pS2 immunoreactivity and the clinicopathological 
parameters under analysis. These results contrast with those 
of Muller and Borchard [14] who found, in a series of 120 
gastric carcinomas, a significant relationship between pS2 
expression and extent of tumour growth (pT stage). 
There was a lack of agreement between the results of 
immunohistochemical study of pS2 expression and those 
obtained by IRMA, except for the demonstration of higher 
levels of pS2 in the non-neoplastic mucosas compared with 
carcinomas. By IRMA, we did not find any significant corre-
lation between pS2 levels and the different clinicopathological 
parameters, namely regarding the histological type of the 
tumours. The discrepancy between immunohistochemistry 
and IRMA may reflect both the effect of tumoural heterogen-
eity regarding pS2 expression and the effect of stromal con-
tamination. The latter possibility provides a putative expla-
nation for the finding of similar pS2 levels, detected by IRMA, 
in diffuse and intestinal carcinomas, in contrast to immuno-
histochemical results which showed that pS2 expression was 
significantly higher in diffuse than in intestinal carcinomas, 
since the abundance of stromal, non-neoplastic tissue, is 
higher in the former than in the latter. It remains to be seen if 
the correction of cytosolic values for percentage of epithelial 
cells in the tumour samples will provide less discrepant results 
with the two methods, as recently suggested by Willemse and 
colleagues [27]. 
At variance with breast cancer, pS2 expression does not 
correlate in gastric carcinoma with the expression of oestrogen 
receptors (ER). In 39 of 50 cases included in the present 
series, we found no expression of female sex hormone recep-
tors (ER and progesterone receptors) in the normal mucosa of 
the stomach nor in the cells of the carcinomas [28]. 
In gastric carcinomas, we found a good correlation between 
the amount and topographic distribution of pS2 positive and 
mucus-secreting cells. Our preliminary studies (data not 
shown) on the immunoexpression of MUC-5, in serial sec-
tions, indicate a topographic overlap between pS2 positive 
and MUC-5 positive cells. These findings support the concept 
that there is a co-expression of pS2 and mucins, as previously 
suggested by Wright and colleagues [29]. 
We found no statistically significant difference in the sur-
vival of patients with pS2-positive and pS2-negative tumours. 
Despite the too short follow-up of most cases, our results are 
in keeping with those obtained by Mûller and Borchard [14] 
in their series of 120 gastric carcinomas, and contrast with the 
results observed in breast cancer [6] and lung cancer [17], 
in which pS2 immunoreactivity is associated with a more 
favourable or a less favourable prognosis, respectively. 
In conclusion, our results show that in gastric carcinomas, 
pS2 expression reflects gastric-type differentiation and is sig-
nificantly associated to the diffuse typ'e of gastric carcinoma. 
pS2 expression is neither associated with features of tumour 
aggressiveness nor influences the survival of patients with 
gastric carcinoma, thus being of no value for prognostic pur-
poses. 
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SUMMARY 
The expression of two trefoil peptides (TFF1 and TFF2) and four mucins (MUC1, MUC2, MUC5AC, and MUC6) was evaluated by 
immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) in 29 gastric polyps, 10 hyperplastic and 19 
adenomatous, eight of which displayed malignant transformation. The aims of this study were to characterize the expression profile of 
these molecules in each type of polyp and to investigate possible modifications of the profile during the process of malignant 
transformation. AH hyperplastic polyps displayed immunoreactivity for TFF1, MUC5AC, and MUC1 in more than 75 per cent of the 
cells In adenomatous polyps, three main phenotypes could be identified: complete gastric phenotype (co-expression of TFF1 and 
MIJCSAC)—nine cases (47-4 per cent); incomplete gastric phenotype (TFF1 -positive and MUC5AC-negative>-«even cases (36-8 per 
cent)- non-gastric (intestinal) phenotype (no expression of TFF1 or MUC5AQ—three cases (15-8 per cent). Data yielded by 
immunohistochemistry and RT-PCR showed a good correlation for both TFF1 and TFF2. One hyperplastic and seven adenomatous 
polyps with villous architecture displayed foci of diffuse and intestinal-type carcinoma, respectively; in all of these cases, MUC1 
expression and signs of gastric differentiation were observed in both the non-malignant and the carcinomatous component. It is concluded 
that gastric differentiation is a feature of hyperplastic polyps and of a subset of adenomatous polyps which is shared by early carcinomas 
arising in some of these polyps, regardless of the histological type of polyp and of carcinoma. Copyright © 1999 John Wiley & Sons, 
Ltd. 
KEY WORDS—adenomatous polyps; hyperplastic polyps; gastric carcinoma; mucins; stomach; trefoil peptides 
INTRODUCTION 
There are two main types of gastric epithelial polyp: 
hyperplastic and adenomatous polyps. Hyperplastic 
polyps are the most common, consisting of an abnormal 
overgrowth of normal gastric foveolar elements. Adeno-
matous polyps (adenomas) consist of tubular, villous or 
tubulo-villous structures covered by dysplastic epi-
thelium.1-2 The incidence of malignant transformation 
appears to be much lower in hyperplastic polyps than in 
adenomatous polyps (2-6 per cent and up to 75 per cent, 
respectively).1"6 Based on the presence of signs of intes-
tinal differentiation on the adenomatous polyps and 
of intestinal metaplasia (IM) in surrounding gastric 
mucosa, it has been proposed that such polyps may be an 
intermediate step in the process of malignant transfor-
mation leading to intestinal-type gastric carcinoma.7"10 
However, it was recently reported that adenomatous 
polyps of the stomach can also display gastric-type 
differentiation and/or a mixed gastric and intestinal 
phenotype.7-11 
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Trefoil peptides (TFF peptides) are small secreted 
molecules with 1-6 highly conserved 6-cysteine-rich 
regions (P-domains) that have been shown to be closely 
related to mucus-secreting epithelia.12"15 In humans, 
three trefoil peptides have been identified to date: TFF1 
(pS2), TFF2 (hSP), and TFF3 (hITF).16 In normal 
gastric mucosa, TFF1 is mainly expressed in the foveo-
lar and superficial epithelium, whereas TFF2 is seen in 
mucous glands.15-16 Mucins are large-molecular-weight 
glycoproteins synthesized by secretory epithelial tissues 
as membrane-bound or secreted proteins.17 In normal 
gastric mucosa, MUC5AC co-localizes with TFF1 in the 
surface/foveolar epithelium and MUC6 is expressed, like 
TFF2, in the mucous cells of the neck zone and in the 
antral glands.15-18"20 MUC1 is expressed in foveolar 
epithelium and oxyntic glands.21-22 The intestinal mucin 
MUC2 is expressed in the Golgi region of foveolar cells 
in normal gastric antral mucosa and* is expressed de novo 
in goblet cells (GC) of IM.18-23-24 
In the present study we evaluated the expression of 
trefoil peptides (TFF1 and TFF2) and mucins (MUC1, 
MUC2, MUC5AC, and MUC6) in a series of 29 hyper-
plastic and adenomatous polyps of the stomach, eight of 
which displayed foci of malignant transformation. The 
aim of the study was two-fold: to characterize the 
expression profile of trefoil peptides and mucins o a each 
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type of gastric polyp and to investigate any modification 
of the profile associated with malignant transformation. 
MATERIALS AND METHODS 
Tissue material 
Twenty-nine gastric polyps (10 hyperplastic and 19 
adenomatous), examined at Hospital S. João/Medicai 
Faculty and IPATIMUP, Porto, Portugal and the 
Medical Faculty of UFMG, Belo Horizonte, Brazil, 
were studied. Eight samples displayed malignant trans-
formation: one hyperplastic and seven adenomatous 
polyps. Tissue fragments were fixed in 10 per cent 
formaldehyde and embedded in paraffin. Serial sections 
of 4//m were stained with haematoxylin and eosin 
(H&E) and by immunohistochemistry. 
Histological study 
The presence of GC, intestinal-type absorptive cells 
(AC), and Paneth cells (PC) was evaluated in each 
lesion. Adenomatous polyps were classified into two 
groups, tubular and villous, including in the latter 
those with a tubulo-villous structure. Malignant foci 
were classified according to Lauren as intestinal- and 
diffuse-type carcinoma.25 
Immunohistochemistry 
A modification of the avidin-biotin-peroxidase 
method was applied26 with 3,3'-diaminobenzidine as the 
chromogen. Sections were incubated overnight at 4°C 
with monoclonal antibodies against TFF1 (BC4, diluted 
1:4; Cis Bio International, Gif-Sur-Yvette, France), 
TFF2 (diluted 1:4; kindly provided by Dr G. Elia), 
MUC1 (HMFG-1, diluted 1:100; Immunotech, 
Marseille, France),22 MUC2 (PMH1, undiluted),24 
MUC5AC (CLH2, diluted 1:1000; Chemicon Inter-
national Inc., Temecula, CA, U.S.A.),19 and MUC6 
(CLH5, diluted 1:2; kindly provided by Drs C. Reis and 
H. Clausen). All series included positive controls; nega-
tive controls were performed by replacement of the 
primary antibodies with immunoglobulins of the same 
class and concentration. 
Scoring of immunoreactivity 
Immunoreactivity was scored according to the pres-
ence of immunoreactive cells: - , none or rare positive 
cells (<5 per cent); +, 5-25 per cent; + + , 25-75 per 
cent; + + +, >75 per cent. 
RT-PCR study 
Semi-quantitative RT-PCR studies were performed in 
formalin-fixed, paraffin-embedded material from six 
hyperplastic and four adenomatous polyps. Microdis-
section of the lesions was performed in four serial 
sections of 10 fim each, selected by examination of a 
consecutive H&E section. The material was incubated 
Copyright © 1999 John Wiley & Sons, Ltd. 
with xylol (5 min), ethanol (5 min), and acetone (1 min), 
being recovered by centrifugation at 13 000 g (1 min), 
after each incubation step. Total RNA was extracted as 
previously described.27 First-strand synthesis was made 
by random 6-mer priming using M-MLV reverse tran-
scriptase at 42°C for 15 min in the presence of 7 mM 
MgCl2. For PCR, we used Taq polymerase in the 
presence of 2 mM MgCl2. Semi-quantitation of TFF1 
and TFF2 mRNA expression levels was performed by 
co-amplification of the target gene (TFF1 or TFF2) and 
the housekeeping gene GAPDH, and correction of 
expression levels relative to GAPDH levels. For each 
sample, the PCR bands resulting from co-amplification 
of TFF1 or TFF2 and GAPDH were quantified separ-
ately using the computer software Multi-Analyst/PC 
(Bio-Rad Laboratories, Hercules, CA, U.S.A.). Relative 
expression levels of both TFF1 and TFF2 were defined 
as percentage ratios of TFF1 /GAPDH and TFF2/ 
GAPDH, respectively. Specific primers for TFF1 
(5'-TTTGGAGCAGAGAGGAGGCAATG and 5'-ACC 
ACAATTCTGTCTTTCACGGGG), TFF2 (5'-AGTT 
GGAGAAGCAGCACTTCC and 5'-GGATCAGTGC 
GTCATGGAG), and GAPDH (5'-ACCCAGAAGAC 
TGTGGATGG and 5'-GGATGACCTTGCCCACAG) 
were chosen. Cycling conditions were 95°C for 30 s, 55°C 
for 30 s, and 72°C for 30 s. After determination of the 
PCR exponential phase for the three amplicons, PCRs 
were amplified for 25 cycles. Negative controls were 
performed by replacement of the template DNA with 
water. As positive controls, we used total RNA 
extracted from whole normal gastric mucosa for 
TFF1 and from the microdissected glandular zone for 
TFF2. 
Pattern of cellular differentiation 
Regarding TFF1 and MUC5AC expression and the 
presence of intestinal-type cells (GC, AC, and PC), three 
main phenotypes were defined: (1) complete gastric 
phenotype, with co-expression of TFF1 and MUC5AC 
and absence of intestinal-type cells; (2) incomplete 
gastric phenotype, with consistent expression of TFF1, 
no expression of MUC5AC, and very rare GC; (3) 
non-gastric (intestinal) phenotype, with no expression 
of TFF1 or MUC5AC, and with the presence of 
intestinal-type cells. 
Statistical analysis 
For statistical analysis, the chi-square test with Yates' 
correction was performed. Fisher's exact test was used 
whenever appropriate. Differences were taken to be 
significant at p<005. 
RESULTS 
Histological analysis 
In hyperplastic polyps, AC, PC, and IM were not 
observed. Foci of diffuse-type carcinoma were present in 
one of the ten hyperplastic polyps. 
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ig. [—Normal gastric mucosa of the antrum displaying strong expression of TFF1 (a) and MUC5AC (b) in the foveolar/superficial epithelium 
nd cells of the neck zone. MUC1 is also expressed (c), though less intensely, in the surface epithelium and neck zone cells 
^ In adenomatous polyps, villous or tubulo-villous 
•architecture was observed in 12 cases (63-1 per cent). 
0 ; oci of intestinal-type carcinoma were observed in seven 
^adenomatous polyps (36-8 per cent). Carcinomatous 
Woci were significantly more common in adenomas 
f r i t h villous features (7/12) than in those with tubular 
architecture (0/7) (/>=001). 
^Expression of trefoil peptides and mucins 
0 Normal gastric mucosa—TFF1 expression was seen in 
^ h e cytoplasm of superficial/foveolar epithelium of 
a n t r a l and oxyntic mucosa and mucopeptic cells of the 
£ieck, and focally in antral glands. TFF2 expression was 
^bserved in the cytoplasm of mucopeptic cells of the 
' i e c k zone, mucous glands of the antrum, and principal 
Aclls of the body. MUC1 expression was observed in 
^uperficial/foveolar and neck zone cells; the chief and 
•parietal cells showed diffuse cytoplasmic staining or 
ffcanalicular system staining, respectively. MUC2 expres-
sion was observed in the Golgi region of some foveolar 
IRells of the normal antral mucosa. MUC5AC was 
^bserved in the perinuclear region in superficial/foveolar 
^ e l l s and mucopeptic cells of the neck region. MUC6 
expression was observed in mucopeptic cells of the neck 
^ o n e and in mucous glands of the antrum. Figure 1 
^ h o w s the pattern of expression of TFF1 (a), MUC5AC 
(fcb), and MUC1 (c) in normal gastric mucosa. 
™ Gastric polyps—Hyperplastic polyps: TFF1 and 
J^1UC5AC were detected in every case in the cytoplasm 
^>f more than 75 per cent of the cells (Figs 2a and 2b). 
• M u C l was also expressed in every hyperplastic polyp in 
^no re than 75 per cent of the cells, both in the cytoplasm 
and at the cell membrane (Fig. 2c). Two cases presented 
ÍMTJC6 expression in fewer than 25 per cent of the cells. 
£MUC2 expression was detected, focally, in another two 
^ ^ o p y right © 1999 John Wiley & Sons, Ltd. 
cases. TFF2 expression was not observed in any case 
(Table I). 
Adenomatous polyps: TFF1 expression was observed 
in 16 cases (84-2 per cent). MUC1 was detected in 14 
cases (73-7 per cent), predominantly at the apical 
membrane and, focally, in the cytoplasm. All but one 
case expressing TFF1 also exhibited MUC1 immuno-
reactivity. MUC2 expression was detected in seven cases 
(36-8 per cent). No relationship was observed between 
MUC2 immunoreactivity and expression of TFF1 or 
other mucins. MUC5AC expression was observed in 
nine cases (47-4 per cent), all of them co-expressing 
TFF1 and MUC1. MUC6 was expressed in seven 
cases (36-8 per cent), all of them displaying also 
TFF1, MUC1, and MUC5AC immunoreactivity. TFF2 
expression was not detected in any case (Table I). 
Pattern of cell differentiation—All hyperplastic polyps 
exhibited a complete gastric phenotype (Table II). In 
adenomatous polyps, three main phenotypes could be 
identified: complete gastric phenotype (high expression 
of TFF1 and MUC5AC)—nine cases (47-4 per cent) 
(Fig. 3); incomplete gastric phenotype (consistent 
expression of TFF1, no expression of MUC5AC, and 
rare GC)—seven cases (36-8 per cent); non-gastric 
(intestinal) phenotype (lack of expression of both TFF1 
and MUC5AQ—3 cases (15-8 per cent) (Fig. 4) 
(Table II). 
RT-PCR—In hyperplastic polyps, we detected high 
levels of TFF1 mRNA expression as evaluated by 
semi-quantitative RT-PCR, ranging from 115-5 to 861-1 
per cent (expressed as a percentage of GAPDH expres-
sion). In the adenomatous polyps, TFF1 relative expres-
sion levels ranged from 33-1 to 257-6 per cent (Table III 
and Fig. 5). TFF2 mRNA was not detected in any of the 
ten samples of gastric polyps. In normal gastric mucosa 
J. Palhol. 187: 541-548(1999) 
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Fig. 2—Hyperplastic polyp displaying the complete gastric phenotype: immunoreactivity for TFF1 (a) and MUC5AC (b) is observed in almost 
every cell and co-localizes with MUC1 (c) 
Table I—Pattern of expression of trefoil peptides and mucins in hyperplastic and adenomatous polyps 
Expression of trefoil peptides and 
No. of positive cases (%) 
mucins 
Polyps TFF1 TFF2 MUC1 MUC2 MUC5AC MUC6 
Hyperplastic (« = 10) 10(100%) 
Adenomatous («= 19) 16 (84-2%) 
0 (0%) 
0 (0%) 
10 (100%) 2 (20%) 
14 (73-7%) 7 (36-8%) 
10 (100%) 
9 (47-4%) 
2 (20%) 
7 (36-8%) 
Table II—Pattern of cellular differentiation in hyperplastic and adenomatous polyps 
Phenotype* 
Complete gastric 
Polyps n (%) 
Incomplete gastric 
n (%) 
Non-gastric (intestinal) 
n (%) 
Hyperplastic {n= 10) 10 (100%) 
Adenomatous (n= 19) 9 (47-4%) 
0 (0%) 
7 (36-8%) 
0 (0%) 
3 (15-8%) 
*See text for definitions. 
used as a positive control, both TFF1 and TFF2 
mRNAs were detected (data not shown). 
The expression data yielded by immunohistochemis-
try and by RT-PCR showed a good correlation for 
TFF1 in every case (Table III). All cases were negative 
for TFF2 expression, both at the mRNA and at the 
protein level. 
Relationship between architecture and 
immunohistochemistry 
We observed a significant relationship between villous 
architecture of the polyps and MUC1 expression 
(p<004) (as well as between villous architecture and 
i 
Copyright © 1999 John Wiley & Sons, Ltd. 
signs of (complete or incomplete) gastric differentiation 
(jrxO-04). 
Malignant transformation 
Foci of malignant transformation were observed in 
eight cases: a diffuse carcinoma occurring in a hyperplas-
tic polyp and seven intestinal-type carcinomas occurring 
in adenomatous polyps. 
Signs of complete gastric differentiation were 
observed in the hyperplastic polyp and the correspond-
ing diffuse carcinoma. MUC6 was observed in the 
neoplastic cells of this case, despite being undetectable in 
the hyperplastic cells of the polyp (Table IV). 
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Wt- 3—Adenomatous polyp with villous structure displaying the «iplei.e gastric phenotype, characterized by co-localization of TFF1 and MUC5AC (b). (c) Immunoreactivity for MUC1 is observed in 
Ac apical region and membrane in more than SO per cent of the cells 
lyright © 1999 John Wiley & Sons, Ltd. 
Five adenomatous polyps with malignant transform-
ation exhibited signs of complete gastric differentiation 
in both components. In the remaining two cases, the 
adenomatous epithelium displayed signs of incomplete 
gastric differentiation, whereas in the corresponding 
carcinomas, both TFF1 and MUC5AC were expressed 
(Table IV). 
MUC1 was detected in both the non-malignant and 
the malignant components of every hyperplastic and 
adenomatous polyp with malignant transformation. 
MUC2 and MUC6 were irregularly expressed in the 
hyperplastic and adenomatous polyps and correspond-
ing malignant foci (Table IV). 
The relationship between malignancy and morpho-
logical and/or immunohistochemical features was 
stronger for villous architecture (p<0-02) than for 
MUC1 expression (p=0l\) or gastric phenotype 
0;=0-26). 
DISCUSSION 
We undertook the present study in order to charac-
terize the patterns of cell differentiation in hyperplastic 
and adenomatous polyps of the stomach, with and 
without malignant transformation. For this purpose, we 
evaluated the expression of trefoil peptides (TFF1 and 
TFF2) and mucins (MUC1, MUC2, MUC5AC, and 
MUC6). In agreement with data on record,14-15-19 we 
observed co-expression of TFF1 and MUC5AC in the 
foveolar/superficial epithelium of gastric mucosa. 
MUC1 was also expressed in the foveolar/superficial 
epithelium and neck zone cells. In keeping with data on 
record,15 immunohistochemical expression of TFF2 was 
not observed at the surface epithelium, although the 
expression of the corresponding mRNA has been pre-
viously reported by in situ hybridization.15 In the 
mucous cells of the antrum, the chief cells of the body, 
and neck zone cells, we observed, as have others, expres-
sion of both TFF2 and MUC6.13-15-16-18-21 In normal 
gastric mucosa, immunoreactivity for MUC2 was 
restricted to the Golgi region of some foveolar cells of 
the antrum. Altogether these results show that trefoil 
peptides and mucins are highly regulated in gastric 
mucosa, being expressed in a cell-specific manner. 15~18,21 
Based on the pattern of expression of TFF1 and 
MUC5AC and on the cell types observed by con-
ventional histology, we identified three types of differ-
entiation: complete gastric, incomplete gastric, and non-
gastric (intestinal) differentiation. The definition of the 
incomplete gastric phenotype was based on the lack of 
MUC5AC expression and the consistent expression of 
TFF1. Since TFF1 expression was previously shown in 
the distal colon,28 we cannot exclude the possibility that 
some of the cases expressing TFF1 alone may have a 
mixed (gastric/intestinal) phenotype. 
In hyperplastic polyps, we observed co-expression of 
TFF1 and MUC5AC, similar to the pattern observed in 
normal gastric mucosa. MUC1 was also observed in a 
high percentage of cells, whereas TFF2 and MUC6 were 
not detected. These findings reinforce the concept that 
hyperplastic polyps represent an overgrowth of l:he 
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Fig. 4 Adenomatous polyp displaying the non-gastric phenotype: the tubular structures of the lesion do not display TFF1 (a) or MUC5AC (b) 
immunoreactivity, in contrast with the intense immunostaining observed in the adjacent gastric mucosa, (c) Immunoreactivity for MUC1 is 
observed at the membrane of every cell of the adenomatous lesion (arrows) 
superficial zone of gastric mucosa.2 The level of expres-
sion of trefoil peptides (TFF1 and TFF2) as evaluated 
by immunohistochemistry was in keeping with the 
expression of their RNAs as determined by RT-PCR: 
high expression of TFF1 and no expression of TFF2. It 
is tempting to suggest that the latter result probably 
reflects the low sensitivity of the method that we 
employed, using paraffin-embedded material, since one 
would expect some level of TFF2 mRNA expression in 
polyps originating in the surface epithelium.15 
In adenomatous polyps, the pattern of expression 
of trefoil peptides and mucins was heterogeneous. Com-
plete gastric differentiation was detected in 47-4 per cent 
of the cases, incomplete gastric differentiation in 36-8 per 
cent, and no gastric differentiation in 15-8 per cent. 
Our results reinforce data on record showing that 
adenomatous polyps may exhibit different types of cell 
Table III—Comparison of TFF1 expression as evaluated by 
semi-quantitative RT-PCR and immunohistochemistry in ten 
gastric polyps 
Case Polyp RT-PCR IHC 
No. type (%) (% cells) 
1 H 486-7 >75 
4 H 748-3 >75 
5 H 350-9 >75 
6 H 861-1 >75 
7 H 364-7 >75 
8 H 115-5 >75 
16 A 40-5 <25 
17 A 38-3 <25 
21 A 331 <25 
29 A 257-6 >75 
differentiation, gastric-, mixed- or intestinal-types.2-7-11 
The study of TFF1 both by immunohistochemistry and 
by RT-PCR also showed the heterogeneity of the series 
of adenomatous polyps (Table III). 
A significant relationship was found between villous 
structure and maligant transformation in adenomatous 
polyps, in keeping with previous reports.1-2-6 
Kushima et al.1 showed that in adenomas with 
intestinal-type differentiation, the immunoexpression of 
p53 was higher than in adenomas with gastric-type 
differentiation. In a preliminary study on p53 expres-
sion in a series of gastric polyps, we did not find a 
relationship between immunoreactivity for p53 and the 
pS2/GAPDH ratio (%) 
364.7 486.7 38.3 115.5 
A=adenomatous; H = hyperplastic; IHC=imrnunohistochemistry. 
Copyright © 1999 John Wiley & Sons, Ltd. 
Fig. 5—TFF1 expression evaluated by semi-quantitative RT-PCR. 
Co-amplification of TFF1 (146 bp) and GAPDH (11:5 bp) analysed on 
a 5 per cent PAA gel stained with ethidium bromide. Bars 1 and 2 
represent band intensities of TFF1 and GAPDH, respectively. Expres-
sion levels of TFF1 were calculated as a TFF1/GAPDH ratio. Case 
numbers refer to those in Table III. Neg = negative control 
J. Pathol. 187: 541-548 (1999) 
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Table IV—Pattern of expression of trefoil peptides and mucins in polyps and corresponding malignant foci 
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Cases 
Case 10 
Hyperplastic epithelium 
Diffuse­type carcinoma 
Case 14 
Adenomatous epithelium 
Intestinal­type carcinoma 
Case 18 
Adenomatous epithelium 
Intestinal­type carcinoma 
Case 22 
Adenomatous epithelium 
Intestinal­type carcinoma 
Case 25 
Adenomatous epithelium 
Intestinal­type carcinoma 
Case 26 
Adenomatous epithelium 
Intestinal­type carcinoma 
Case 27 
Adenomatous epithelium 
Intestinal­type carcinoma 
Case 28 
Adenomatous epithelium 
Intestinal­type carcinoma 
Phenotype* TFF1 TFF2 MUC1 MUC2 MUC5AC MUC6 
Complete gastric + + + 
Complete gastric + 
Incomplete gastric + 
Complete gastric + 
Incomplete gastric + + 
Complete gastric + 
Complete gastric 
Complete gastric 
Complete gastric 
Complete gastric 
+ 
+ 
+ + 
+ 
Complete gastric + + 
Complete gastric + + 
Complete gastric + + 
Complete gastric + + 
Complete gastric + + + 
Complete gastric + + + 
+ + + — + + + — + + — + + 
+ + — — — 
+ + + t + — 
+ + + — — 
+ + + — + — 
+ + + t + + + + + 
+ + + — + + 
+ + + _ + + + + 
+ + + — + + + — 
+ + — + + + 
+ + — + + — 
+ + + — + + — 
+ + + — + + — 
+ + — + + + + 
+ — + + + + 
*See text for definitions and scoring of immunoreactivity. 
fGolgi staining in foveolar­like cells as sometimes observed in normal gastric mucosa. 
"phenotype of the lesions or histological features of 
^aggressiveness, such as the type of structure and the 
_ grade of dysplasia (data not shown). The discrepancies 
•be tween our findings and those reported by Kushima 
Qet al.1 may be due to the different criteria used in the two 
series for the characterization of cell differentiation. One 
• c a n n o t exclude the possibility that cases considered by 
^Kushima et al.1 as having an intestinal phenotype might 
have been classified as incomplete gastric differentiation 
^according to the criteria and markers used in the present 
gkStudy. 
• In the present series, all polyps with foci of malignant 
^transformation exhibited signs of gastric differentiation: 
^complete­type in one hyperplastic polyp and in five 
"adenomatous polyps, and incomplete­type in two 
^adenomatous polyps. 
tmk Eivery carcinoma developing in a gastric polyp 
•corresponded to carcinomas in the early stages of devel­
Aopment and exhibited expression of TFF1 and 
MUC5AC, which are usually considered markers of 
•ga s t r i c differentiation.1419 These findings are in keeping 
^ w i t h those reported by Reis et al.19 and Ho et al.,21 
showing that gastric differentiation is a common event in 
0 t h e first stages of malignant transformation in the 
^s tomach. Our findings show that a subset of the 
•so­cal led 'intestinal' carcinomas of the stomach exhibits 
£s igns of gastric differentiation at the cellular level,19 
^thus supporting our contention that they should be 
•designated as 'glandular' rather than 'intestinal' 
^carcinomas.2 9 
^Copyright © 1999 John Wiley & Sons, Ltd. 
MUC1 was detected in all hyperplastic polyps, in the 
cytoplasm and at the cell membrane, in 14 adenomatous 
polyps (73­7 per cent), and in every carcinoma. In 
adenomatous and carcinomatous lesions, immuno­
reactivity was predominantly expressed at the cell 
membrane. For practical purposes, the evaluation of 
MUC1 expression should not be dissociated from the 
architecture of adenomatous polyps. In fact, every 
adenomatous polyp with malignant transformation had 
villous architecture and displayed MUC1 immuno­
reactivity, whereas the single villous adenomatous polyp 
without MUC1 expression did not display malignancy. 
These observations should not, however, obscure the 
absence of malignant foci in tubular adenomatous 
polyps, regardless of the presence or absence of MUC1 
expression. A larger series is necessary to elucidate the 
putative value of MUC1 expression as a predictor of 
malignant transformation in adenomatous polyps. 
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SUMMARY 
We have previously described the expression of trefoil peptides (TFF1 and TFF2) and 
mucins (MUC1, MIJC2, MUC5AC and MUC6) in gastric polyps. In the present study 
we characterised the expression profile of the aforementioned trefoil peptides and 
mucins in 96 gastric carcinomas, in an attempt to further the understanding of the 
histogenesis and cell differentiation of gastric carcinoma. Taking together the co-
expression of trefoil peptides and mucins, three phenotypes were defined: complete 
gastric; incomplete gastric; and non-gastric phenotype. Gastric differentiation (complete 
and incomplete) was observed in 30 out of 33 (90.9%) diffuse carcinomas and in 38 out 
of 53 (71.7%) intestinal carcinomas. Non-gastric differentiation was observed only in 
three (9.1%) diffuse carcinomas and in 15 (28.3%) intestinal carcinomas. The 
phenotypes observed in intestinal carcinomas were similar to those previously observed 
in adenomatous polyps whereas most diffuse carcinomas mimic the phenotype of 
hyperplastic polyps. The percentage of cases displaying non-gastric phenotype was 
higher, though not significantly, in tumours that had invaded the gastric wall than in Tl 
tumours, regardless of histotype. We conclude that gastric-type differentiation is 
retained in the majority of gastric carcinomas, being more prominent in diffuse than in 
intestinal carcinomas, and in early than advanced carcinomas (we still ignore if the trend 
towards loss of gastric differentiation along tumour progression is paralleled by 
intestinalisation of the carcinomas). 
Key-words: adenomatous polyps, hyperplastic polyps, gastric carcinoma, mucins, 
stomach, trefoil peptides. 
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INTRODUCTION 
Studies based on the immunohistochemical expression of markers of cell 
differentiation1"7 and on electron microscopic features of neoplastic cells,6'8,9 suggest 
that two main types of cell differentiation — intestinal and gastric — can be recognised 
in gastric carcinoma. 
Trefoil peptides (TFF peptides) constitute a group of small secretory peptides bearing 
one or more trefoil structural motifs (P-domains).10'11 The expression of these peptides 
was shown to be closely related to mucous secreting gastrointestinal epithelia. 
Mucins are large molecular-weight glycoproteins synthesised by secretory epithelial 
1 -j 
tissues as membrane-bound or secreted glycoproteins and are expressed in a cell- and 
tissue-specific pattern.14'15 
In normal gastric mucosa, TFF1 (pS2) co-localises with MUC5AC in the 
surface/foveolar epithelium and TFF2 (hSP) is expressed together with MUC6 in the 
mucous cells of the neck zone of the oxyntic mucosa and in the antral glands.15"18 
MUC1, which is a membrane-bound mucin, is expressed in the foveolar epithelium of 
gastric antrum and oxyntic glands of the gastric body.14,19 The intestinal mucin MUC2 is 
usually not expressed in gastric mucosa.14'20'21 
In previous studies we have analysed the expression of trefoil peptides and mucins in 
pre-malignant lesions of the stomach. ' ' In incomplete intestinal metaplasia (types II 
and HI) a mixed gastric and intestinal phenotype was observed, while complete, type I 
intestinal metaplasia was characterised by a shift from gastric-type to intestinal-type 
phenotype.17 In gastric polyps, we observed that gastric-type differentiation is a feature 
of hyperplastic polyps and of a subset of adenomatous polyps which is shared by early 
carcinomas arising in some of these polyps. ' 
In the present study we evaluated the concurrent expression of two trefoil peptides 
(TFF1 and TFF2) and four mucins (MUC1, MUC2, MUC5AC and MUC6) in a series of 
96 gastric carcinomas. We aimed to characterise the expression profile of trefoil 
peptides and mucins in gastric carcinoma per se and in comparison with the profiles 
previously observed in premalignant lesions of the stomach,18 in an attempt to further 
the understanding of the histogenesis and cell differentiation of gastric carcinoma. 
3 
MATERIALS AND METHODS 
Tissue material 
Surgical specimens from 96 gastric carcinomas resected and diagnosed at Hospital S. 
João/Medicai Faculty and IPATIMUP, Porto, Portugal and Medical Faculty of UFMG, 
Belo Horizonte, Brazil, were studied. Tissue fragments were fixed in 10% formaldehyde 
and embedded in paraffin. Serial sections of 4um were obtained from each block and 
used for routine staining with haematoxylin and eosin and immunohistochemistry 
(IHC). 
Gastric carcinomas were classified according to Lauren as intestinal (n=53), diffuse 
(n=33) and unclassifiable (n=10). Regarding the depth of invasion of the gastric wall, 
the cases were classified as: early, corresponding to Tl (n=13); and advanced (n=83), 
corresponding to T2 (n=16), T3 (n=44) and T4 (n=23). 
Immunohistochemistry 
A modification of the avidin-biotin-peroxidase method was applied with 3,3'-
diaminobenzidine as chromogen. Sections were incubated overnight at 4 C with 
monoclonal antibodies (MoAbs) against TFF1 (GE1,24 diluted 1:1200), TFF2 (hSP,25 
diluted 1:4), MUC1 (HMFG-1, diluted 1:100, Immunotech, Marseille, France), MUC2 
(PMH1,20 undiluted), MUC5AC (CLH2, diluted 1:1000, Chemicon International Inc., 
Temecula, CA, USA) and MUC6 (CLH5,17 diluted 1:2). All series included positive 
controls; negative controls were performed by substitution of the primary MoAbs with 
immunoglobulins of the same class and concentration. A case was considered positive 
whenever more than 5% of cells displayed immunohistochemical staining, irrespective 
of its intensity and localisation. 
Pattern of cell differentiation (Phenotype) 
The pattern of cell differentiation was defined according to the criteria previously 
1 R 
described by Nogueira et al. and based upon the expression of trefoil peptides and 
mucins typically expressed in the superficial zone of normal gastric mucosa. Three main 
phenotypes were defined: 1) complete gastric phenotype — co-expression of TFF1 and 
MUC5AC regardless of the expression of TFF2 and MUC6; 2) incomplete gastric 
4 
phenotype — expression of either TFF1 or MUC5AC regardless of the expression of 
TFF2 and MUC6; 3) non-gastric phenotype — no expression of TFF1, TFF2, MUC5AC 
and MUC6. 
Statistical analysis 
2 
The statistical analysis of the results was performed using the Pearson-X test. 
Differences were considered to be significant at p<0.05 and suggestive at p<0.1. 
RESULTS 
Normal gastric mucosa 
There was co-expression of TFF1 and MUC5AC in the cytoplasm of superficial and 
foveolar epithelium of antral and oxyntic mucosa as well as in mucopeptic cells of the 
neck; TFF1 was also observed focally in antrum glands. In the cytoplasm of mucopeptic 
cells of the neck zone, mucous glands of the antrum, and principal cells of the body 
there was co-expression of TFF2 and MUC6. MUC1 expression was observed in 
superficial/foveolar and neck zone cells; the principal and parietal cells showed a diffuse 
cytoplasmic staining or canalicular system staining, respectively. MUC2 expression was 
observed in the supranuclear Golgi region of rare foveolar cells of the antrum. 
Gastric carcinoma 
TFF1 and TFF2 expression was observed, respectively, in 64 cases (66.7%) and in 10 
cases (10.4%) of the 96 gastric carcinomas (Table I). Immunoreactivity for MUC5AC 
was detected in 61 cases (63.5%) and MUC6 immunoexpression was found in 36 cases 
(37.5%) (Table I). TFF1, TFF2, MUC5AC and MUC6 antigens displayed an 
immunoexpression pattern characterised by diffuse cytoplasmic staining. MUC1 was 
detected in 79 cases (82.3%): predominantly at the apical membrane in intestinal-type 
tumours; and with a diffuse pattern of staining in the cytoplasm of the diffuse-type 
tumours. MUC2 immunoreactivity was detected in 22 cases (22.9%), in the cytoplasm 
of neoplastic cells. 
In the whole series there was a significant correlation between TFF1 and MUC5AC 
expression (p<0.0001): 50 out of 64 cases positive for TFF1 (78.1%) also displayed 
immunoreactivity for MUC5AC; 21 out of 32 cases without expression of TFF1 
(65.6%) were also negative for MUC5AC expression. No significant correlation was 
found between the immunohistochemical expression of TFF2 and MUC6: six out of 10 
cases positive for TFF2 (60.0%) were positive for MUC6; 56 out of 86 cases without 
expression of TFF2 (65.1%) were also negative for MUC6 expression. 
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Table I - Comparison between the immunoexpression pattern of trefoil peptides and 
mucins and the histological type of 96 gastric carcinomas. 
Histological type IHC positive cases (%) 
TFF1 MUC5AC TFF2 MUC6 MUC1 MUC2 
Diffuse ca (n = 33) 25 (75.8) 23 (69.7) 5(15.2) 8 (24.2) 24 (72.7) 8 (24.2) 
Intestinal ca (n = 53) 30(56.6) 29(54.7) 4(7.5) 22(41.5) 46(86.8) 11(20.8) 
Unclassifiable ca (n = 10) 9(90.0) 9(90.0) 1(10.0) 6(60.0) 9(90.0) 3(30.0) 
p value 0.05 0.07 0.53 0.10 0.20 0.80 
Total (n = 96) 64 (66.7) 61 (63.5) 10 (10.4) 36 (37.5) 79 (82.3) 22 (22.9) 
The comparison between the immunohistochemical expression of the antigens under 
study and the histological classification of the tumours revealed a significant association 
(p=0.05) between the expression of TFF1 and the diffuse and unclassifiable histological 
types (Table I). A suggestive association (p=0.07) was observed between MUC5AC 
expression and the diffuse and unclassifiable histotypes (Table I). No relationship was 
found between the expression of TFF2, MUC1, MUC2 or MUC6 and the histotype of 
the tumours. 
According to the expression pattern of trefoil peptides and mucins, 50 cases (52.1%) 
presenting co-expression of TFF1 and MUC5AC were identified as complete gastric-
type (Table H) (Figs. 1 and 2). Incomplete gastric phenotype was observed in 28 cases 
(29.2%) (Table II); three cases negative for TFF1, TFF2 and MUC5AC but expressing 
MUC6 were included in the group of incomplete gastric-type differentiation. Lack of 
expression of TFFl, TFF2, MUC5AC and MUC6 was found in the remaining 18 cases 
(18.7%), therefore identified as non-gastric phenotype (Table H) (Fig. 3). 
Table II - Comparison between phenotypic differentiation and histological type 
of gastric carcinomas. 
Histological type 
Cases 
Phenotype (%) 
Complete Incomplete Non-gastric P 
(%) Gastric gastric value 
Diffuse ca 33 (34.4) 18 (54.5) 12 (36.4) 3 (9.1) 
Intestinal ca 53 (55.2) 24 (45.3) 14 (26.4) 15 (28.3) 0.06 
Unclassifiable ca 10(10.4) 8 (80.0) 2 (20.0) 0(0) 
Total 96(100) 50(52.1) 28 (29.2) 18(18.7) 
Fig. 1 - Diffuse gastric carcinoma displaying complete gastric phenotype: TFF1 (A) and 
MUC5AC (B) immunostaining is observed in the cytoplasm of tumour cells, and co-
localise with the expression of MUC1 (C). (X 840) 
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Fig. 2 - Intestinal gastric carcinoma presenting complete gastric-type differentiation 
characterised by the co-localisation of TFF1 and MUC5AC expression; MUC1 (C) is 
highly expressed in the same area. (X 420) 
Fig. 3: Non-gastric phenotype in a gastric carcinoma of the intestinal histotype: no 
immunoreactivity is observed for TFF1 (A) and MUC5AC (B); MUC1 (C) expression is 
observed at the apical membrane of some neoplastic glands. (X 420) 
The prevalence of MUC1 expression was similar in the three phenotypes: in 44 out of 
50 cases (88.0%) with complete gastric-type differentiation; in 22 out of 28 cases 
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(78.6%) presenting incomplete gastric-type differentiation; and in 13 out of 18 cases 
(72.2%) classified as non-gastric phenotype. The same holds true regarding the 
expression of MUC2, which was seen in 14 out of 50 cases (28.0%) displaying complete 
gastric phenotype; in six out of 28 cases (21.4%) presenting incomplete gastric-type 
differentiation; and in two out of 18 cases (11.1%) with non-gastric phenotype. 
The comparison between the histological type of the cases and the phenotype disclosed 
a suggestive association (p=0.06) between the diffuse and unclassifiable histotypes and 
the gastric (complete and incomplete) phenotypes, and between the intestinal histotype 
and the non-gastric phenotype (Table H). 
Table III - Comparison between phenotypic differentiation and extent of 
wall invasion of gastric carcinomas, according to the histological type. 
T stage 
Cases 
Phenotype (%) 
Complete Incomplete Non-gastric p value 
Gastric gastric 
Diffuse 
Early 5 3 (60.0) 2 (40.0) 0 0.75 
Advanced 28 15 (53.5) 10 (35.7) 3 (10.7) 
Intestinal 
Early 8 5 (62.5) 2 (25.0) 1 (12.5) 0.48 
Advanced 45 19 (42.2) 12 (26.7) 14(31.1) 
Total 
Early 13 8(61.5) 4 (30.8) 1 (7.7) 0.53 
Advanced 83 42 (50.6) 24 (28.9) 17 (20.5) 
Most of the early tumours were identified as complete gastric-type (8/13 - 61.5%) or 
incomplete gastric-type (4/13 - 30.8%) and only one early tumour, with intestinal 
histotype, was found to present a non-gastric phenotype (7.7%) (Table III); in contrast to 
this, in the group of advanced tumours, 17 out of 83 cases (20.5%) had a non-gastric 
phenotype (Table III); these differences did not attain, however, the threshold of 
statistical significance (p=0.53) (Table HI). The same holds true regarding MUC2 
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expression, which was found to be more prevalent, though not significantly, in advanced 
tumours than in early tumours (p=0.16) (Table IV). 
Table IV - Comparison between MUC2 expression and extent 
of wall invasion of gastric carcinomas according to the 
histological type. 
T stage 
Cases 
MUC2IHC(%) 
+ - p value 
Diffuse 
Early 5 0(0) 5 (100) 0.17 
Advanced 28 8 (28.6) 20(71.4) 
Intestinal 
Early 8 1 (12.5) 7 (87.5) 0.53 
Advanced 45 10 (22.2) 35 (77.8) 
Total 0.16 
Early 13 1 (7.7) 12 (92.3) 
Advanced 83 21 (25.3) 62 (74.7) 
DISCUSSION 
The expression of mucins and trefoil peptides follows a cell- and tissue-specific pattern 
in normal tissues.14'15 In the stomach, there is co-expression of TFF1 and MUC5AC in 
the surface/foveolar epithelium and TFF2 is expressed together with MUC6 in the 
] C 10 
mucous cells of the neck zone of the oxyntic mucosa and in the antral glands. " These 
features are in keeping with the hypothesis that the expression of trefoil peptides is 
closely related to mucous secreting epithelia10"12 and that TFF peptides and mucins may 
act in a synergistic manner to protect and reconstitute epithelial tissues.2 ' 7 Changes in 
the pattern of expression of trefoil peptides and mucins were previously described in 
IS 17 19 77 78 79 
premalignant and malignant lesions of the stomach. ' ' ' ' ' 
In the present study we observed that TFF1 and MUC5AC were similarly expressed in 
gastric carcinomas (66.7% and 63.5%, respectively). Co-expression of TFF1 and 
MUC5AC was detected in 50 of the 96 cases (52.1%). At variance with this, expression 
of TFF2 and MUC6 was observed in a much lower percentage of the cases (10.4% and 
37.5%, respectively) and co-expression of TFF2 and MUC6 was detected only in six of 
the 96 cases (6.3%). 
Based on the pattern of expression of the different mucins and trefoil peptides, and in 
accordance with previously reported criteria,18 we defined three main phenotypes of cell 
differentiation: complete gastric, incomplete gastric and non-gastric phenotype. 
Overall, our study shows that the majority of gastric carcinomas retain signs of complete 
(52.1%) or incomplete (29.2%) gastric-type differentiation. Such signs are more often 
exhibited in diffuse and unclassifiable carcinomas than in intestinal-type carcinomas. 
However, gastric-type differentiation was also observed in intestinal-type carcinomas, 
supporting our contention that gastric carcinomas forming glands should be designated 
as "glandular" instead of "intestinal" carcinomas, in order to avoid mixing structural 
with cell differentiation concepts.6'30 In 18.7% of the cases, mostly of the intestinal 
histotype, we found no signs of gastric-type differentiation. 
MUC1 is a very ubiquitous epithelial mucin14'19 whereas MUC2 is characteristically 
expressed in goblet cells of native intestinal epithelium.14,20 In the present study MUC1 
expression was observed in the majority of the cases (82.3%) whereas MUC2 was 
expressed in relatively few cases (22.9%). We found no significant relationship between 
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the expression of both MUC1 and MUC2 and the histotype and cell differentiation 
pattern of the tumours, in keeping with previously reported data.19"21 The expression of 
MUC2 in carcinomas displaying a gastric phenotype may indicate the existence of a 
mixed differentiation (gastric and intestinal) in these tumours; this possibility remains 
however disputable because we observed a low prevalence of MUC2 expression in the 
group of tumours that in principle should depict the highest degree of intestinal 
differentiation: carcinomas of the intestinal histotype with a non-gastric phenotype. 
It is generally accepted that there are two main pathways of malignant transformation of 
gastric mucosa: one via intestinal metaplasia and adenomatous (flat or polypoid) 
dysplasia, leading to intestinal carcinomas; the other via hyperplastic or de novo 
changes, with or without concurrent non-metaplastic dysplasia, leading to diffuse 
carcinomas and to a subset of intestinal carcinomas6'31 (Fig. 4). 
In previous studies, we analysed the cell differentiation phenotypes of distinct pre-
malignant lesions of the stomach, through the evaluation of the expression patterns of 
trefoil peptides and mucins.17'18'22 We observed that complete gastric differentiation is a 
feature of hyperplastic lesions and that the cell differentiation of adenomatous lesions is 
heterogeneous, encompassing both gastric (complete and incomplete) and non-gastric 
phenotypes. In figure 4 we summarised the results obtained in the present study together 
with the aforementioned results having as background the model of gastric 
carcinogenesis previously mentioned. The comparison of these results highlights four 
points: firstly, the demonstration that intestinal metaplasia of incomplete type displays 
immunohistochemical markers of gastric differentiation, such as gastric type mucins17 
and TFF122 fits with the hypothesis that, in the cascade of events leading to intestinal 
carcinoma, incomplete intestinal metaplasia (namely type HI) may serve as precursor of 
the adenomatous/dysplastic lesions exhibiting signs of gastric differentiation. Secondly, 
the three types of cell differentiation are similarly prevalent in the adenomatous lesions 
and in the intestinal type carcinomas (Fig. 4) thus supporting the hypothesis that 
adenomatous/dysplastic lesions do serve as precursors of intestinal-type gastric 
carcinoma. Thirdly, cell differentiation of gastric type is characteristically retained along 
the process of gastric carcinogenesis that leads to diffuse carcinomas (Fig. 4), in keeping 
with the origin of these tumours either de novo or from hyperplastic lesions. Fourthly, 
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we observed that the absence (loss?) of signs of gastric differentiation occurs in both 
pathways of gastric carcinogenesis, though more prominently in that leading to 
intestinal-type carcinomas than that leading to diffuse carcinomas. 
47.4% 
45.3% 
Phenotype 
Complete Incomplete Non 
Gastric Gastric Gastric 
36.8 % 
26.4% 
15.8% 
Normal mucosa 
Chronic gastritis 
i 
Intestinal metaplasia 
Chronic gastritis 
/ \ 
/ \ 
/ \ 
/ \ 
/ 
Adenomatous 
dysplasia 
\ Hyperplastic 1 0 0 % 
lesions 
28.3% Intestinal carcinoma 
\ 
Diffuse carcinoma 54.5% 
Phenotype 
Complete Incomplete Non 
Gastric Gastric Gastric 
36.4 % 9.11 
Fig. 4: Simplified model of gastric carcinogenesis illustrating the two main pathways of malignant 
transformation, and the prevalences of complete gastric, incomplete gastric and non-gastric phenotypes 
observed in the different types of pre-malignant and malignant lesions. (Data on the premalignant lesions 
were previously published18'22). 
Finally our results indicate that the absence (loss?) of gastric differentiation appears to 
be related with tumour progression, increasing from early to advanced carcinomas, both 
in intestinal and diffuse carcinomas (e.g. the only three diffuse carcinomas displaying a 
non-gastric phenotype were advanced cases). Ultrastructural and immunohistochemical 
data on record1'5'7'8 led to the suggestion that there is acquisition of signs of intestinal 
differentiation along with gastric carcinoma progression. Our data support this 
assumption but did not attain the threshold of statistical significance. A detailed study of 
MUC2 and other putative markers of intestinal differentiation in a larger series of early 
and advanced carcinomas and, within the latter, in superficial and deep areas appears 
thus necessary to find whether or not the loss of gastric differentiation along with 
tumour progression is paralleled by intestinalisation of the carcinomas. 
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E-Cadherin Expression Is Correlated with 
the Isolated Cell/Diffuse Histotype and with 
Features of Biological Aggressiveness 
of Gastric Carcinoma 
José C. Machado, MSc* Fátima Carneiro, MD, PhD,* 
Stefanie Beck, PhD,t Simone Rossi, MD,* Joanne Lopes, MD,§ 
António Taveira-Gomes, MD," and Manuel Cardoso-Oliveira, MD, PhD 
We studied the pattern of immunohistochemical expression of E-cadherin in a series 
of 50 gastric carcinomas, aiming to analyze its relationship with histotype and fea-
tures of biological aggressiveness of the tumors and survival of the patients. Abnor-
mal E-cadherin expression was significantly (p=.0007) higher in diffuse/isolated-cell-
type carcinomas than in intestinal/glandular carcinomas. In mixed carcinomas 
abnormal E-cadherin expression in the diffuse/isolated-cell-type component 
(94.4%) was significantly (p=.007) higher than in intestinal/glandular component 
(55.6%). Significant relationships were observed between abnormal E-cadherin ex-
pression and nodal metastases (p=.004) and pTNM stages (p=.05). Survival of pa-
tients with tumors displaying abnormal E-cadherin expression was worse than that 
of patients with tumors presenting normal expression, though not attaining the 
threshold of statistical significance (p=.19). We conclude that abnormal E-cadherin 
expression is correlated with diffuse/isolated-cell histotype and features of biological 
aggressiveness of gastric carcinoma. Int J Surg Pathol 6(3):135-144,1998 
Key words: cancer, cell adhesion, E-cadherin, gastric carcinoma, prognosis, stomach. 
served tandem repeated sequences, known as cad-
herin domains [2]. Each of these domains contains 
two highly conserved Ca2 +-binding motifs [2], 
which play a key role in adhesion specificity [31. 
The function of E-cadherin is also dependent on the 
interaction of its conserved cytoplasmic domain (C-
terminal) with the cytoskeleton via molecular com-
plexes involving a-, p*- and y-catenin [2]. The E-cad-
herin protein is expressed in all normal epithelial 
tissues: polarized at the lateral cell-cell boundaries 
in ductal and glandular epithelia and localized cir-
cumferentially in the whole cell membrane in squa-
mous and transitional epithelia [4]. * 
It has been postulated that changes in expression 
or function of E-cadherin may account for the abil-
ity of cancer cells to detach from the parent tumor 
structure and invade locally. Indeed, reduction 
135 
E-cadherin belongs to the cadherin family of Ca2+ 
dependent cell adhesion molecules [1]. These mol-
ecule:; are localized at the adherens junction of ep-
ithelial cells and regulate the process of homo-
philic/homotypic adhesion between epithelial cells 
[1J. E-cadherin is a transmembrane glycoprotein 
presenting at its extracellular part (N-terminal) con-
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and/or loss of expression of E-cadherin has been ob-
served in several types of carcinoma, and frequently 
associated with poorly differentiated/undifferenti-
ated carcinomas and/or invasive tumors [5—10]. 
Loss of expression of E-cadherin has been associated 
with mutation of the E-cadherin gene and loss of 
heterozygosity (LOH) in 16q22 in infiltrative lobu-
lar carcinomas of the breast [11,12]. Becker et al. 
[13] described mutations of the E-cadherin gene in 
50% of diffuse carcinomas of the stomach and re-
ported a gastric carcinoma case presenting LOH 
with retention of a mutated E-cadherin allele. These 
findings support a role of E-cadherin as a tumor 
and/or invasion suppressor gene, as previously sug-
gested by in vitro observations [14,15]. 
The first descriptions of E-cadherin expression in 
gastric carcinoma were provided by Shimoyama 
and Hirohashi [16] and Shiozaki et al. [17]. While 
Shiozaki et al. [17] reported a reduced E-cadherin 
expression in poorly differentia ted/undifferentiated 
carcinomas, Shimoyama and Hirohashi [16] could 
not find any correlation between E-cadherin ex-
pression and the differentiation of the tumors. This 
initial discrepancy was clarified by further studies 
on the expression of E-cadherin in gastric carci-
noma that pointed to a trend toward an association 
between reduction/loss or abnormal expression of 
E-cadherin and two histotypes of gastric carcinoma: 
poorly differentiated/undifferentiated carcinomas 
and diffuse carcinomas [5,18-23]. Moreover, in 
some of these studies a significant relationship was 
observed between altered expression of E-cadherin 
and features of aggressiveness of the tumors and/or 
poor survival of the patients [5,18,19,22,23]. 
Altogether, the data on record support the exis-
tence of a close association between alfaíê&expres-
sion of E-cadherin and infiltrative/invasive growth 
pattern of the tumors with reduced or no adhesion 
between cancer cells, features that are shared by 
both diffuse gastric carcinoma [19,23] and invasive 
lobular carcinoma of the breast [10]. 
We undertook the present immunohistochemical 
study of E-cadherin expression in a series of gastric 
carcinomas in an attempt to settle the aforemen-
tioned controversy on the putative association be-
tween altered expression of E-cadherin and the dif-
ferent histotypes of gastric carcinoma. The study of 
E-cadherin expression was carried on in carcinomas 
of 'pure" histologic type (intestinal/glandular carci-
nomas and diffuse/isolated-cell-type carcinomas) as 
well as in a subgroup of mixed gastric carcinomas 
[24]. In these mixed carcinomas E-cadherin expres-
sion was evaluated separately in the different histo-
logic components of the tumors. To the best of our 
knowledge this is the first report describing differ-
ences in E-cadherin expression in the different his-
tologic components of mixed gastric carcinomas. 
Materials and Methods 
Tissue Material 
Surgical specimens from 50 gastric carcinomas con-
secutively resected at Hospital SJoão-Medical Fac-
ulty, Porto, Portugal, were studied. The noninvolved 
mucosa adjacent to each case was also studied. 
The tissue fragments were fixed in 10% 
formaldehyde and embedded in paraffin. Serial sec-
tions of 4 urn were cut from each block and used for 
routine staining with hematoxylin and eosin (H&E) 
and immunohistochemical study. 
Immunohistochemistry 
Monoclonal antibody (MoAb) HECD-1 (Zymed, 
San Francisco, CA) was used for immunohisto-
chemical (IHC) study of the expression of E-cad-
herin in formalin-fixed paraffin-embedded tissues. 
A modification of the avidin-biotin-peroxidase 
complex method [25] was applied with an addi-
tional step for microwave antigen retrieval. The 
paraffin sections (4 pm thick) were dewaxed and 
antigen retrieval was done by microwave treatment 
5 x 1.5 min at 750 W in a 0.1% detergent solution 
[26]. The sections were treated with 0.3% hydrogen 
peroxide in methanol for 30 minutes to block en-
dogenous peroxidase, washed in TBS, and then in-
cubated for 20 minutes with normal rabbit serum, 
at a dilution of 1:5 in TBS containing 25% bovine 
serum albumin (BSA). Excess normal serum was 
removed and replaced by the MoAb HECD-1 di-
luted at 1:400. After overnight incubation (18 
hours) at 4°C, slides were washed with TBS and the 
sections incubated with a 1:200 dilution of biotin-
labeled secondary antibody for 30 minutes. After 
washing with TBS, sections were incubated with 
avidin-biotin-peroxidase complex (10 mg/mL of bi-
otin-Iabeled peroxidase) for 60 minutes. This was 
followed by staining the sections for 6 minutes with 
0.05% diaminobenzidine, freshly prepared in 0.05 
M TRIS buffer, pH 7.6, containing 0.01% hydrogen 
peroxide. Finally, sections were counterstained with 
hematoxylin, dehydrated, and mounted. Dilution 
of primary antibodies, biotin-Iabeled secondary an- « 
tibodies, and avidin-biotin-peroxidase complex 
were made with TBS containing 12.5% BSA. 
AH series included normal gastric mucosa as pos-
itive controls. Negative controls were performed by 
substitution of the primary antibody with IgGl im-
munoglobulins of the same subclass and concentra-
tion as the MoAb. 
•7 
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Scoring 
For purposes of data analysis, all tumors with loss 
of normal membranous pattern of staining were 
classified as abnormal. Staining was scored in a 
semiquantitative fashion from 0 to 3, according to 
the evaluation criteria described by Jawhari et al. 
[5]: 0, absence of staining; 1, diffuse cytoplasmic 
staining; 2, heterogeneous staining (i.e., both nor-
mal and abnormally staining areas); and 3, normal 
membranous pattern of staining. Whenever the 
staining patterns varied within the same tumor, the 
score was based on the dominant pattern, provided 
this was observed in more than 90% of neoplastic 
cells. Cases exhibiting more than one pattern of im-
munoreactivity were classified as heterogeneous 
whenever each of the patterns was observed in 
more than 10% of neoplastic cells. 
Statistical Analysis 
The statistical analysis of the results was per-
formed by Pearson-x2 test. Differences were consid-
ered to be statistically significant at values of p<.05. 
The relationship between the expression of E-cad-
herin and survival of the patients was assessed by 
use of both univariate and multivariate analysis. 
Survival curves were calculated according to the 
method of Kaplan and Meier and compared statisti-
cally by the Generalized Savage (Mantel-Cox) test. 
The Cox's proportional hazards model was em-
ployed to evaluate the influence on survival of E-
cadherin expression in relation to other clinico-
pathologic variables. The MPLR (maximum partial 
likelihood ratio) method was employed to perform a 
linear stepwise multivariate regression of the factors 
that are significantly or suggestively related to the 
survival. The assumed limit for significance to enter 
a term was .1 and the limit to remove a term .15. 
Results 
Normal Mucosa 
E-cadherin staining was observed in every case 
throughout the gastric epithelium of noncancerous 
areas, including areas of intestinal metaplasia. At the 
cellular level, E-cadherin expression was mainly lo-
calized at the lateral cell-cell boundaries, but staining 
was also seen in the paranuclear Golgi area (Fig. 1). 
Gastric Carcinoma 
Table 1 summarizes the clinicopathologic features 
of the 50 cases included in the present series and the 
immunohistochemical findings regarding E-cad-
herin expression. 
According to Lauren's classification [27], cases 
were classified as intestinal (n=20), diffuse (n=28), 
and unclassifiable (n=two). According to the classi-
fication proposed by Carneiro et al. [24], cases were 
classified as glandular (n=19), isolated-cell-type 
(n=ll), solid (n=two), and mixed (n=18). 
A normal pattern of E-cadherin expression, i.e., a 
membranous staining pattern, was observed in 13 
of the 50 carcinomas (26.0%) of the whole series. 
This pattern of immunoreactivity was observed in 
11/20 (55.0%) intestinal carcinomas (Fig. 2A) and 
in 2/28 (7.1%) diffuse carcinomas (Fig. 2B). Intesti-
nal carcinomas displayed immunoreactivity at the 
lateral cellular membrane (polarized pattern) (Fig. 
2A), whereas, in diffuse carcinomas, membranous 
staining was localized in the whole cell membrane 
(nonpolarized pattern) (Fig. 2B). 
Abnormal pattern of E-cadherin staining was ob-
served in 37 of the 50 gastric carcinomas (74.0%). In 
intestinal carcinomas we observed an abnormal pat-
tern of E-cadherin expression in 9/20 (45.0%) cases 
(Fig. 3A), encompassing cases scored as: 1, 3/9 
(33.3%); and 2, 6/9 (66.7%). Abnormal pattern of 
E-cadherin expression was observed in 26/28 
(92.9%) diffuse carcinomas (Fig. 3B), encompassing 
cases scored as: 0, 1/26 (3.8%); 1, 11/26 (42.3%); 
and 2, 14/26 (53.8%). The comparison of the results 
obtained in the two histotypes yielded statistically 
significant differences (p=.0007) (Table 1). 
Eighteen cases, classified according to the pre-
dominant histologic type as intestinal or diffuse car-
cinomas, displayed small foci with a structure dif-
ferent from the main component of the tumor—foci 
of intestinal carcinoma in diffuse carcinomas (n=17) 
and foci of diffuse carcinoma in an intestinal carci-
noma (n=l ). These cases were subclassified, accord-
ing to the classification proposed by Carneiro et al. 
[24], as mixed carcinomas. In these cases, immuno-
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Table 1. R e l a t i o n s h i p B e t w e e n the C l i n i c o p a t h o l o g i c Fea tu r e s of Gas t r ic C a r c i n o m a s a n d E-cadher in Expre s s ion 
E-cadherin IHC 
Age 
<40 years 
40-65 years 
565 years 
Gender 
Male 
Female 
Lauren's classification 
Intestinal 
Diffuse 
Unclassified 
Carneiro, et al. classification 
Isolated-cell ca 
Glandular ca 
Solid ca 
Mixed ca 
Depth of invasion 
Tl (mucosa + submucosa) 
T2 (muscular + subserosa) 
>T3 (serosa + adjacent organs) 
Venous invasion 
Absent 
Present 
Lymph node metastasis 
Absent 
Present 
pTNM stage 
I 
II 
III 
IV 
Survival 
<3 years 
S3 years 
Total 
No. of Cases (%) 
NS: not significant. 
7 (14.0) 
27 (54.0) 
16 (32.0) 
34 (68.0) 
16 (32.0) 
20 (40.0) 
28 (56.0) 
2 (4.0) 
II (22.0) 
19 (38.0) 
2 (4.0) 
18 (36.0) 
5(10.0) 
7(14.0) 
38 (76.0) 
30 (60.0) 
20 (40.0) 
18(36.0) 
32 (64.0) 
16 (32.0) 
8 (16.0) 
25 (50.0) 
1 (2.0) 
35 (70.0) 
15 (30.0) 
50(100.0) 
Normal (%) Abnormal (%) 
1 (14.3) 
8 (29.6) 
4(25.0) 
10 (29.4) 
3 (18.8) 
11 (55.0) 
2(7.1) 
0 (0.0) 
1 (9.1) 
11 (57.9) 
0 (0.0) 
1 (5.6) 
1 (20.0) 
3 (42.9) 
9 (23.7) 
8 (26.7) 
5 (25.0) 
9 (50.0) 
4(12.5) 
8 (50.0) 
2 (25.0) 
3 (12.0) 
0 (0.0) 
5 (14.3) 
8(53.3) 
13(26.0) 
6 (85.7) 
19(70.4) 
12 (75.0) 
24 (70.6) 
13 (81.3) 
9 (45.0) 
26 (92.9) 
2 (100.0) 
10(90.9) 
8 (42.1) 
2 (100.0) 
17(94.4) 
4 (80.0) 
4(57.1) 
29 (76.3) 
22 (73.3) 
15 (75.0) 
9 (50.0) 
28 (87.5) 
8 (50.0) 
6 (75.0) 
22 (88.0) 
1 (100.0) 
30 (85.7) 
7 (46.7) 
37 (74.0) 
p Value 
NS 
NS 
.0007 
.001 
NS 
NS 
.004 
.05 
.004 
histochemical expression of E-cadherin was evaluated 
separately in each component of the tumor (Table 2). 
Seventeen cases displayed an overall abnormal pat-
tern of E-cadherin expression corresponding, accord-
ing to Lauren's classification, to 16 diffuse carcinomas 
and to one intestinal carcinoma. The remaining case 
exhibited a normal pattern of immunoreactivity. 
In seven of these mixed carcinomas a normal pat-
tern of immunoreactivity was observed in the in-
testinal/glandular component and an abnormal pat-
tern was seen in the diffuse/isolated-cell 
component (Table 2) (Fig. 4). In 10 cases both com-
ponents of mixed carcinomas displayed an abnor-
mal pattern of immunoreactivity and, in the re-
maining case, a normal pattern of immunostaining 
was observed in the two components (Table 2). 
In the whole series, we found a significant associ-
ation between E-cadherin staining and metastiza-
tion to lymph nodes (p=.004) and pTNM staging 
(p=.05) (Table 1). No significant relationship was 
found between E-cadherin expression and the age 
or gender of patients, depth of penetration of gastric 
wall, and venous invasion (Table 1). 
Regarding the survival time, the patients were di-
vided into two groups: short survivors (survival 
time <3 years) and long survivors (survival time >3 
years). The percentage of cases with abnormal E-
cadherin expression was significantly higher in 
short survivors (85.7%) than in long survivors 
(46.7%) (p=.004) (Table 1). In univariate analysis of 
survival, the survival time of patients with gastric 
carcinomas displaying normal E-cadherin expres-
sion (mean survival time, 42.3 months) was better 
than that of patients with an abnormal staining pat-
tern (mean survival time, 29.1 months), though the 
comparison of the respective survival curves did not 
reach the threshold of statisticaj significance (p=.19) 
(Fig. 5). The multivariate analysis of the whole se-
ries showed that venous invasion was the strongest 
independent prognostic factor followed by pTNM 
stage. E-cadherin expression did not stand as an in-
dependent prognostic factor. 
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Fig. 2. Normal pattern of E-cadherin expression: (A) Intestinal carcinoma expressing E-cadherin at the lateral cellular 
membrane (polarized pattern); (B) Diffuse carcinoma showing membranous staining localized in the whole cell mem-
brane (nonpolarized pattern). 
Fig. 3. Abnormal pattern of E-cadherin staining: (A) Intestinal carcinoma displaying immunoreactivity for E-cadherin in 
the cytoplasmic and paranuclear Golgi area; (B) Diffuse carcinoma with E-cadherin faintly expressed in the cytoplasm of 
the neoplastic cells. 
Discussion 
We found abnormal E-cadherin expression in 
74.0% of gastric carcinomas, a prevalence close to 
that reported by Yonemura et al. [19] and Gabbert 
e ta l . [22]. In other studies [5,17,18,20,21], the per-
centage of altered E-cadherin expression in gastric 
carcinoma ranged from about 17% in the study of 
Shimoyama and Hirohashi [16] to about 92% in the 
study of Mayer et al. [23]. Differences in the anti-
bodies and in the evaluation criteria used in the dif-
ferent series probably account for the aforemen-
tioned discrepancies. 
According to the system we used to score im-
munoreactivity in our series, one case was scored as 
0 (absence of immunoreactivity), 16 cases were 
scored as 1 (diffuse cytoplasmic staining), and 20 
cases were scored as 2 (heterogeneous staining). Al-
together, these results show that, in a large propor-
tion of cases (36/50), E-cadherin immunoreactivity 
was detected in the cytoplasm (alone or in combi-
nation with expression at the cell membrane). Cy-
toplasmic localization of E-cadherin in gastric carci-
noma had already been described by other authors 
[5,17,22]. Several processes may account for this 
ectopic localization of E-cadherin: endocytic inter-
i 
: 
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Table 2. Pattern of E-cadherin Immunoexpression in Separate Histologic Components 
of 18 Cases of Mixed Gastric Carcinoma 
Case 
Predominant 
Component 
Pattern of IHC (Score) 
Diffuse/Isolated-Cell-
Type Component 
1 Diffuse Abnormal (0) 
2 Diffuse Abnormal (1) 
} Diffuse Abnormal (1) 
4 Diffuse Abnormal (1) 
5 Diffuse Abnormal (1) 
6 Diffuse Abnormal (1) 
7 Diffuse Abnormal (1) 
8 Diffuse Abnormal (1) 
9 Diffuse Abnormal ( 1 ) 
10 Intestinal Abnormal (2) 
11 Diffuse Abnormal (1) 
12 Diffuse Abnormal (1) 
13 Diffuse Abnormal (1) 
14 Diffuse Abnormal (1) 
15 Diffuse Abnormal ( 1 ) 
16 Diffuse Abnormal ( 1 ) 
17 Diffuse Abnormal ( 1 ) 
18 Diffuse Normal (3) 
Intestinal/Glandular 
Component 
0, absence of staining; 1, diffuse cytoplasmic staining; 2, heterogeneous staining 
abnormally staining areas); 3, normal membranous pattern of staining. 
Abnormal (0) 
Abnormal (1) 
Abnormal (2) 
Abnormal (2) 
Abnormal (2) 
Abnormal (0) 
Abnormal (2) 
Abnormal (2) 
Abnormal (2) 
Abnormal (2) 
Normal (3) 
Normal (3) 
Normal (3) 
Normal (3) 
Normal (3) 
Normal (3) 
Normal (3) 
Normal (3) 
(i.e., both normal and 
nalization of cell contact domains containing junc-
tional cadherins [28]; deficient transport of an ab-
normal E-cadherin protein (possibly due to the oc-
currence of mutations in the E-cadherin gene) into 
the endoplasmic reticulum (ER); retrograde trans-
port of the protein from the ER to the cytoplasm in-
volving the detection of protein abnormalities by 
the quality control system present in the ER [29]; 
and, finally, we cannot exclude the possibility that 
the diffuse cytoplasmic localization of E-cadherin 
may be due to the vesiculation of the Golgi appara-
tus, a structural change that has been described to 
occur in tumor cells [30]. 
We found a significantly higher frequency of ab-
normal E-cadherin expression in diffuse carcinomas 
(92.9%) than in intestinal carcinomas (45.0%). 
This finding is in agreement with those reported by 
other authors who also found a correlation between 
altered expression of E-cadherin and either diffuse 
or poorly differentiated/undifferentiated gastric car-
cinoma [5,17-23]. In our series, the correlation be-
tween histotype and E-cadherin expression was 
maintained when the cases were classified accord-
ing to the classification proposed by Carneiro et al. 
[24] into glandular, isolated-cell-type, solid, and 
mixed carcinomas. The percentage of cases exhibit-
ing abnormal expression of E-cadherin was signifi-
cantly higher in isolated-cell-type (90.9%) and 
mixed (94.4%) carcinomas than in glandular carci-
nomas (42.1%). The high prevalence of mixed car-
cinomas displaying abnormal E-cadherin expres-
sion (94.4%) is in agreement with the fact that in 
17/18 mixed carcinomas the predominant compo-
nent was constituted by diffuse/isolated-cell-type 
carcinoma. The separate evaluation of E-cadherin 
expression in distinct histologic components of the 
mixed carcinomas consistently reproduced the asso-
ciation between E-cadherin expression pattern and 
the histotype. E-cadherin expression was scored as 
Fig. 4. In this 'm ixed ' carcinoma the immunoexpression 
pattern of E-cadherin differs in each component of the 
tumor: Intestinal component (left) displays a normal pattern 
of immunoreactivity (polarized at the lateral cell mem-
brane), whereas the diffuse component (right) depicts ab-
normally expressed E-cadherin (diffuse in the cytoplasm). 
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Fig. 5. Survival curves of patients according to the pattern of E-cadherin expression in gastric carcinomas. 
abnormal in the diffuse/isolated-cell-type compo-
nent in 17/18 (94.4%) mixed carcinomas. At vari-
ance with this, in the intestinal/glandular compo-
nent of mixed carcinomas, abnormal E-cadherin 
expression was observed in 10/18 (55.6%) cases, 
the remaining eight cases (44.4%) exhibiting, in the 
glandular areas, a polarized pattern of E-cadherin 
expression at the cell membrane. 
The significant relationship between an abnormal 
expression of E-cadherin and diffuse/isolated-cell-
type carcinomas, which is kept both in "pure" carci-
nomas and in the diffuse component of mixed car-
cinomas, is in keeping with the hypothesis that 
E-cadherin plays a crucial role in the adhesion 
among neoplastic cells, which, if disrupted, leads to 
dissociation of cells and scattered growth. This hy-
pothesis is challenged by the existence of a small 
percentage of diffuse/isolated-cell-type carcinomas 
displaying a normal E-cadherin expression and by 
the occurrence of carcinomas with glandular struc-
ture, in which neoplastic cells are cohesive, despite 
an abnormal expression of E-cadherin. In the latter 
group, one cannot exclude that E-cadherin is still 
expressed at the junctional complexes of the cell 
membrane at a level not easily detectable by im-
munohistochemistry. Furthermore, it is admissible, 
on the basis of evidence previously reported [31], 
that the abnormal expression of E-cadherin may re-
flect a temporary modulation phenomenon occur-
ring in tumors that are heterogeneous regarding E-
cadherin expression, i.e., displaying E-cadherin 
both in the cytoplasm and at the cell membrane. In 
fact, recent studies suggest that modulation of E-
cadherin expression in carcinomas is a very com-
plex process, subjected to temporary microenviron-
mental influences as demonstrated by Mareei et al. 
[31]. These authors showed that injection into nude 
mice of homogeneously E-cadherin-positive cells, 
which were noninvasive in vitro, led to the forma-
tion of invasive and sometimes metastatic tumors 
that were heterogeneous with regard to E-cadherin 
expression. According to these data and as put for-
ward also by other authors [32-34], loss of E-cad-
herin could be, at least in some tumors, a temporary 
phenomenon that would allow invasion to last long 
enough for metastization to occur. In keeping with 
this hypothesis, the majority of tumors with intesti-
nal/glandular phenotype from our series, with ab-
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normal expression of E-cadherin, correspond to 
cases showing a heterogeneous pattern of E-cad-
herin expression (score 2), characterized by the co-
existence of areas displaying normal (membranous) 
E-cadherin expression and areas exhibiting abnor-
mal (cytoplasmic) expression of E-cadherin. 
Regarding the isolated-cell-type/diffuse carcino-
mas ("pure" histotypes or components of mixed 
carcinomas) displaying a membranous expression 
of E-cadherin, one has to admit that in such cases 
the adhesion of neoplastic cells is disrupted by an al-
teration at another level of the cell adhesion system. 
In fact, E-cadherin is only part of a complex cell ad-
hesion system and its function is dependent on the 
interaction of its conserved cytoplasmic domain (C-
terminal) with the cytoskeleton via molecular com-
plexes involving a-, P-, and y-catenin. Alterations in 
the associated cytoplasmic molecules, such as the 
catenins, are thought to impair cell adhesion in tu-
mors exhibiting normal E-cadherin expression. This 
hypothesis is supported by in vitro experimental ev-
idence [35] and by data on record on the expression 
of catenins in several types of cancer [5,8,36-39]. 
Jawhari et al. [5] studied the expression of E-cad-
herin and a-, 0-, and y-catenin in a series of 89 gas-
tric carcinomas and reported abnormal expression, 
of at least one of the antigens, in about 90% of the 
cases. Moreover. Jawhari et: al. [5] found a strong 
correlation between abnormal expression of the E-
cadherin/catenin complex and the diffuse type of 
gastric carcinoma. Furthermore, recent data indi-
cate that phosphorylation of tyrosine residues of p"-
catenin, via epidermal g rowth factor receptor 
and/or c-erbB2 activation, may inhibit the assembly 
of the E-cadherin-catenin-cytoskeleton complex, 
leading to the disruption of the adhesion system 
[40]. These mechanisms would help to explain the 
group of tumors with diffuse/isolated-cell pheno-
type that keep normal membranous expression of 
E-cadherin and, nevertheless, display a scattered 
structure with complete lack of adhesiveness be-
tween the tumor cells. 
Remaining to be fully elucidated is the role played 
by mutations in E-cadherin gene regarding the ab-
normal pattern of E-cadherin expression as ob-
served at the immunohistochemical level. In a se-
ries of 53 gastric carcinomas studied by Becker et al. 
[13], E-cadherin mutations were detected in 13/26 
(50.0%) diffuse carcinomas. Our own preliminary 
results on the study of alterations in the E-cadherin 
gene point to a similar frequency of E-cadherin 
gene mutations in diffuse/isolated-cell-type gastric 
carcinomas (unpublished data). Similarly, muta-
tions of the E-cadherin gene have also been de-
scribed in a significant proportion of infiltrative lob-
ular breast carcinomas, which also display a "dif-
fuse" phenotype with an infiltrative growth pattern 
and scattered tumor cells [11,12]. Altogether, these 
results provide a genetic basis for the existence of 
(permanent ) al terat ions of E-cadherin expres-
sion/function in diffuse/isolated-cell-type carcino-
mas of the stomach. 
Besides the role of E-cadherin in the establish-
ment of the tumor histotype, it has also been sug-
gested that alterations in E-cadherin expression 
may contribute to explain the invasive and metasta-
tic abilities of the tumors. In our series we found no 
relationship between E-cadherin expression and lo-
cal invasion, in keeping with the fact that invasion 
is a complex process also involving mechanisms 
other than disruption of cell-cell adhesion, such as 
alterations of cell-matrix interactions and extracel-
lular protease activity [41]. No significant relation-
ship was also observed between E-cadherin expres-
sion and venous invasion, suggesting that the ability 
of neoplastic cells to invade vessels is not entirely 
dependent on the ability to dissociate from each 
other. Furthermore, Cowley et al. [42] showed that 
in 40% of adenocarcinomas E-cadherin levels are 
elevated in their intravascular tumor compartment 
in comparison to their extravascular compartments, 
pointing to the possibility of modulation of E-cad-
herin expression. 
We observed a significant association between ab-
normal E-cadherin expression and the presence of 
lymph node metastases and high pTNM stages. Our 
results are in agreement with those reported by 
other authors [18-20,23,36], although such rela-
tionships could not be demonstrated by Gabbert et 
al [22] in a series of 413 gastric carcinomas. These 
apparent discrepancies are probably influenced by 
the different criteria used in the evaluation of the 
immunoreactivity. The relationship between abnor-
mal E-cadherin expression and the aforementioned 
parameters of biological aggressiveness is reflected 
on the survival of the patients with tumors display-
ing an abnormal pattern of E-cadherin expression. 
Our finding of the worse prognosis of patients with 
tumors displaying abnormal expression of E-cad-
herin is in accordance with those reported by Mayer 
et al. [23] and Gabbert et al. [22], who observed 
that patients with tumors presenting loss or abnor-
mal expression of E-cadherin had statistically signif-
icant worse survival rate than those with tumors 
displaying normal E-cadherin expression. 
In conclusion, our results show that abnormal ex-
pression of E-cadherin is strongly correlated with 
diffuse/isolated-cell histotype of gastric carcinoma. 
This feature is kept both in tumors with "pure" his-
tologic type and in the diffuse/isolated-cell-type 
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c o m p o n e n t of mixed carcinomas, regardless of the 
p a t t e r n of E-cadher in express ion in the o ther ( s ) 
componen t ( s ) of the mixed tumors . Further, abnor-
mal E-cadher in expression is correlated wi th fea-
tures of aggressiveness of the tumors and poor sur-
vival of the pat ients . 
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E­Cadherin Gene Mutations Provide a Genetic Basis 
for the Phenotypic Divergence of Mixed 
Gastric Carcinomas 
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SUMMARY: Inactivation of the E­cadherin gene has been described previously in gastric carcinomas. In the present study, we 
investigated the alterations of the E­cadherin gene in gastric carcinomas and analyzed the relationship between such alterations 
and the histotypes of the tumors. We performed PCR/single­strain conformation polymorphism mutation screening and loss of 
heterozygosity analysis of the E­cadherin gene in a series of 26 gastric carcinomas, including 10 "pure" intestinal, 10 "pure" 
diffuse, and 6 mixed gastric carcinomas, the latter with Intestinal and diffuse components. Fifteen mutations of the E­cadherin 
gene were identified In 12 cases (46.2%). Mutations included 10 missense mutations, 7 of which occurred in sequences coding 
for calcium binding motifs, 3 splice site mutations, 1 nonsense mutation, and 1 frameshift deletion. We found mutations of the 
E­cadherin gene in 7 of 10 "pure" diffuse carcinomas (70.0%) and in 5 of 6 mixed carcinomas (83.3%). No mutations were found 
In "pure" intestinal carcinomas. In mixed carcinomas, inactivating E­cadherin mutations were exclusively observed In the diffuse 
component of the tumors. We conclude that E­cadherin inactivation is significantly related with the diffuse histotype In gastric 
carcinomas, not only in "pure" diffuse carcinomas but also in the diffuse component of mixed tumors. To the best of our 
knowledge, this is the first report advancing a genetic basis for the phenotypic divergence of mixed gastric carcinomas. (Lab 
Invest 1999, 79:1-000). 
T7 ­Cadherin is a member of the cadherin family of 
12/ calcium­dependent cell adhesion molecules 
(Takeichi, 1991). These molecules are localized in 
lateral cell­cell contacts of epithelial cells and regulate 
the process of homophilic/homotypic adhesion be­
tween epithelial cells (Takeichi, 1991). It has been 
postulated that changes in the expression or function 
of E­cadherin may account for the ability of cancer 
■cells to detach from the parent tumor structure and 
invade locally. Indeed, abnormal E­cadherin expres­
sion (characterized by loss, reduced, and/or cytoplas­
mic expression) has been observed In several types of 
(carcinoma, and is frequently associated with poorly 
differentiateayundifferentiated carcinomas and/or in­
vasive tumors (Smith and Pignatelli, 1997). Moreover, 
imitations of the E­cadherin gene and/or loss of het­
erozygosity (LOH) in 16q22.1 have been reported In 
diffuse gastric carcinoma pecker et al, 1994; Guilford 
et al, 1998; Muta et al, 1996), lobular carcinoma of the 
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breast (Berx et al, 1995,1996), and carcinomas of the 
endometrium and ovary (Risinger et al, 1994), support­
ing a role for E­cadherin as a tumor suppressor gene. 
In gastric carcinoma, there is an association be­
tween abnormal expression of E­cadherin and the 
diffuse (isolated­cell) histotype (Gabbert et al, 1996; 
Jawhari et al, 1997; Machado et al, 1998; Mayer et al, 
1993; Shino et al, 1995). Becker et al (1994) described 
mutations of the E­cadherin gene in 50% of diffuse 
carcinomas of the stomach. Recently, the report of 
germline mutations in kindred with early onset diffuse 
gastric carcinoma became the first description of a 
molecular basis for familial gastric cancer of the dif­
fuse type (Gayther et al, 1998; Guilford et al, 1998). 
In a previous study, we confirmed that abnormal 
E­cadherin expression was significantly associated 
with the diffuse type of gastric carcinoma (Machado et 
al, 1998) and we observed that in most mixed carci­
nomas the diffuse component exhibited an abnormal 
E­cadherin expression, whereas the intestinal compo­
nent displayed a normal (polarized at the lateral cell 
membrane) pattern of E­cadherin expression 
(Machado et al, 1998). It remains to be elucidated 
whether the differential expression of E­cadherin, in 
individual histologic components of mixed carcino­
mas, represents an epigenetic phenomenon or, in 
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alternative, reflects the existence of genotypically di-
vergent clones. 
In the current study, we performed PCR/single-
strain conformation polymorphism (SSCP) mutation 
screening and LOH analysis of the E-cadherin gene in 
a series of gastric carcinomas, litis study was carried 
on in carcinomas of "pure" histologic type as well as in 
a subgroup of mixed gastric carcinomas. In the latter 
group, molecular analysis was performed separately in 
the different histologic components of the tumors. Our 
main goal was to investigate whether or not the 
putative alterations of E-cadherin were restricted to 
the diffuse component of the mixed gastric carcino-
mas. 
Results 
Mutational Analysts of the E-Cadherln Gene 
By using PCR/SSCP, we identified mobility shifts in 24 
of the 26 gastric carcinoma cases. Comparison with 
SSCP patterns observed in normal DNA counterparts 
revealed that in 14 cases there were band shifts that 
were not tumor restricted, suggesting a polymorphic 
nature. Sequencing analysis of these bands revealed 
either silent or intronic substitutions, previously de-
scribed as polymorphisms perx et al, 1998) (Table 1). 
In 12 of the 26 cases (46.2%), we observed tumor 
restricted mobility shifts: 9 cases harbored a single 
shift, and 3 cases presented two different mobility 
shifts each (Table 2). In two of these cases there were 
also polymorphisms. 
The sequencing of the tumor restricted bands re-
sulted in the identification of 15 mutations, spanning 
the region between exons 7 and 12 of the E-cadherin 
gene (Table 2). One nonsense mutation and one 
firameshift deletion, resulting In premature down-
stream stop codons, were detected in cases 2 and 5, 
respectively. A G-+ A transition in the last nucleotide of 
Intron 7, resulting in the loss of the normal acceptor 
splice site, was identified in three cases (cases 7,13, 
and 16). Ten missense mutations were found, causing 
single amino acid substitutions: 7 missense mutations 
occurred in highly conserved sequences coding for 
calcium binding motifs of the E-cadherin extracellular 
domain (cases 3, 4, 5, 10, 11, 14, and 15); the 
Table 1. Polymorphisms" Identified In the E-Cadherin 
Gene of Nine Patients with Gastric Carcinoma 
Nucleotide 
change* 
Intron/Exon No. Codon No. (Amlnoacid) Frequency 
Intron 4 — 531 + 10G-+C 1/26 
Exon12 632 1896C-*T (H->H) 1/26 
Intron 12 — 1937-13T-+C 3/26 
Exon13 692 2076C-»T (A-»A) 11/26 
Exon 16 879 2637C-*T (G-+G) 2/26 
'AH these polymorphisms have been described previously (For review see 
«erx et al. 1998. 
'Numbering Is according to the cONA starting at the A in the start codon 
(Antonarakis. 1998) (Genbank Accession No. Z13009). 
remaining 3 missense mutations (cases 6, 7, and 16) 
took place in nonconserved sequences of the 
E-cadherin gene. 
Comparison between E-cadherin Mutational Status and 
the Histologic Type of the Cases 
In the group of 10 "pure" intestinal carcinomas, no 
mutations were found. Of the 10 "pure" diffuse carci-
nomas, we found mutations in seven cases (70.0%) 
(Table 2). 
E-Cadherin mutations were detected in five of the 
six cases of mixed gastric carcinoma (83.3%) (Table 
2). In four cases, we detected mutation of the 
E-cadherin gene restricted to the diffuse component 
of the tumors (Fig. 1) (cases 11, 13, 14, and 15). In 
case 16, we found two different mutations in the 
distinct histologic components of the tumor: a mis-
sense mutation in the intestinal type component; and 
a splice site mutation in the diffuse type component 
(Table 2). 
A significant relationship was found between the 
diffuse histotype (both in "pure" and in mixed carci-
nomas) and E-cadherin mutations (p < 0.0001). In 16 
samples of the diffuse type (10 "pure" diffuse carcino-
mas and 6 diffuse components of mixed carcinomas), 
we found 12 samples (75.0%) presenting E-cadherin 
mutations. In contrast to this, only 1 of the 16 samples 
of the intestinal type displayed an E-cadherin muta-
tion, corresponding to the intestinal component of a 
mixed carcinoma. 
LOH Analysis 
All cases included in the present study were informa-
tive for at least one of the two microsatellite markers. 
One case of the 26 (3.8%) showed LOH for marker 
D16S301 (data not shown). In this case, a missense 
mutation in one of the calcium binding sequences of 
the gene was also found (Table 2, case 3). Regarding 
the polymorphisms detected, the same pattern was 
observed in tumoral and matched constitutional DMA 
Discussion 
We detected E-cadherin gene mutations in 46.2% of 
gastric carcinomas. By sequencing analysis, we iden-
tified 15 mutations, mostly of the missense type. In a 
previous study that used a strategy based on reverse 
transcriptase (RT)-PCR, Becker et al (1994) reported 
E-cadherin gene mutations in 50% of gastric carcino-
mas of the diffuse type and described a high fre-
quency of exon skipping of E-cadherin gene affecting 
exons 8 and 9. 
In accordance with the results of Becker et al (1994), 
we found that mutations were clustered in the central 
region of the E-cadherin gene (exons 7 to 12). This 
region codes for the five extracellular cadherin do-
mains of the protein, each containing two highly 
conserved calcium binding motifs (Kemler, 1993), that 
play a key role in the adhesion process (Overduin et al, 
1995; Shapiro et al, 1995). Seven of the 10 missense 
mutations detected in the present study occurred in 
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Table 2. Summary of the Results Regarding E­cadherin Mutations In 16 Gastric Carcinomas with "Pure" Diffuse and 
Mixed Hlstotypes . 
Mutation 
Case 
Histologic 
type 
Exon 
No. Codon 
1 
2 
3 
4 
5 
Diffuse 
Diffuse 
Diffuse 
Diffuse 
Diffuse 
6 
7 
Diffuse 
Diffuse 
8 
9 
10 
11 
Diffuse 
Diffuse 
Diffuse 
Mixed 
D 
i 
12 
1 
Mixed 
D ■ 
13 
i 
Mixed 
D 
i 
14 i Mixed 
D 
i 
15 i Mixed 
D i 
116 i Mixed 
D 
1 
8 353 
8 370 
10 479 
8 343 
9 402 
12 581 
Intron 7 — 
8 347 
— — 
— — 
7 334 
8 369 
Nucleotide change* 
1057G­*T 
1108G­*C 
1436A­+G 
1027delC 
1204G­»A 
1742T­»C 
1009­1 G^­A 
1040C­+T 
1000G­+C 
1105A­>G 
Predicted protein change 
E353X (stop) 
D370H (missense) 
D479G (missense) 
Frameshift 
D402N (missense) 
L581P (missense) 
In frame deletion 
A347V (missense) 
D334H (missense) 
N369D (missense) 
Intron 7 
Intron 7 
8 
400 
370 
365 
1009­1 G­»A 
1198G­*T 
1108G­+C 
1009­1 G­>A 
1093G­>C 
In frame deletion 
D400Y (missense) 
D370H (missense) 
In frame deletion 
V365L (missense) 
^ « r U ^ r * is according to thecONA starting i t the A In the start codon (Antonarakis. 1998) (Genoank Accession No. Z13009). 
D, diffuse component of mixed carcinoma; I. intestinal component of mixed carcinoma. 
one of the sequences coding for calcium motifs, being 
expected to Impair cell­cell adhesion by interference 
with the calcium dependent cell adhesion zipper (Sha­
piro et al, 1995). In fact, it was previously shown that 
conservative point mutations within the N­terminal 
calcium binding pocket are enough to abolish cell­cell 
adhesion (Ozawa et al, 1990). The remaining three 
missense mutations led to two conservative substitu­
tions and one nonconservative substitution. The latter, 
leading to the replacement of a leucine by a proline 
residue (case 6), probably causes major alterations in 
the protein structure. The two conservative substitu­
tions, corresponding to nonconserved sequences of 
the gene, are not expected to produce severe alter­
eitions in the resulting protein structure and, conse­
quently, in its function. One of these mutations oc­
curred in case 7 together with a potentially inactivating 
splice site mutation, and the other was restricted to 
the intestinal component of a mixed carcinoma (case 
116). On the other hand, it is interesting that some 
missense mutations seem to have their major effect by 
Induction of aberrant splicing (Oda et al, 1994). 
The nonsense mutation and the frameshift deletion, 
resulting in premature downstream stop codons, are 
expected to produce truncated peptides lacking the 
transmembrane and the cytoplasmic p­catenin bind­
ing domains. In three cases, we found a mutation 
affecting intron 7 acceptor splice site. Unavailability of 
corresponding mRNA prevented us from further ana­
lyzing the consequences of such alteration at the 
transcription level. Mutations occurring in the same 
splice site were previously described by Berx et al 
(1996) and by Becker et al (1994), resulting in exon 8 
skipping. 
In the classic two­hit model of tumo^ suppressor 
gene inactivation. mutations in one allele *are accom­
panied by deletion of the remaining normal allele. Our 
results appear to challenge this model because LOH 
of 16q22.1 was found in only 1 of the 12 cases 
presenting mutation of the E­cadherin gene. Notewor­
thy, in case 5, two different inactivating mutations 
were identified, thus fulfilling also the two­hit inactiva­
tion model. These findings contrast with those of Berx 
et al (1996) in lobular carcinoma of the breast, showing 
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Fijjure I. 
E-Cadherin gene mutation restricted to the diffuse component in a mixed gastric carcinoma (case 15). a, Hematoxylin and eosin staining of mixed gastric carcinoma 
presenting adjacent intestinal (top) and diffuse (bottom) histologic components (original magnification, X140) . b, Exon 8 PCR/single-strain conformation 
polymorphism (SSCP) analysis of intestinal component showing a regular band pattern, c, Sequencing analysis of the bands represented in b showing a normal 
E-cadherin sequence corresponding to codons 368 to 372. d, In the diffuse component two band shifts (arrows) were found by PCIVSSCP analysis of exon 8, in 
addition to the regular bands, e, Sequencing analysis of the abnormal bands represented in d, revealed a missense mutation (1108G-»C; D370H) in the E-cadherin 
gene {arm*). 
that 93% of cases with E-cadherin gene mutation 
displayed also LOH. Alternative inactivation mecha-
nisms of the remaining normal allele may include 
specific allelic exclusion (Becker and Hofler, 1995) or 
alterations at the gene promoter level (Hennig et al, 
1995). Methylation within the promoter or the 5'-CpG 
island of the E-cadherin gene has been shown in 
breast and prostate carcinomas (Graff et al, 1995; 
Hennig et al, 1995; Yoshiura et al, 1995). Additionally, 
one can speculate that the mutation of one allele may 
result in a dominant-negative effect over the remaining 
normal allele. Cadherins exist at the cell surface as 
dimers linked by interactions at each cadherin domain 
(Shapiro et al, 1995). One may admit that a mutated 
E-eadherin protein may still bind to wild-type protein 
leading to a nonfunctional E-cadherin complex. 
In the present series, E-cadherin mutations oc-
curred in 70% of "pure" diffuse gastric carcinomas 
and were not detected in "pure" intestinal carcinomas. 
This very strong association between E-cadherin mu-
tations and the diffuse histotype is in agreement with 
the results of Becker et al (1994), who reported muta-
tions of the E-cadherin gene in 50% of diffuse gastric 
carcinomas and its absence in intestinal type carcino-
mas. Furthermore, E-cadherin mutations were de-
tected in gastric carcinoma cell lines with a diffuse 
phenotype (Oda et al, 1994) and in families of patients 
with diffuse gastric carcinoma (Gayther et al, 1998; 
Guilford et al, 1998). In mixed gastric carcinomas, we 
observed that inactivating E-cadherin mutations were 
restricted to the diffuse component of the tumors in 
five of six cases. This finding suggests the existence of 
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carcinoma. 
Altogether, these results suggest that inactivation of 
the E-cadherin gene determines the diffuse histotype 
of gastric carcinoma. This putative cause-effect rela-
tionship between E-cadherin inactivation and the dif-
fuse histotype Is challenged by the existence of a 
small percentage of cases presenting diffuse histo-
type without detectable E-cadherin mutations (cases 8 
and 9 and diffuse component of case 12). In such 
cases, one has to admit that the adhesion of neoplas-
tic cells is disrupted by an alteration at another level of 
the cell adhesion system. In fact, E-cadherin is only 
one of the constituents of a complex cell adhesion 
system, and its function is dependent on the interac-
tion of its conserved cytoplasmic domain (C-terminal) 
with the cytoskeleton by means of molecular com-
plexes involving a-, 6-, and -v-catenin (Kemler, 1993). 
Alterations in the associated cytoplasmic molecules, 
such as the catenins, are thought to impair cell adhe-
sion in tumors exhibiting normal E-cadherin expres-
sion (Bukholm et al, 1998; Jawhari et al, 1997; Shi-
moyama et al, 1992; Smith and Pignatelli, 1997). 
Furthermore, recent data indicate that phosphoryla-
tion of tyrosine residues of /3-catenin, by means of 
epidermal growth factor receptor and/or c-ert»B2 ac-
tivation, may inhibit the assembly of the E-cadherin-
catenin-cytoskeleton complex leading to the disrup-
tion of the adhesion system (Vermeulen et al, 1996). 
Alternatively, we cannot rule out the possibility that 
some mutations were not detected by the present 
analysis, although SSCP is expected to be highly 
sensitive. 
Summing up, we observed that E-cadherin inacti-
vation is significantly related with the diffuse histotype 
in gastric carcinomas, not only in "pure" diffuse car-
cinomas but also in the diffuse component of mixed 
tumors. To the best of our knowledge, this is the first 
report advancing a genetic basis for the phenotypic 
divergence of mixed gastric carcinomas. 
Materials and Methods 
Tissue Material 
Surgical specimens from 26 gastric carcinomas re-
sected and diagnosed at Hospital S. João/Medicai 
Faculty and IPAT1MUP, Porto, Portugal, were studied. 
According to Lauren's classification (Lauren, 1965), 
casses were classified as intestinal (n = 10) and diffuse 
(n - 16). Six cases, classified according to the pre-
dominant histologic type as diffuse carcinomas, also 
displayed foci of intestinal carcinoma. These cases 
were subclassified, according to the classification 
proposed by Carneiro et al (1995), as mixed carcino-
mas. 
Tumor Microdissection and Genomic DNA Extraction 
Genomic DNA extraction was earned out in serial 
sections of formalin-fixed, paraffin-embedded tumor 
material. To reduce contamination from nontumor 
surrounding tissue, we performed microdissection of 
the Itumor areas in four 10-pun serial sections, after 
examination of hematoxylin and eosin-stained serial 
sections. Microdissection was also used to obtain 
separate samples of distinct histologic components of 
mixed carcinomas. Microdissected tissues were de-
pleted of embedding material by incubation with xy-
lene (5 minutes), ethanol (5 minutes), and acetone (1 
minute). After each incubation step, the material was 
recovered by centrifugation at 13,000 x g (1 minute). 
Genomic DNA was retrieved from the resulting mate-
rial by using standard phenol/chloroform extraction. 
Mutation Screening by PCR/SSCP 
SSCP analysis was performed by PPJdCTP radioac-
tive PCR amplification of the complete E-cadherin 
E-Codherin Gent Mutations in Mixed Gastric Carcinomas 
coding sequence and primers were designed to am-
plify individually each E-cadherin exon, including 
exon/intron boundaries. Primer sequences and PCR 
conditions were based on those reported by Berx et al 
(1995), except for exons 2, 4, and 5, which are shown 
in Table 3, along with optimal annealing temperatures 
and expected product size information. Cycling con-
ditions were 30 seconds at 94° C, 30 seconds at the 
appropriate annealing temperature, and 1 minute at 
72° C for 35 cycles. PCR negative controls were 
performed by replacing the template DNA with water. 
Before electrophoresis, PCR reaction products were 
diluted 1:1 with loading buffer (95% formamide, 
0.05% bromophenol blue, and 0.05% xylene cyanol), 
denatured at 99° C for 2 minutes and cooled on ice for 
5 minutes. Electrophoresis of the denatured PCR 
products was carried out in nondenaturing gels (5% 
polyacrylamide with 2% cross-linking), and run at 3 W, 
8° C. Gels were blotted onto 3MM Whatman paper, 
dried, and exposed to x-ray film at room temperature. 
All cases presenting band shifts were submitted to a 
second analysis (new PCR amplification and SSCP 
analysis), and only reproducible bands were consid-
ered. 
Sequencing Analysis 
Abnormal bands, as well as corresponding normal 
bands, detected by SSCP, were recovered from the 
gels and submitted to nonradioactive PCR reamplifi-
cation with the original set of primers. Reamplification 
products were purified and sequenced by using the 
ABI Prism Dye Terminator Cycle Sequencing kit 
(Perkin-Elmer, Foster City, California) and an ABI 
Prism 377 DNA Sequencer perkin-Elmer). Sequenc-
ing was performed on both strands, by using the 
original primers. 
L0H Analysis 
The LOH study was done on the same tumor DNA 
used for SSCP analysis and on matched constitutional 
DNA. Radioactive PCR amplification of microsatellite 
markers D16S265 and D16S301 (Table 1) (Human 
Gene Mapping Kit, Isogen, Amsterdam, Netherlands) 
was performed according to the procedures de-
Table 3. Primer Sequences and PCR Conditions for PCR/SSCP and LOH Analysis 
Analysis Primer name Primer sequence (5' - 3') Product size (bp) TA (°C) 
PCR/SSCP 2F 
2R 
TCACCCGGTTCCATCTAC 
TTCCAACCCCTCCCTACT 
198 58 
4F CTTGnCCTCATCTTCTrTC 237 58 
4R CCCTTTCTCTCCTTGGTACT • 
5F GTTGGGATCCTTCTTTACTA 256 58 
5R AAATCCTGGGTGGATGTTAC 
LOH D16S265F 
D16S265R 
CCAGACATGGCAGTCTCTA 
AGTCCTCTGTGCACTTTGT 
89-117 58 
D16S301F GATCCTAAGGACAAATGTAGATGCTCT 142-152 58 
D16S301R AGCCACTTCCCAGAACTTGGCnCC 
F, forward primer; R, revere* primer; TA, annealing temperature; SSCP. single-strain conformation polymorphism; LOH. loss of heterozygosity. 
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scribed above for PCR/SSCP. PCR products were run 
in a denaturing gel (6% poiyacrylamide with 5% 
crosslinking) and exposed to x­ray film at room tem­
perature. Polymorphisms of the E­cadherin gene were 
used as intragenic markers for the detection of LOH at 
the E­cadherin locus. 
Statistical Analysis 
The statistical analysis of the results was performed by 
using the Pearson tf test. Differences were consid­
ered to be significant at p < 0.05. 
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